A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
| Excerpt | Reference |
|---|
| "Type 2 diabetes mellitus is characterised by resistance of peripheral tissues to insulin and a relative deficiency of insulin secretion." | ( Bergman, RN; Kahn, CR; Krolewski, AS; Martin, BC; Soeldner, JS; Warram, JH, 1992) |
| "Type 1 and type 2 diabetes mellitus are both characterized by increased cardiovascular mortality and morbidity." | ( Giberti, B; Micossi, P; Parlavecchia, M; Ruotolo, G; Zoppo, A, 1991) |
| "Type 2 diabetes mellitus is associated with an exaggerated glucose dependent insulinotropic polypeptide response to oral glucose and mixed meals which is independent of any effect of obesity." | ( Hayes, TM; Jones, IR; Luzio, S; Owens, DR; Williams, S, 1989) |
| "Type 2 diabetes mellitus is a dynamic disease whose natural history is characterized by a progressive aggravation leading to a progressively severe hyperglycaemia, which generally requires a more complex therapy as time progresses." | ( Lefèbvre, PJ; Paquot, N; Scheen, AJ, 1999) |
| "Type 2 diabetes mellitus is a chronic metabolic disorder that results from defects in both insulin secretion and insulin action." | ( DeFronzo, RA, 1999) |
| "Type 2 diabetes mellitus is one of the most common chronic metabolic diseases in man." | ( Ferreira, FM; Palmeira, CM; Santos, MS; Seiça, R, 1999) |
| "Type 2 diabetes mellitus is a progressive disorder, and although oral monotherapy is often initially successful, it is associated with a high secondary failure rate, which contributes to the development of long-term diabetes complications resulting from persistent hyperglycemia." | ( Riddle, M, 2000) |
| "Type 2 diabetes mellitus is characterized by impaired glucose uptake." | ( Cheng, WY; Feng, HF; Hu, XJ; Peng, F; Zhang, ZH; Zhou, HQ, 2000) |
| "Type 2 diabetes mellitus is characterised by abnormal beta-cell function (present at the time of diagnosis) that is often associated with insulin resistance." | ( Lauritzen, T; Nattrass, M, 2000) |
| "Type 2 diabetes mellitus is a growing problem not only in the United States but also across the world." | ( Henry, RR; Mudaliar, S, 2001) |
| "Type 2 diabetes mellitus is a complex heterogenous metabolic disorder in which peripheral insulin resistance and impaired insulin release are the main pathogenetic factors." | ( Landgraf, R, 2000) |
| "Type 2 diabetes mellitus is a common metabolic disorder that has become a major public health problem because of the long-term microvascular and macrovascular complications associated with it." | ( Kumar, S; Valsamakis, G, 2000) |
| "Type 2 diabetes mellitus is characterised by impaired insulin secretion, diminished peripheral insulin action and increased hepatic glucose production." | ( Huijberts, MS; Sels, JP; Wolffenbuttel, BH, 2001) |
| "Type 2 diabetes mellitus is characterized by insulin deficiency but in particular by insulin resistance." | ( Rybka, J, 2001) |
| "Type 2 diabetes mellitus is associated with accelerated atherosclerosis and a high rate of arterial thrombotic complications." | ( Badimon, JJ; Crandall, JP; Fallon, JT; Fuster, V; Heflt, G; Herson, P; Lev, EI; Osende, JI; Rabito, P; Rauch, U; Rodriguez, OJ; Vidhun, R; Zaman, A, 2001) |
| "Type 2 diabetes mellitus is characterized by insulin-resistant glucose and lipid metabolism." | ( Davis, AO; Klein, S; McGill, JB; Racette, SB, 2002) |
| "Hyperglycemia and type 2 diabetes mellitus are more common in schizophrenia than in the general population." | ( Cooper, BP; Fucetola, R; Haupt, DW; Melson, AK; Newcomer, JW; Schweiger, JA; Selke, G, 2002) |
| "Type 2 diabetes mellitus is a common disease whose complications have great costs, both in quality of life and expense of treatment." | ( Caro, J; Salas, M; Ward, A, 2002) |
| "Type 2 diabetes mellitus is a social and civilization-related disease that leads to various micro- and macroangiopathic complications, including diabetic nephropathy." | ( Bartłomiejczyk, I; Kropiewnicka, HE; Paczek, L; Senatorski, G, 2002) |
| "Type 2 diabetes mellitus is associated with a heavy burden of suffering." | ( Donahue, K; Frame, P; Harris, R; Lohr, KN; Rathore, SS; Woolf, SH, 2003) |
| "Type 2 diabetes mellitus is characterized by both insulin deficiency and insulin resistance." | ( Bokhari, SU; Duckworth, WC; Gopal, UM, 2003) |
| "Type 2 diabetes mellitus is frequently accompanied by hypercoagulability and hypofibrinolysis." | ( Brussaard, HE; Kluft, C; Krans, HM; Leuven, JA, 2002) |
| "Type 2 diabetes mellitus is the commonest form of diabetes." | ( Ramachandran, A, 2002) |
| "Type 2 diabetes mellitus is an increasingly prevalent disorder associated with multiple metabolic derangements." | ( Basu, A; Kudva, YC; Zangeneh, F, 2003) |
| "Type 2 diabetes mellitus is a major health problem associated with excess morbidity and mortality." | ( Scheen, AJ, 2003) |
| "Type 2 diabetes mellitus is characterised both by impaired release of insulin and by resistance to the action of insulin." | ( Pørksen, N, 2002) |
| "Type 2 diabetes mellitus is characterised by insulin resistance as well as progressive pancreatic beta cell dysfunction." | ( Diamant, M; Heine, RJ, 2003) |
| "The prevalence of type 2 diabetes mellitus is increasing in children and adolescents worldwide, particularly among minority youth." | ( Homko, CJ; Reece, EA, 2003) |
| "Patients with type 2 diabetes mellitus are associated with insulin resistance and/or impaired insulin secretion." | ( Odawara, M, 2003) |
| "Patients with type 2 diabetes mellitus are at an increased risk of atherosclerosis including peripheral arterial disease (PAD)." | ( Emoto, M; Kimoto, E; Koyama, H; Nishizawa, Y; Shinohara, K; Shoji, T; Tanaka, S; Yokoyama, H, 2003) |
| "Patients with type 2 diabetes mellitus are at increased risk for postangioplasty restenosis, which results from excessive intimal hyperplasia." | ( Bruemmer, D; Law, RE, 2003) |
| "Type 2 diabetes mellitus is a major health problem associated with excess morbidity and mortality." | ( Schernthaner, G, 2003) |
| "The risk of type 2 diabetes mellitus is increased in people who have low birth weights and who subsequently become obese as adults." | ( Barker, DJ; Bhargava, SK; Biswas, SK; Fall, CH; Lakshmy, R; Osmond, C; Prabhakaran, D; Ramji, S; Reddy, KS; Sachdev, HS, 2004) |
| "Type 2 diabetes mellitus is the consequence of both insulin resistance and impaired insulin secretion." | ( Abrahamson, MJ, 2004) |
| "Type 2 diabetes mellitus is the most common serious metabolic condition in the world, and results from a subnormal response of tissues to insulin (insulin resistance) and a failure of the insulin-secreting beta cells to compensate." | ( Klover, PJ; Mooney, RA, 2004) |
| "Type 2 diabetes mellitus is associated with impaired endothelial function and increased levels of TNF-alpha, IL-6 and sVCAM-1, especially in patients with DM and CAD." | ( Antoniades, C; Stefanadis, C; Tentolouris, C; Tountas, C; Tousoulis, D; Toutouza, M; Toutouzas, P; Tsioufis, C; Vasiliadou, C, 2004) |
| "Type 2 diabetes mellitus is a condition characterized by impaired insulin secretion and resistance to insulin-mediated glucose uptake and utilization." | ( Bates, PC; Dietrich, K; Lübben, G; Seufert, J, 2004) |
| "The management of type 2 diabetes mellitus is complicated by the presence of risk factors related to overweight and obesity, particularly visceral adiposity." | ( Berber, A; Campos-Franco, E; Fanghänel, G; Martínez-Rivas, L; Sánchez-Reyes, L; Yamamoto, J, 2004) |
| "Type 2 diabetes mellitus is associated with an augmented risk for cardiovascular disease." | ( Alcaraz Tafalla, MS; Carrillo Alcaraz, A; Illán Gómez, F; Pascual Díaz, M, 2004) |
| "Type 2 diabetes mellitus is a growing epidemic." | ( Anderson, DC, 2005) |
| "Type 2 diabetes mellitus is a common problem in patients after solid organ transplantation." | ( Baldwin, D; Luther, P, 2004) |
| "Type 2 diabetes mellitus is a progressive and complex disorder that is difficult to treat effectively in the long term." | ( Bailey, CJ; Krentz, AJ, 2005) |
| "Rates of type 2 diabetes mellitus are increasing worldwide at an explosive rate." | ( Leiter, LA; Lewanczuk, RZ, 2005) |
| "Patients with type 2 diabetes mellitus are at high risk of cardiovascular disease." | ( Forst, T; Füllert, SD; Hohberg, C; Kann, P; Konrad, T; Langenfeld, MR; Lübben, G; Pfützner, A; Sachara, C, 2005) |
| "Type 2 diabetes mellitus is a widespread disease, affecting millions of people globally." | ( Barbetti, F; Brunetti, A; Brunetti, L; Chiefari, E; Croce, CM; Fedele, M; Foti, D; Fusco, A; Iuliano, R; Manfioletti, G; Paonessa, F, 2005) |
| "Type 2 diabetes mellitus is a disease with a high incidence and prevalence in the world." | ( Arredondo, M; Leiva, E; Mujica, V; Orrego, R; Prieto, M, 2005) |
| "Type 2 diabetes mellitus is a chronic metabolic disorder that results from defects in both insulin secretion and insulin action." | ( Giorgino, F; Laviola, L; Leonardini, A, 2005) |
| "Type 2 diabetes mellitus is increasing globally and is an established risk factor for the development of atherosclerotic vascular disease." | ( Channer, KS; Jones, TH; Kapoor, D; Malkin, CJ, 2005) |
| "Type 2 diabetes mellitus is a heterogeneous condition in which the clinical manifestation of hyperglycemia is a reflection of the impaired balance between insulin sensitivity and insulin secretion." | ( Arslanian, S; Bacha, F; Gungor, N; Hannon, T; Libman, I, 2005) |
| "Type 2 diabetes mellitus is a chronic disease with potentially devastating long-term complications." | ( Jacobson-Dickman, E; Levitsky, L, 2005) |
| "The prevalence of type 2 diabetes mellitus is rapidly increasing." | ( Dounis, V; Hansen, A; Malmberg, K; Rydén, L; Thrainsdottir, IS; Von Bibra, H, 2005) |
| "Patients with type 2 diabetes mellitus are at increased risk of cardiovascular disease, partly owing to dyslipidaemia, which can be amenable to fibrate therapy." | ( Barter, P; Best, J; Colman, P; d'Emden, M; Davis, T; Drury, P; Ehnholm, C; Forder, P; Glasziou, P; Hunt, D; Keech, A; Kesäniemi, YA; Laakso, M; Pillai, A; Scott, R; Simes, RJ; Sullivan, D; Taskinen, MR; Whiting, M, 2005) |
| "The prevalence of type 2 diabetes mellitus is increasing rapidly in industrialized countries, and adrenal glucocorticoids may intensify this disease." | ( Born, J; Dodt, B; Fehm, HL; Oltmanns, KM; Peters, A; Raspe, HH; Schultes, B; Schweiger, U, 2006) |
| "Type 2 diabetes mellitus is a major cause of morbidity and mortality worldwide, and the prevalence is set to increase dramatically over the coming decades." | ( Petersen, KF; Shulman, GI, 2006) |
| "Type 2 diabetes mellitus is increasing to near epidemic proportions, with a reported 190 million patients worldwide." | ( Sawyer, TS; Spiller, HA, 2006) |
| "Type 2 diabetes mellitus is a multigenic disease with evident genetic predisposition, and complex pathogenesis in which environmental and genetic factors interact." | ( Chang, YS; Fang, FD; He, AB; Liu, XJ, 2006) |
| "Type 2 diabetes mellitus is associated with abnormal MBF response to CPT, which can be significantly improved by euglycaemic control with glyburide and metformin." | ( Cadenas, J; Facta, AD; Hsueh, WA; Prior, JO; Quinones, MJ; Schelbert, HR; Schindler, TH, 2007) |
| "Type 2 diabetes mellitus is a cause of primary NAFLD." | ( Chung, CH; Leung, CH; Liu, SC; Wang, CH, 2006) |
| "Type 2 diabetes mellitus is usually preceded by impaired glucose tolerance (IGT) and/or impaired fasting glucose (IFG), which are often referred to as pre-diabetes." | ( Schwartz, S, 2006) |
| "Type 2 diabetes mellitus is the single most common cause of chronic kidney disease (CKD); however its real impact on renal anaemia has not been established." | ( Andreucci, M; Faga, T; Francesco, M; Fuiano, G; Li Vecchi, M; Mancuso, D; Provenzano, R; Sponton, A; Tozzo, C, 2007) |
| "Type 2 diabetes mellitus is the result of a combination of impaired insulin secretion with reduced insulin sensitivity of target tissues." | ( Bentley, E; Cheeseman, M; Connor, SC; Cox, RD; Griffin, JL; Haselden, JN; Hough, T; Maguire, ML; Nunez, D; Rubtsov, DV; Salek, RM; Sweatman, BC, 2007) |
| "Most patients with type 2 diabetes mellitus are overweight or obese, and the relation between obesity, especially of the visceral compartment, and the risk for developing diabetes is well recognized." | ( Aronne, LJ; Lee, M, 2007) |
| "Type 2 diabetes mellitus is a strong predictor of cerebrovascular disease, yet few studies have assessed the incidence of stroke and the role of other risk factors in unselected type 2 diabetes mellitus populations." | ( Alegiani, SS; Avogaro, A; Ferrannini, E; Giorda, CB; Lombardo, F; Maggini, M; Mannucci, E; Raschetti, R; Turco, S; Velussi, M, 2007) |
| "Patients with type 2 diabetes mellitus are at increased risk for macrovascular disease complications." | ( McGuire, DK; Stancoven, A, 2007) |
| "Type 2 diabetes mellitus is twice as prevalent in African Americans and Hispanic Americans as in non-Hispanic whites." | ( Cobitz, AR; Davidson, JA; McMorn, SO; Waterhouse, BR, 2007) |
| "Type 2 diabetes mellitus is associated with elevated plasma triglyceride levels, low high-density lipoprotein cholesterol, and a high incidence of cardiovascular disease." | ( Bergeron, J; Couture, P; Gagné, C; Hogue, JC; Lamarche, B; Tremblay, AJ, 2008) |
| "Type 2 diabetes mellitus is associated with progressive decreases in pancreatic beta-cell function." | ( Gutkin, SW; Nauck, MA; Van Gaal, LF, 2008) |
| "Type 2 diabetes mellitus is a common age-dependent disease." | ( Cheon, GJ; Cho, KA; Ha, MK; Jun, HS; Khil, LY; Lee, TS; Oh, YS; Park, SC; Ryu, SJ; Yoon, JW, 2008) |
| "Type 2 diabetes mellitus is usually accompanied by concomitant disorders, such as dyslipidemia, hypertension and atherosclerosis." | ( Elisaf, MS; Liberopoulos, EN; Mikhailidis, DP; Rizos, CV, 2008) |
| "Type 2 diabetes mellitus is associated with elevated level of oxidative stress, which is one of the most important factors responsible for the development of chronic complications of this disease." | ( Blasiak, J; Drzewoski, J; Kasznicki, J; Sliwinska, A, 2008) |
| "Patients with type 2 diabetes mellitus are at increased risk for the development of atherosclerosis." | ( Ayers, CR; Hedrick, CC; Mauldin, JP; McNamara, CA; Nagelin, MH; Skaflen, MD; Srinivasan, S; Wojcik, AJ, 2008) |
| "A review of Type 2 diabetes mellitus is presented." | ( Hall, MA, 2008) |
| "Type 2 diabetes mellitus is characterized by insulin resistance, impaired glucose-induced insulin secretion, and inappropriately elevated glucagon levels which eventually result in hyperglycemia." | ( Knop, FK; Vilsbøll, T, 2008) |
| "Type 2 diabetes mellitus is a worldwide health problem." | ( Sriwijitkamol, A; Thongtang, N, 2008) |
| "Type 2 diabetes mellitus is a complex disease characterized by beta-cell failure in the setting of insulin resistance." | ( Bernal-Mizrachi, E; Chang-Chen, KJ; Mullur, R, 2008) |
| "New treatments for type 2 diabetes mellitus are needed to retain insulin-glucose coupling and lower the risk of weight gain and hypoglycaemia." | ( Bode, B; Garber, A; Garcia-Hernandez, PA; Hale, PM; Henry, R; Olvera-Alvarez, I; Ratner, R; Rodriguez-Pattzi, H; Zdravkovic, M, 2009) |
| "Type 2 diabetes mellitus is associated with an increased risk of cardiovascular diseases and accelerated atherosclerosis, which has been associated to hyperglycemia and chronic inflammation." | ( Bernard, EA; de Souza, LF; de Souza, MM; Jardim, FR; Sauter, IP, 2008) |
| "Type 2 diabetes mellitus is a metabolic disease leading to microvascular and macrovascular complications including coronary artery disease and stroke." | ( Fonseca, VA; John-Kalarickal, J; Wani, JH, 2008) |
| "Type 2 diabetes mellitus is associated with a marked increase in the risk of coronary heart disease (CHD) or stroke (by a factor of two to three compared with non-diabetic patients), and cardiovascular disease (CVD) accounts for the majority of deaths among patients with diabetes." | ( Balasubramanian, R; Baliga, VP; Bolmall, C; Kathale, A; Nagraj, LM; Nayak, UP; Periyandavar, I; Sharma, A; Varadharajan, S, 2008) |
| "Type 2 diabetes mellitus is an increasingly prevalent condition worldwide." | ( Feinglos, M; Green, J, 2008) |
| "Type 2 diabetes mellitus is the leading cause of macrovascular diseases and related death." | ( Erem, C; Ersoz, HO; Hacihasanoglu, AB; Karti, SS; Ukinc, K, 2009) |
| "Type 2 diabetes mellitus is a growing public health concern throughout the world." | ( Conway, JR; MacNair, D; Marble, RJ; Patasi, B, 2009) |
| "Type 2 diabetes mellitus is a multifactorial metabolic disorder." | ( Fonseca, VA; John-Kalarickal, J; Surampudi, PN, 2009) |
| "Type 2 diabetes mellitus is a major and increasingly prevalent independent risk factor for cardiovascular morbidity and mortality worldwide." | ( Gore, MO; McGuire, DK, 2009) |
| "Type 2 diabetes mellitus is a progressive disease characterized by persistent insulin resistance and a relentless decline in insulin secretion that is accelerated by chronic hyperglycemia." | ( Rosenstock, J, 2004) |
| "Type 2 diabetes mellitus is associated with high mortality and morbidity, mainly due to coronary artery disease and atherosclerosis, although female gender is a protective factor in the development of, for example, atherosclerosis and hypertension." | ( Kamata, K; Kobayashi, T; Matsumoto, T; Taguchi, K; Takenouchi, Y, 2009) |
| "Type 2 diabetes mellitus is a complex metabolic disease that is caused by insulin resistance and beta-cell dysfunction." | ( Fritsche, A; Häring, HU; Machicao, F; Staiger, H, 2009) |
| "Type 2 diabetes mellitus is a common, chronic and progressive metabolic disorder, which accounts for 90% of diabetes cases worldwide." | ( Casellini, CM; Fernández Landó, L, 2009) |
| "Type 2 diabetes mellitus is a disease characterized by persistent and progressive deterioration of glucose tolerance." | ( Del Prato, S, 2009) |
| "Type 2 diabetes mellitus is associated with low high-density lipoprotein (HDL) cholesterol levels, which is an independent cardiovascular risk factor." | ( Schultheiss, HP; Spillmann, F; Tschöpe, C; Van Linthout, S, 2010) |
| "Type 2 diabetes mellitus is a chronic debilitating disease characterized by insulin resistance and progressive pancreatic dysfunction." | ( Henry, RR; Mudaliar, S, 2010) |
| "Type 2 diabetes mellitus is a complicated metabolic disease affecting millions of individuals worldwide." | ( Parkin, CG; Unger, J, 2010) |
| "The increase in type 2 diabetes mellitus is associated to cardiovascular morbidity and mortality." | ( Ghiadoni, L, 2010) |
| "Type 2 diabetes mellitus is associated with increased risk of malignancy (mainly cancer of the pancreas, breast, colon, endometrium and bladder)." | ( Maltezos, E; Mikhailidis, DP; Papanas, N, 2010) |
| "Patients with type 2 diabetes mellitus are characterized by increased incidence of cardiovascular events and enhanced thromboxane-dependent platelet activation." | ( Davì, G; Mucci, L; Santilli, F, 2011) |
| "T2D (Type 2 diabetes mellitus) is a major health issue that has reached epidemic status worldwide." | ( Bushell, M; Ferland-McCollough, D; Ozanne, SE; Siddle, K; Willis, AE, 2010) |
| "Type 2 diabetes mellitus is a well-established risk factor for cardiovascular disease (CVD)." | ( Adamidou, F; Anagnostis, P; Athyros, VG; Karagiannis, A; Kita, M; Mikhailidis, DP; Panagiotou, A, 2011) |
| "Type 2 diabetes mellitus is increasing in prevalence at alarming rates." | ( Giorgino, F; Laviola, L; Leonardini, A; Natalicchio, A, 2011) |
| "Type 2 diabetes mellitus is an independent risk factor for the development of cardiovascular disease." | ( Alvarez de Sotomayor, M; Herrera, MD; Justo, ML; Mingorance, C; Rodríguez-Rodríguez, R, 2011) |
| "Type 2 diabetes mellitus is a complex metabolic disease and its pathogenesis involves abnormalities in both peripheral insulin action and insulin secretion by pancreatic beta cells." | ( Benito, M, 2011) |
| "The incidence of type 2 diabetes mellitus is increasing worldwide." | ( Chawla, S; Ghosh, RK; Ghosh, SM; Jasdanwala, SA, 2012) |
| "Type 2 diabetes mellitus is one of the significant comorbidities of obesity." | ( Eid, WE, 2011) |
| "It was studied that type 2 diabetes mellitus is connected with increased plasma lipid peroxidation (lipid peroxidation expressed as malondialdehyde)." | ( Marjani, A, 2010) |
| "Type 2 diabetes mellitus is characterised by beta cell failure, which frequently develops in the setting of insulin resistance." | ( Drucker, DJ; Rosen, CF, 2011) |
| "Type 2 diabetes mellitus is associated with a 2- to 4-fold increased risk of coronary heart disease (CHD)." | ( Arora, R; Dey, S; Kandhwal, K; Monif, T; Nazarudheen, S; Rao, S; Reyar, S; Singh, MK; Thudi, NR, 2011) |
| "Type 2 diabetes mellitus is a growing problem in pediatrics and there is no consensus on the best treatment." | ( Hoffman, RP; Meyer, SL, 2011) |
| "Type 2 diabetes mellitus is associated with a progressive decline in insulin-producing pancreatic β-cells, an increase in hepatic glucose production, and a decrease in insulin sensitivity." | ( Holst, JJ; McGill, MA, 2012) |
| "Type 2 diabetes mellitus is frequently accompanied by fatty liver/nonalcoholic fatty liver disease." | ( Ishii, S; Ohta, T; Sakai, K; Shiraishi, M; Tsuchida, T, 2012) |
| "Type 2 diabetes mellitus is likely the third modifiable risk factor for pancreatic cancer after cigarette smoking and obesity." | ( Li, D, 2012) |
| "Type 2 diabetes mellitus is thought to be a significant risk factor for Alzheimer's disease." | ( Kasahara, R; Matsubara, T; Naruse, K; Sato, T; Sobue, K; Suzuki, K; Tanida, M; Taniura, H; Yamamoto, N, 2012) |
| "Type 2 diabetes mellitus is a progressive disease characterized by multiple abnormalities that extend beyond β-cell dysfunction and insulin resistance." | ( Freeman, JS, 2012) |
| "The prevalence of type 2 diabetes mellitus is high among the elderly population." | ( Marrs, JC, 2012) |
| "Type 2 diabetes mellitus is a multisystem disease that is characterized by hyperglycemia and is associated with the dysfunction and failure of various organs." | ( Kim, KJ; Lee, BY; Yoon, KY, 2012) |
| "Type 2 diabetes mellitus is the main cause of chronic kidney disease in developed countries." | ( Ardiles A, L; Parra L, X; Villarroel R, P, 2012) |
| "Type 2 diabetes mellitus is a major global public health problem in the worldwide and is increasing in aging populations." | ( Cheng, FC; Huang, JH; Lee, JN; Lu, YF; Tsai, LC, 2012) |
| "Type 2 diabetes mellitus is increasing over time as result of the obesity epidemics." | ( Castagneto-Gissey, L; Mingrone, G, 2012) |
| "Patients with type 2 diabetes mellitus are at 2 to 4 times increased risk of cardiovascular events compared with those without diabetes, both among patients with multiple risk factors only and those with established atherothrombosis." | ( Bhatt, DL; Braunwald, E; Davidson, J; Hirshberg, B; Raz, I; Scirica, BM; Steg, PG; Udell, JA, 2012) |
| "Type 2 diabetes mellitus is associated with a higher risk of hepatocellular carcinoma (HCC), which is attenuated by the use of metformin." | ( Chang, CC; Chen, HP; Chen, TT; Lin, JH; Lin, JT; Shieh, JJ; Wu, CY; Wu, MS, 2013) |
| "Type 2 diabetes mellitus is characterized by insulin resistance with a relative deficiency in insulin secretion." | ( Bouzakri, K; Halban, PA; Plomgaard, P, 2012) |
| "Type 2 diabetes mellitus is associated with risk of congestive heart failure (CHF), cognitive dysfunction and depression." | ( Deary, IJ; Feinkohl, I; Price, JF; Reynolds, RM; Sattar, N; Strachan, MW; Welsh, P, 2012) |
| "Type 2 diabetes mellitus is associated with an increased blood thrombogenicity among NSTE-ACS patients on currently recommended medical therapy." | ( Badimon, JJ; Balasubramaniam, K; Marshall, SM; Schechter, CB; Viswanathan, GN; Zaman, AG, 2012) |
| "Type 2 diabetes mellitus is characterized by insulin resistance and progressive β cell failure; therefore, β cell secretagogues are useful for achieving sufficient glycemic control." | ( Basit, A; Fawwad, A; Riaz, M, 2012) |
| "Patients with type 2 diabetes mellitus are routinely treated with combinations of glucose-lowering agents." | ( Boardman, MK; Haber, H; Liutkus, JF; Norwood, P; Pintilei, E; Trautmann, ME, 2012) |
| "Type 2 diabetes mellitus is a multifactorial and polygenic disease, which is considered as a major life threatening problem all over the world." | ( Abbas, S; Ahmed, F; Fatima, J; Mahdi, F; Raza, ST; Zaidi, ZH, 2012) |
| "Type 2 diabetes mellitus is a chronic dysmetabolic condition characterized by hyperglycemia and accompanied by dyslipidemia (low HDL, high triglycerides), and hypertension associated with insulin resistance in obesity." | ( de Galan, BE; Simsek, S, 2012) |
| "Type 2 diabetes mellitus is associated with reduced incretin effects." | ( Chan, JC; Deng, Y; Fan, RR; Kang, ZF; Laybutt, DR; Luzuriaga, J; Xu, G; Zhou, Y, 2013) |
| "Type 2 diabetes mellitus is widely prevalent and is often coexistent with obesity." | ( Davies, MJ; Kela, R; Khunti, K; Nisal, K, 2012) |
| "Type 2 diabetes mellitus is a progressive disease characterized by an impairment of insulin action, and failure of pancreatic β-cells to compensate for the enhanced insulin demand." | ( Sesti, G, 2012) |
| "Type 2 diabetes mellitus is characterized by hyperglycaemia." | ( Hak, L; Wolnik, B, 2013) |
| "Type 2 diabetes mellitus is a metabolic noncommunicable disease with an expanding pandemic magnitude." | ( Berlanga-Acosta, J; García-Siverio, M; Guillen-Nieto, G; Herrera-Martínez, L; López-Mola, E; Schultz, GS, 2013) |
| "Type 2 diabetes mellitus is a rising cause of cardiovascular morbidity and mortality." | ( Elisaf, MS; Rizos, CV, 2013) |
| "Type 2 diabetes mellitus is characterized by insulin resistance in peripheral tissues and relative impairment in insulin secretion from pancreatic beta cell." | ( Shimomura, I; Yasuda, T, 2013) |
| "Type 2 diabetes mellitus is the most common endocrine disease all over the world, while existing therapies can only ameliorate hyperglycemia or temporarily improve the response to insulin in target tissues, they cannot retard or improve the progressive β-cell dysfunction persistently." | ( Gao, H; Hu, J; Sun, R; Wang, F; Wang, L; Wang, Y; Wang, Z; Yan, S; Yu, X; Zhao, W, 2014) |
| "Type 2 diabetes mellitus is a pandemic, with millions of new diagnoses made each year." | ( Davidson, JA; Grimm, M; Nikkel, C, 2013) |
| "Type 2 diabetes mellitus is an increasingly common threat to the health of elderly Americans." | ( Marcy, TR; Zhao, Q, 2013) |
| "Type 2 diabetes mellitus is characterized by prolonged hyperinsulinemia, insulin resistance, and progressive hyperglycemia." | ( Berg, RL; Doi, SA; Engel, JM; Glurich, I; Onitilo, AA; Stankowski, RV; Williams, GM, 2014) |
| "Type 2 diabetes mellitus is increasing dramatically in sub-Saharan Africa, and genetic predisposition is likely involved in that." | ( Bedu-Addo, G; Danquah, I; Frank, LK; Mockenhaupt, FP; Othmer, T; Schulze, MB, 2013) |
| "Type 2 diabetes mellitus is a complex and progressive disease that is showing an apparently unstoppable increase worldwide." | ( Capuano, A; Esposito, K; Giugliano, D; Maiorino, MI; Rossi, F; Sportiello, L, 2013) |
| "Type 2 diabetes mellitus is a troubling chronic disease and diabetic nephropathy is one of the most important complications of diabetes mellitus." | ( Ardalan, MR; Baradaran, A; Mardani, S; Momeni, A; Nasri, H; Rafieian-Kopaei, M, 2013) |
| "Type 2 diabetes mellitus is a major risk factor for melioidosis, which is caused by Burkholderia pseudomallei." | ( Ato, M; Bancroft, GJ; Kewcharoenwong, C; Lertmemongkolchai, G; Rinchai, D; Suwannasaen, D; Utispan, K, 2013) |
| "Type 2 diabetes mellitus is increasingly diagnosed in obese children and adolescents." | ( Narasimhan, S; Weinstock, RS, 2014) |
| "Type 2 Diabetes Mellitus is most common form of diabetes." | ( Garg, K; Kumar, S; Tripathi, CD, 2013) |
| "Individuals with type 2 diabetes mellitus are at increased risk of developing atherosclerosis." | ( Greenberg, AS; Lamon-Fava, S; Lichtenstein, AH; Matthan, NR; Obin, MS; Ronxhi, J; Spartano, NL, 2014) |
| "Type 2 diabetes mellitus is a progressive and heterogeneous disease." | ( de Kalbermatten, B; Jaafar, J; Jornayvaz, FR; Philippe, J, 2014) |
| "Type 2 diabetes mellitus is associated with a poor quality of life and considerable health-care costs and can be difficult to control." | ( Derosa, G; Maffioli, P, 2014) |
| "Type 2 diabetes mellitus is highly prevalent among the elderly." | ( Ferriolli, E; Marchesi, JC; Pessanha, FP, 2014) |
| "Type 2 diabetes mellitus is affecting more than 382 million people worldwide." | ( Beales, PL; Berggren, PO; Christou-Savina, S; Gerdes, JM; Karlsson-Edlund, P; Leibiger, B; Leibiger, IB; Moede, T; Moruzzi, N; Östenson, CG; Xiong, Y, 2014) |
| "Type 2 diabetes mellitus is one of the most frequent causes of death in Mexico, characterized by chronic hyperglycemia." | ( Allen, K; Flores-Fernandez, JM; Lazcano-Díaz, E; Owolabi, MS; Padilla-Camberos, E; Villanueva-Rodríguez, S, 2014) |
| "Type 2 diabetes mellitus is a progressive disease that requires pharmacologic treatment to prevent microvascular and macrovascular complications." | ( Gurgle, H; McAdam-Marx, C; Schauerhamer, MB, 2015) |
| "Type 2 diabetes mellitus is the predominant form of diabetes." | ( Chang, SL; Lee, YC; Liao, HY; Lin, JG; Sun, MF, 2015) |
| "Type 2 diabetes mellitus is a vast growing progressive disease that almost affects one person among every twelve globally." | ( Abdulla, MM; Badrey, MG; Eldebss, TM; Gomha, SM; Mayhoub, AS, 2015) |
| "Type 2 diabetes mellitus is characterised by persistent thromboxane (TX)-dependent platelet activation, regardless of disease duration." | ( Davì, G; Pignatelli, P; Santilli, F; Violi, F, 2015) |
| "Type 2 diabetes mellitus is an important risk factor in the development of coronary artery disease (CAD) and is often associated with severe disease." | ( Bhat, NM; Kamath, PK; Mahabala, C; Manjrekar, PA; Pai, ND; Srinivasan, MP, 2015) |
| "Type 2 diabetes mellitus is a chronic metabolic disorder that has become the fourth leading cause of death in the developed countries." | ( Lee, CY, 2016) |
| "Patients with type 2 diabetes mellitus are known to have an increased risk of colorectal neoplasia." | ( Abe, Y; Fujiwara, K; Higuchi, K; Iguchi, M; Inoue, T; Kakimoto, K; Kawakami, K; Nouda, S; Okada, T; Takeuchi, T; Yorifuji, N, 2016) |
| "Type 2 diabetes mellitus is a complex metabolic disease, and cardiovascular disease is a leading complication of diabetes." | ( Antunes, M; Burgeiro, A; Carvalho, E; Carvalho, RA; Cherian, S; Espinoza, D; Fuhrmann, A; Jarak, I; Loureiro, M; Patrício, M, 2016) |
| "Patients with type 2 diabetes mellitus are at risk for accelerated cognitive decline and dementia." | ( Biessels, GJ; Groeneveld, ON; Kappelle, LJ, 2016) |
| "Obesity and type 2 diabetes mellitus are increasing worldwide, reaching pandemic proportions." | ( Celik, A; Celik, BO; Dixon, JB; Gupta, A; Karaca, FC; Pouwels, S; Santoro, S; Ugale, S, 2016) |
| "Because type 2 diabetes mellitus is associated strongly with an increased risk of cardiovascular diseases, the number of patients with diabetes with chronic heart failure is increasing steadily." | ( Ako, J; Anzai, T; Eguchi, K; Inoue, T; Kitakaze, M; Murohara, T; Node, K; Oyama, J; Saito, Y; Sakata, Y; Sata, M; Sato, Y; Shimizu, W; Suzuki, M; Taguchi, I; Tanaka, A; Tomiyama, H; Ueda, S; Uematsu, M; Watada, H; Yamashina, A, 2016) |
| "Type 2 diabetes mellitus is the result of impaired systemic control of glucose homeostasis, in part through the dysregulation of the hormone glucagon." | ( Birnbaum, MJ; Miller, RA, 2016) |
| "Type 2 diabetes mellitus is associated with regulation of several miRNAs in skeletal muscle." | ( Armitage, JA; Heywood, SE; Kingwell, BA; Latouche, C; Natoli, A; Reddy-Luthmoodoo, M, 2016) |
| "Obesity and type 2 diabetes mellitus are risk factors for developing Alzheimer disease." | ( Gupta, D; Jones, AM; Jones, KP; Pratley, RE; Smith, J; Tharp, WG, 2016) |
| "Type 2 diabetes mellitus is characterized by chronic hyperglycemia and associated with oxidative stress resulting from accumulation of free radicals in body's tissues, which especially affects beta cells in pancreas and is an important factor in the development of diabetes and its complications." | ( Askar, T; Mansour, AA; Mergani, A; Mohammed, MA; Mustafa, AM; Saleh, OM; Zahran, RN, 2016) |
| "Type 2 diabetes mellitus is often complicated by osteoporosis, a process which may involve osteoblast autophagy." | ( Liu, F; Liu, JH; Meng, HZ; Shi, PX; Sun, GH; Yang, B; Yang, MW; Yang, RF; Zhang, WL, 2016) |
| "Type 2 diabetes mellitus is a progressive disease associated with significant morbidity and mortality." | ( Anderson, R; Hayes, J; Stephens, JW, 2016) |
| "Type 2 diabetes mellitus is characterized by the dysregulation of glucose homeostasis, resulting in hyperglycaemia." | ( Puigserver, P; Rines, AK; Sharabi, K; Tavares, CD, 2016) |
| "Type 2 diabetes mellitus is a complex metabolic disease and its pathogenesis involves abnormalities in both peripheral insulin action and insulin secretion." | ( Álvarez, C; Beneit, N; Benito, M; Chambon, P; Di Scala, M; Diaz-Castroverde, S; Escribano, O; Fernández, S; Fernández-Millán, E; García-Bravo, M; García-Gómez, G; Gómez-Hernández, A; González-Aseguinolaza, G; González-Rodríguez, Á; Perdomo, L, 2016) |
| "Type 2 diabetes mellitus is associated with accelerated cognitive decline." | ( Backes, WH; Edden, RAE; Hofman, PAM; Jansen, JFA; Puts, NAJ; Schram, MT; Stehouwer, CDA; van Boxtel, MPJ; van Bussel, FCG; Wildberger, JE, 2016) |
| "Type 2 diabetes mellitus is closely associated with adipogenesis and their factors." | ( Arasu, MV; Choi, KC; Ilavenil, S; Kim, da H; Lee, JS; Roh, SG; Srigopalram, S; Vijayakumar, M, 2016) |
| "Type 2 diabetes mellitus is associated strongly with an increased risk of micro- and macro-vascular complications, leading to impaired quality of life and shortened life expectancy." | ( Eguchi, K; Higashi, Y; Inoue, T; Ishizu, T; Kadokami, T; Kario, K; Kitakaze, M; Kodera, S; Maemura, K; Matsuhisa, M; Murohara, T; Nanasato, M; Nishio, Y; Node, K; Ohishi, M; Oyama, J; Sata, M; Sato, Y; Shimabukuro, M; Suzuki, M; Taguchi, I; Tanaka, A; Teragawa, H; Tomiyama, H; Ueda, S; Yamada, H, 2016) |
| "Type 2 diabetes mellitus is chronic metabolic disorder." | ( Bhadada, SK; Malik, A; Morya, RK; Rana, S; Sachdeva, N; Sharma, G, 2016) |
| "Type 2 diabetes mellitus is prevalent especially in Gulf countries and poses serious long-term risks to patients." | ( Al-Saber, F; Aldosari, W; Alselaiti, M; Darwish, A; Harb, G; Kaladari, A; Khalfan, H; Khan, G; Koda, A; Kudo, S; Nakajima, M; Rehani, R; Tanaka, T, 2016) |
| "Type 2 diabetes mellitus is characterized by insulin resistance in various insulin target tissues, such as the liver, adipose tissue, and skeletal muscle, and insufficient insulin secretion from pancreatic β-cells." | ( Kaku, K; Kaneto, H; Kimura, T; Matsuoka, TA; Obata, A; Okauchi, S; Shimo, N; Shimoda, M, 2017) |
| "Type 2 diabetes mellitus is a polygenic disease with a variable phenotype." | ( Sharma, A; Vella, A, 2017) |
| "Type 2 diabetes mellitus is associated with a progressive decline in insulinproducing pancreatic β-cells, an increase in hepatic glucose production, and a decrease in insulin sensitivity." | ( Holst, JJ; McGill, MA, 2012) |
| "Type 2 diabetes mellitus is a pandemic associated with disturbance in haemostasis that could contribute to the development of diabetic vascular disease and accelerated atherosclerosis." | ( Bester, J; Pretorius, E; Soma, P; Swanepoel, AC, 2017) |
| "Type 2 diabetes mellitus is a progressive disease with multiple underlying pathophysiologic defects." | ( Dey, J, 2017) |
| "Expert commentary: Type 2 diabetes mellitus is an epidemic disease and represents a challenge for all health care systems." | ( Acurcio, FA; De Oliveira, GL; Godman, B; Guerra Júnior, AA, 2017) |
| "Type 2 diabetes mellitus is a disease with no cure and chronic disease that results in major morbidity and mortality." | ( Abougalambou, AS; Abougalambou, SSI; Ahmed, NO, 2017) |
| "Type 2 Diabetes Mellitus is a very well known metabolic disorder that has reached epidemic proportions worldwide." | ( Achalli, S; Babu, S; Bhat, M; Kumari, S; Madi, M; Madiyal, A; Shetty, S, 2016) |
| "Type 2 diabetes mellitus is the most common form of diabetes that occurs in both human and nonhuman primates." | ( Gash, DM; Quintero, JE; Yue, F; Zhang, G; Zhang, Z, 2017) |
| "Type 2 diabetes mellitus is a worldwide epidemic and its atherosclerotic complications determine the high morbidity and mortality of diabetic patients." | ( Deleanu, M; Niculescu, LS; Sanda, GM; Sima, AV; Stancu, CS; Toma, L, 2017) |
| "Type 2 diabetes mellitus is characterized by relative insulin deficiency and insulin resistance." | ( Anzaldi, L; Fesseha, B; Galiatsatos, P; Kim, HN; Sidhaye, A; Tsao, A, 2018) |
| "Type 2 diabetes mellitus is associated with increased fracture risk, and recent studies show crosstalk between bone and glucose metabolism." | ( Grimnes, G; Jorde, R; Larsen, AU, 2018) |
| "Type 2 diabetes mellitus is a common disease, affecting up to 13." | ( Azinheira, J; Capitão, RM; Sequeira Duarte, J; Tavares Bello, C; Vasconcelos, C, 2017) |
| "Type 2 diabetes mellitus is associated with cognitive dysfunction and an increased risk of dementia." | ( Biessels, GJ; Espeland, MA; Janssen, J; Johansen, OE; Mattheus, M; van den Berg, E; Zinman, B, 2018) |
| "Type 2 diabetes mellitus is a polygenic metabolic disorder resulting from oxidative stress, the root cause of insulin resistance, β-cell dysfunction and impaired glucose tolerance." | ( Chen, Z; Hu, Z; Liu, D; Liu, L; Song, Z; Wang, Y, 2018) |
| "Type 2 diabetes mellitus is now a worldwide health problem with increasing prevalence." | ( Liu, DM; Liu, JM; Mosialou, I, 2018) |
| "Type 2 diabetes mellitus is characterized by peripheral insulin resistance and low-grade systemic inflammation." | ( Barden, A; Beilin, L; Hodgson, JM; Mas, E; Mori, TA; Phillips, M; Puddey, I; Shinde, S, 2018) |
| "Type 2 diabetes mellitus is a worldwide health problem." | ( Czyrski, A; Hermann, T; Resztak, M, 2018) |
| "Type 2 diabetes mellitus is a common and severe chronic metabolic disease, which confers increased risk of cardiovascular disease and mortality." | ( Christensen, MB; Sørensen, AM, 2018) |
| "Individuals with type 2 diabetes mellitus are at increased risk for heart failure (HF), particularly those with coexisting atherosclerotic cardiovascular disease and/or kidney disease." | ( Alexander, JH; Baanstra, D; Cooper, ME; George, JT; Johansen, OE; Kahn, SE; Marx, N; McGuire, DK; Meinicke, T; Perkovic, V; Pfarr, E; Rosenstock, J; Schnaidt, S; Toto, RD; von Eynatten, M; Wanner, C; Zinman, B, 2019) |
| "Type 2 diabetes mellitus is among the most common diseases seen in primary care practices and can lead to significant complications." | ( Holley, A; Martinez, LC; Sherling, D, 2019) |
| "Type 2 diabetes mellitus is a major risk factor for cardiovascular disease." | ( Al-Salameh, A; Becquemont, L; Bucher, S; Chanson, P; Ringa, V, 2019) |
| "Patients with type 2 diabetes mellitus are at an increased risk of adverse cardiovascular events compared to those without diabetes." | ( Kolluri, N; Lerman, A; Lerman, LO; Sara, JD; Taher, R; Vella, A, 2019) |
| "Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available." | ( Agarwal, R; Bakris, G; Bompoint, S; Brenner, BM; Bull, S; Cannon, CP; Capuano, G; Charytan, DM; Chu, PL; de Zeeuw, D; Edwards, R; Greene, T; Heerspink, HJL; Jardine, MJ; Levin, A; Mahaffey, KW; Meininger, G; Neal, B; Perkovic, V; Pollock, C; Wheeler, DC; Yavin, Y; Zhang, H; Zinman, B, 2019) |
| "Type 2 diabetes mellitus is a complex metabolic disorder requiring polypharmacology approaches for effective treatment." | ( Babkov, DA; Babkova, VA; Borisov, AV; Borodkin, GS; Brigadirova, AA; Kolodina, AA; Litvinov, RA; Morkovnik, AS; Sochnev, VS; Sokolova, EV; Spasov, AA; Zhukowskaya, ON, 2019) |
| "Type 2 diabetes mellitus is a major health concern worldwide; however, the molecular mechanism underlying its development is poorly understood." | ( Cooper, GJS; Liu, H; McCann, MJ; Nie, T; Vazhoor Amarsingh, G; Zhang, S, 2019) |
| "The prevalence of type 2 diabetes mellitus is expected to rise in the frail elderly population, which will have significant consequences for the health economy." | ( Muraleedharan, V; Rabindranathnambi, A; Sathyanarayanan, A, 2019) |
| "Type 2 diabetes mellitus is a chronic metabolic disorder characterized by elevated blood glucose and/or high serum free fatty acids." | ( Hua, Q; Kong, X; Li, XY; Liu, CX; Lv, K; Ma, MZ; Su, Q; Wang, GD; Yang, H; Yao, XM; Zhang, HM, 2019) |
| "Type 2 diabetes mellitus is a major risk factor for developing cardiovascular disease, and many patients with diabetes have prevalent cardiovascular complications." | ( Ceriello, A; Ferrini, M; La Sala, L; Marx, N; Prattichizzo, F; Rydén, L; Valensi, P, 2019) |
| "Type 2 diabetes mellitus is an important public health problem, with a significant impact on cardiovascular morbidity and mortality and an important risk factor for chronic kidney disease." | ( Foresto, RD; Gonzalez, DE; Ribeiro, AB, 2020) |
| "Type 2 diabetes mellitus is often companied with osteoporosis, a process which involves osteoclast activation." | ( Gong, Y; Lei, X; Liu, H; Song, Z; Xie, J; Yang, M; Zhou, L, 2020) |
| "Obesity and type 2 diabetes mellitus are global emergencies and long noncoding RNAs (lncRNAs) are regulatory transcripts with elusive functions in metabolism." | ( Awazawa, M; Büning, H; Cao, H; Dhaouadi, I; Dieterich, C; Edwards, PA; Fernandez-Rebollo, E; Frommolt, P; Hansmeier, NR; Heeren, J; Heine, M; Jesus, DF; Khani, S; Kiefer, CA; Klemm, P; Knippschild, U; Kornfeld, JW; Kulkarni, RN; Larsen, BD; Lee, RG; Link, JC; Loureiro, R; Meola, N; Oliverio, M; Pradas-Juni, M; Scheja, L; Schmidt, E; Schwarzer, R; Topel, H; Tröder, SE; Ulitsky, I; Vallim, TQA; Yamamoto, M; Yang, L; Zevnik, B, 2020) |
| "Type 2 diabetes mellitus is associated with an increased risk of heart failure." | ( Bondugulapati, LNR; Morgan, H; Nana, M, 2021) |
| "Type 2 diabetes mellitus is associated with pNET metastasis and not an independent risk factor for poor prognosis in pNETs." | ( Cheng, H; Fan, K; Fan, Z; Gong, Y; Huang, Q; Jin, K; Liu, C; Luo, G; Ni, Q; Yang, C; Yu, X, 2020) |
| "Objectives Type 2 Diabetes mellitus is a progressive metabolic disease characterized by relative insulin insufficiency and insulin resistance resulting in hyperglycemia." | ( Abrahams-October, Z; Adeniyi, OV; Benjeddou, M; Johnson, R; Masilela, CM; Ongole, JJ; Pearce, B; Xhakaza, L, 2020) |
| "Type 2 Diabetes mellitus is associated with aging and shortened telomere length." | ( Abdolahi, A; Block, RC; Brenna, JT; Godugu, K; Holub, A; Mousa, S; Tu, XM, 2020) |
| "Type 2 diabetes mellitus is a chronic disease that is characterized by hyperglycemia, insulin resistance, and dysfunctional insulin secretion." | ( Ho, HJ; Komai, M; Shirakawa, H, 2020) |
| "Type 2 diabetes mellitus is a heterogeneous disease." | ( Birkenfeld, AL; Fritsche, A; Gallwitz, B; Häring, HU; Heni, M; Kellerer, M; Peter, A; Wagner, R, 2022) |
| "Type 2 diabetes mellitus is a heterogeneous disease." | ( Birkenfeld, AL; Fritsche, A; Gallwitz, B; Häring, HU; Heni, M; Kellerer, M; Peter, A; Wagner, R, 2022) |
| "The incidence of type 2 diabetes mellitus is increasing worldwide and nowadays T2D already became a global epidemic." | ( Danilova, MM; Glotov, AS; Mikhailova, AA; Nasykhova, YA; Tonyan, ZN, 2020) |
| "Obesity and type 2 diabetes mellitus are the most extended current chronic diseases and also Alzheimer pathology which is a progressive degenerative neurological disorder." | ( Cano-Lamadrid, M; Carbonell-Barrachina, ÁA; Hernández, F; Lech, K; Nowicka, P; Tkacz, K; Turkiewicz, IP; Wojdyło, A, 2021) |
| "Type 2 diabetes mellitus is closely related to nonalcoholic fatty liver disease(NAFLD)." | ( Guo, W; Lin, L; Tian, W; Xu, X, 2020) |
| "Type 2 diabetes mellitus is responsible for high mortality and morbidity globally and in India." | ( Babu, GR; Gudlavalleti, AG; Lewis, MG; Murthy, GVS; Schaper, NC; van Schayck, OCP, 2020) |
| "Type 2 diabetes mellitus is characterized by insulin resistance and elevated blood glucose levels." | ( Handschuh, P; Lanzenberger, R; Noe, CA; Noe, CR; Noe-Letschnig, M; Soucek-Noe, D; Wolfslehner, L, 2020) |
| "Type 2 diabetes mellitus is strongly associated with cardiac mitochondrial dysfunction, which is one of the main reasons for cardiovascular diseases." | ( Gopala, S; Jayakumari, NR; Parambil, ST; Rajendran, RS; Reghuvaran, AC; Sivasailam, A; Sreelatha, HV, 2021) |
| "Aging, obesity and type 2 diabetes mellitus are associated with perfusion abnormalities leading to cognitive impairment, neurodegeneration and future development of dementia." | ( Barna, S; Budai, Á; Esze, R; Garai, I; Káplár, M; Képes, Z; Nagy, F; Somodi, S; Varga, J, 2021) |
| "Type 2 diabetes mellitus is a complicated metabolic disorder with no definite treatment." | ( Akhtar, B; Hassan, SU; Malik, M; Muhammad, F; Saeed, M; Sharif, A, 2022) |
| "Type 2 diabetes mellitus is a severe public health issue worldwide." | ( Alfonsetti, M; Allegretti, M; Brandolini, L; Castelli, V; Cimini, A; Cocchiaro, P; d'Angelo, M; Giorgio, C; Lombardi, F, 2021) |
| "Type 2 diabetes mellitus is a chronic metabolic disorder that tends to disarray various metabolic pathways." | ( Jayachandran, M; Li, X; Xu, B, 2021) |
| "Type 2 Diabetes mellitus is a chronic disease considered one of the most severe global health emergencies." | ( Cardullo, N; Floresta, G; Muccilli, V; Rescifina, A; Tringali, C, 2021) |
| "Type 2 diabetes mellitus is a complex metabolic disorder associated with obesity, glucose intolerance and insulin resistance." | ( Bo, P; Fang, P; Han, L; Han, S; Huang, Y; Wang, M; Yu, M; Zhang, Z, 2022) |
| "Type 2 diabetes mellitus is one of the most common and life-threatening diseases found across the globe." | ( Chellappan, DK; Dua, K; Dureja, H; Gulati, M; Gupta, G; Gupta, PK; Gupta, S; Jha, NK; Jha, SK; Khursheed, R; Kumar, B; Pandey, NK; Prasher, P; Sharma, A; Singh, SK; Vishwas, S, 2022) |
| "Type 2 diabetes mellitus is known to be a risk factor for Alzheimer’s disease (AD), but the underlying mechanisms remain unclear." | ( Nomura, S; Shigemori, K; Takeda, S; Tomiyama, T; Umeda, T, 2022) |
| "Type 2 diabetes mellitus is one of the most globally common chronic diseases." | ( Abuzaid, O; Al-Sheikh, R; Albannawi, M; Alhajjmohammed, D; Alkubaish, Z; Althani, R; Altheeb, L; Altuwajiry, H; Ayoub, H; Khattab, R; Mutwalli, H; Purayidathil, T, 2023) |
| "The incidence of type 2 diabetes mellitus is increasing among youths." | ( Arslanian, SA; Barrientos-Pérez, M; Bismuth, E; Boucher-Berry, C; Chao, LC; Cho, JI; Cox, D; Dib, S; Hannon, T; Zeitler, P, 2022) |
| "Type 2 diabetes mellitus is a chronic disease associated with obesity and dysregulated human feeding behavior." | ( Allbritton, NL; Sims, CE; Villegas-Novoa, C; Wang, Y, 2022) |
| "Type 2 diabetes mellitus is a high-risk factor for acute cardiovascular events." | ( Shao, G, 2022) |
| "Type 2 diabetes mellitus is a global epidemic disease, which leads to a severe complication named increased bone fracture risk." | ( Gong, H; Hu, X; Jia, S; Li, J; Wu, X, 2022) |
| "Type 2 diabetes mellitus is a chronic disease most often characterized by increased glucose levels." | ( Ashchi, A; Berner, J; Goldfaden, R; Gore, A; Huston, J; Langley, L; Schaffner, H; Sheikh-Ali, M; Skrable, B; Sutton, D, 2022) |
| "Obesity and Type 2 diabetes mellitus are growing health problems all over the world." | ( Keskin, L; Yaprak, B, 2022) |
| "Type 2 diabetes mellitus is considered to be a substantial socioeconomic burden worldwide on both patients and governments." | ( Abdelwahab, MF; AlYahya, KA; Ibrahim, HM; Khalil, HE; Mohamed, AA; Radwan, AS; Waz, S, 2022) |
| "Type 2 diabetes mellitus is a metabolic disorder resulting from impaired insulin secretion and resistance." | ( Chhabria, S; Mathur, S; Mishra, P; Paital, B; Sahoo, DK; Vadakan, S, 2022) |
| "Type 2 diabetes mellitus is a metabolic disorder resulting from impaired insulin secretion and resistance." | ( Chhabria, S; Mathur, S; Mishra, P; Paital, B; Sahoo, DK; Vadakan, S, 2022) |
| "T2DM (Type 2 diabetes mellitus) is considered a disease that affects old age group." | ( Eid, Y; Elhalawany, S; Elhefnawy, M; Halawa, M; Hegab, A; Hendawy, L, 2022) |
| "Type 2 diabetes mellitus is associated with an increased risk of dementia, potentially through multifactorial pathologies, including neuroinflammation." | ( Ihara, M; Iwasa, M; Iwashita, K; Kato, H; Kato, S; Kawamoto, A; Nishimura, H; Saito, S; Satoh-Asahara, N; Suganami, T; Tanaka, M; Yamakage, H, 2023) |
| "Type 2 diabetes mellitus is a globally prevalent chronic disease characterised by hyperglycaemia and oxidative stress." | ( Acevedo, F; Folch, C; Galarce-Bustos, O; Obregón, C; Vallejos-Almirall, A, 2023) |
| "Type 2 diabetes mellitus is characterized by hyperglycemia and insulin resistance." | ( Ahmed Rasheed, R; Asim, M; Aysha Iftikhar, Z; Chen, TW; Farooq, M; Musaed Almutairi, S; Mushtaq, U; Ubaid, M; Ul Ain, I, 2023) |
| "Type 2 diabetes mellitus is a chronic metabolic disease with no cure." | ( Krause-Hauch, M; Lui, A; Patel, NA; Patel, RS; Sparks, RP, 2023) |
| Excerpt | Reference |
|---|
| "Women with type 2 diabetes mellitus have a higher prevalence of polycystic ovaries than that reported in the general population." | ( Conn, JJ; Conway, GS; Jacobs, HS, 2000) |
| "Type 2 diabetes mellitus has never previously been described in UK children, although an increasing incidence in childhood is recognized in international studies." | ( Barrett, TG; Ehtisham, S; Shaw, NJ, 2000) |
| "Patients with type 2 diabetes mellitus have an elevated risk of morbidity and mortality from cardiovascular disease." | ( Erkelens, DW, 2001) |
| "Patients with lean type 2 diabetes mellitus has some difference of insulin secretion and action in comparison with obese type 2 diabetes mellitus and there are evidences to support that lean type 2 diabetes mellitus is slow emerging type 1 diabetes mellitus in our population." | ( Behre, A; Singh, MK; Singh, SK, 2001) |
| "Patients with type 2 diabetes mellitus have markedly increased risks of developing vascular diseases." | ( Chalmers, J, 2003) |
| "Patients with Type 2 diabetes mellitus have increased levels of hemostatic risk variables for cardiovascular disease, such as fibrinogen, von Willebrand factor (VWF), factor (F)VIIa, d-dimer and plasminogen activator inhibitor-1 (PAI-1)." | ( De Maat, MP; Huisman, MV; Kluft, C; Meinders, AE; Princen, HM; Van De Ree, MA, 2003) |
| "Patients with type 2 diabetes mellitus have a higher rate of restenosis following angioplasty." | ( Desouza, CV; Diez, J; Dunne, B; Fonseca, VA; Matta, AS; McNamara, DB; Murthy, SN, 2003) |
| "Previous studies of type 2 diabetes mellitus have indicated a benign renal outcome after long-term follow-up." | ( Bryer, A; Keeton, GR; Smit, Rv, 2004) |
| "Type 2 diabetes mellitus has become a true epidemic and significant growth is expected in the next decades." | ( Cebrián Blanco, S; Durán García, S; Rodríguez Bernardino, A, 2005) |
| "Patients with type 2 diabetes mellitus have increased risk of cardiovascular disease." | ( Antonopoulou, S; Fragopoulou, E; Ginis, A; Karantonis, HC; Mitsou, E; Mourelatos, A; Phenekos, C; Rementzis, J; Sitara, M, 2006) |
| "Yet, patients with type 2 diabetes mellitus have a much higher baseline risk for cardiovascular events." | ( Davidson, MH, 2007) |
| "Type 2 diabetes mellitus has been associated with a higher incidence of Alzheimer disease (AD)." | ( Cao, D; Lewis, TL; Li, L; Lu, H, 2007) |
| "Type 2 diabetes mellitus has been identified as a risk factor for Alzheimer's disease, and insulin signalling is often impaired in Alzheimer's disease, contributing to the neurodegenerative process." | ( Gault, VA; Hölscher, C, 2008) |
| "Individuals with type 2 diabetes mellitus have increased cardiovascular disease risk compared with those without diabetes." | ( Chait, A; Mazzone, T; Plutzky, J, 2008) |
| "Type 2 diabetes mellitus has reached epidemic proportions; therefore, the search for novel antihyperglycemic drugs is intense." | ( Alpert, E; Ben Yakir, M; Cerasi, E; Cohen, G; Elgart, A; Gruzman, A; Hoffman, A; Katzhendler, Y; Sandovski, D; Sasson, S; Shamni, O, 2008) |
| "Patients with type 2 diabetes mellitus have an increased vascular risk and a series of modifiable risk factors play a crucial role in the atherosclerotic process." | ( Hatzitolios, AI; Papadimitriou, DK; Tsantilas, D; Tziomalos, K, 2009) |
| "The prevalence of type 2 diabetes mellitus has been rapidly increasing, together with the risk of cardiovascular events." | ( Barsotti, A; Di Napoli, P; Emdin, M; Giannoni, A, 2009) |
| "People with type 2 diabetes mellitus have an excess risk of macrovascular disease and a poorer prognosis." | ( Bhattacharya, M; Dormandy, J; van Troostenburg de Bruyn, AR, 2009) |
| "The prevalence of type 2 diabetes mellitus has risen worldwide in large part because of an increase in obesity and sedentary lifestyles." | ( Fonseca, VA; John-Kalarickal, J; Surampudi, PN, 2009) |
| "Type 2 diabetes mellitus has become an enormous and worldwide healthcare problem that is almost certain to worsen." | ( Nauck, MA, 2009) |
| "Known treatments of type 2 diabetes mellitus have limitations such as weight gain, and hypoglycaemias." | ( Verspohl, EJ, 2009) |
| "Type 2 diabetes mellitus has become an enormous and worldwide healthcare problem that is almost certain to worsen." | ( Nauck, MA, 2009) |
| "Patients with type 2 diabetes mellitus have a high risk of developing cardiovascular (CV) disease." | ( Annemans, L; Marbaix, S; Scheen, A; Van Gaal, L; Webb, K, 2010) |
| "Type 2 diabetes mellitus has become a world wide extended disease, and while insulin insensitivity is an early phenomenon partly related to obesity, pancreas beta-cell function declines gradually over time already before the onset of clinical hyperglycaemia." | ( Polakof, S, 2010) |
| "The prevalence of type 2 diabetes mellitus has reached epidemic proportions." | ( Nadeau, DA, 2010) |
| "The incidence of type 2 diabetes mellitus has markedly increased worldwide over the past decades." | ( Fritsche, A; Häring, HU; Machicao, F; Müssig, K; Staiger, H, 2010) |
| "Clinical studies in Type 2 diabetes mellitus have shown that the effects of metformin go beyond improving HbA(1c) and include reductions in cardiovascular endpoints." | ( Boyle, JG; McKay, GA; Salt, IP, 2010) |
| "Type 2 diabetes mellitus has been associated with an increased risk of hepatic, pancreatic, colon, endometrial, breast, and bladder cancer." | ( Cripps, R; McFarland, MS, 2010) |
| "Recently, T2DM (Type 2 diabetes mellitus) has been identified as a risk factor for AD." | ( Hölscher, C, 2011) |
| "Type 2 diabetes mellitus has been associated with an increased cancer risk, which can be modified by specific hypoglycemic drugs." | ( Benso, A; Bo, S; Durazzo, M; Ghigo, E, 2012) |
| "Type 2 diabetes mellitus has been associated with obesity, metabolic syndrome, cardiovascular diseases and cancer." | ( Castro, MM; López-Larrubia, P; Metelo, AM; Pérez-Carro, R, 2012) |
| "The prevalence of type 2 diabetes mellitus has reached epidemic proportions." | ( Paisley, AJ; Paisley, AN; Rao-Balakrishna, P; Soran, H; Yadav, R; Younis, N, 2013) |
| "The prevalence of type 2 diabetes mellitus has reached epidemic proportions worldwide." | ( Afroze, D; Bhat, RA; Ganai, BA; Hameed, I; Masoodi, SR; Naykoo, NA, 2013) |
| "Patients with type 2 diabetes mellitus have an increased risk of chronic liver disease (CLD) such as non-alcoholic fatty liver disease and steatohepatitis, and about one-third of cirrhotic patients have diabetes." | ( Scheen, AJ, 2014) |
| "The dyslipidemia of type 2 diabetes mellitus has multiple etiologies and impairs lipoprotein functionality, thereby increasing risk for cardiovascular disease." | ( Brinck, JW; Brulhart-Meynet, MC; Eriksson, M; Frias, MA; Hoffstedt, J; James, RW; Jornayvaz, FR; Kwak, BR; Lauer, E; Löfgren, P; Morel, S; Pataky, Z; Pramfalk, C; Prost, JC; Thomas, A; van Eck, M, 2016) |
| "Hyperglycemia in type 2 diabetes mellitus has been linked to non-alcoholic fatty liver disease, which can progress to inflammation, fibrosis/cirrhosis, and hepatocellular carcinoma." | ( Ballinger, KR; Davidson, MD; Khetani, SR, 2016) |
| "Individuals with type 2 diabetes mellitus have lower night-time serum melatonin levels and increased risk of comorbid sleep disturbances compared with healthy individuals." | ( Forrestel, AC; Miedlich, SU; Sellix, MT; Wittlin, SD; Yurcheshen, M, 2017) |
| "Many patients with type 2 diabetes mellitus have heart failure and it is important to know about the safety of new treatments for diabetes in these individuals." | ( Bolli, GB; Kothny, W; Kozlovski, P; Krum, H; Lewsey, JD; Lukashevich, V; McMurray, JJV; Ponikowski, P, 2018) |
| "The prevalence of type 2 diabetes mellitus has been increasing worldwide and more than two thirds of the patients may develop diabetic nephropathy (DN)." | ( Bai, L; Chen, X; Li, Y; Meng, X; Qin, Y; Xu, Y; Zhang, Q, 2018) |
| "Type 2 diabetes mellitus has become a growing epidemic and therefore efficient treatment strategies that target its management are needed." | ( Elisaf, MS; Filippatos, TD; Rizos, CV, 2018) |
| "Patients with type 2 diabetes mellitus have an increased risk of fracture despite normal or increased bone mineral density (BMD)." | ( Chen, YI; Cui, J; Goodarzi, MO; Guo, X; Hsueh, WA; Kim, SM; Rhyu, J; Rotter, JI, 2018) |
| "Type 2 diabetes mellitus has become one of the most important public health concerns worldwide." | ( Aguayo-González, Á; Avila-Rojo, JA; Baquerizo-Burgos, JE; Coronel, MFC; Cuevas-Ramos, D; Gomez-Perez, FJ; Gómez-Sámano, MÁ; Gulias-Herrero, A; Molina-Botello, D; Palacios-Báez, L; Villanueva-Martinez, F; Wong-Campoverde, BD; Zentella-Dehesa, A, 2018) |
| "Type 2 diabetes mellitus has undergone a worldwide growth in incidence in the world and has now acquired epidemic status." | ( Ceretta, LB; Da Rocha, FR; Damiani, AP; de Andrade, VM; Fagundes, GE; Longaretti, LM; Macan, TP; Mendes, C; Pereira, M; Rohr, P; Silveira, PCL; Teixeira, JPF; Vilela, TC, 2019) |
| "Type 2 diabetes mellitus has long been recognized as a major risk factor for adverse atherosclerotic cardiovascular disease events; however, recent data indicate that heart failure is now emerging as the most common and morbid cardiovascular complication of type 2 diabetes mellitus." | ( Kosiborod, M; Nassif, ME, 2019) |
| "Obesity and type 2 diabetes mellitus have become a significant public health problem in the past decades." | ( Burlacu, A; Tilinca, MC; Tiuca, RA; Varga, A, 2021) |
| "type 2 diabetes mellitus has become a global public health crisis." | ( Ahmad, N; Ahmad, SB; Hassan, MR; Hayati, F; Ismail, N; Jamhari, MN; Jeffree, MS; Nawi, AM; Rahim, SSSA; Sharif, KY; Sufri, M; Zamzuri, MIA, 2021) |
| "Type 2 diabetes mellitus has been a major health issue with increasing morbidity and mortality due to macrovascular and microvascular complications." | ( Abualnaja, KM; Alhashmialameer, D; Batiha, GE; Khan, A; Khan, I; Manee, S; Mudassir, J; Shah, HS; Usman, F; Zaib, S, 2021) |
| "We also found that type 2 diabetes mellitus has a negative effect on recovery." | ( Krizsan, G; Prinz, G; Sallai, I; Skaliczki, G; Szeker, D; Veres, DS, 2022) |
| "Background: Type 2 diabetes mellitus has recently been identified as a mediator of neurodegeneration." | ( Khaza'ai, H; Md Razip, NN; Mohd Noor, S; Norazit, A; Nordin, N; Sakeh, NM, 2022) |
| "Patients with type 2 diabetes mellitus have a high cardiovascular risk due, in part, to abnormalities of high-density lipoprotein mediated cholesterol efflux." | ( Liu, W; Wang, HJ; Wang, JH; Xu, XN; Zhao, XS, 2023) |
| "The prevalence of type 2 diabetes mellitus has increased in the past decades." | ( Alaeddini, F; Boroumand, M; H Franco, O; Heidari, A; Jalali, A; Karimi, A; Masoudkabir, F; Oraii, A; Saadat, S; Sadeghian, S; Shafiee, A; Vasheghani-Farahani, A, 2022) |
| "Older adults with type 2 diabetes mellitus have an increased risk of fracture despite a paradoxically higher average bone mineral density." | ( Bain, J; Colón-Emeric, C; Ilkayeva, O; Lee, RH; Muehlbauer, M; Pieper, C; Wixted, D, 2023) |
| "In clinical terms, type 2 diabetes mellitus has been consistently associated with increased serum OPG concentrations." | ( Polyzos, SA; Vachliotis, ID, 2023) |
| Excerpt | Reference |
|---|
| "We suggest that treatment of type 2 diabetes mellitus with hypoglycemic sulfonylureas could improve insulin effects by inhibiting cellular transglutaminase activity." | ( Arroyo, J; Casamitjana, R; Casanovas, A; Coves, MJ; Gomis, R; Rivera, F; Sarto, A; Vilardell, E, 1988) |
| "Current agents for the treatment of Type 2 diabetes mellitus improve the metabolic profile but do not reinstate normality." | ( Bailey, CJ; Nattrass, M, 1999) |
| "Sulfonylureas are used to treat patients with type 2 diabetes mellitus when diet and exercise fail." | ( Gomis, R; Raptis, SA; Ravella, R, 2000) |
| "Optimal treatment for type 2 diabetes mellitus should aim to improve insulin resistance and the associated cardiovascular risk factors in addition to achieving glycaemic control." | ( Campbell, IW, 2000) |
| "Currently available oral agents for the treatment of type 2 diabetes mellitus include a variety of compounds from 5 different pharmacologic classes with differing mechanisms of action, adverse effect profiles, and toxicities." | ( Beattie, P; Harrigan, RA; Nathan, MS, 2001) |
| "Therefore, glibenclamide treatment of Type 2 diabetes mellitus may have hazardous cardiovascular effects when used under conditions of ischaemia." | ( Abbink, EJ; Jansen van Rosendaal, A; Lutterman, JA; Pickkers, P; Russel, FG; Smits, P; Tack, CJ, 2002) |
| "Chronic treatment of Type 2 diabetes mellitus with glimepiride or metformin has similar effects on vascular K(ATP) channels compared with chronic glibenclamide treatment." | ( Abbink, EJ; Jansen van Rosendaal, A; Lutterman, JA; Pickkers, P; Russel, FG; Smits, P; Tack, CJ, 2002) |
| "Prevention and treatment of type 2 diabetes mellitus (T2DM) and the metabolic syndrome represent a major clinical challenge, because effective strategies such as fat restriction and exercise are difficult to implement into diabetes treatment." | ( Roden, M; Stingl, H, 2004) |
| "Metformin is commonly prescribed to treat type 2 diabetes mellitus, however it is associated with the potentially lethal condition of lactic acidosis." | ( Cottrell, N; Green, B; Millican, S, 2004) |
| "Metformin is widely used for treating type 2 diabetes mellitus, but its actions are poorly understood." | ( Casauban, L; Farese, RV; Gomez-Daspet, J; Luna, V; Miura, A; Powe, JL; Rivas, J; Sajan, MP; Standaert, ML, 2006) |
| "Effective long-term treatment of Type 2 Diabetes Mellitus (T2DM) implies modification of the disease processes that cause this progressive disorder." | ( Danhof, M; de Winter, W; DeJongh, J; Eckland, D; Moules, I; Ploeger, B; Post, T; Urquhart, R, 2006) |
| "Rosiglitazone is widely used to treat patients with type 2 diabetes mellitus, but its effect on cardiovascular morbidity and mortality has not been determined." | ( Nissen, SE; Wolski, K, 2007) |
| "In the early treatment of type 2 diabetes mellitus (T2DM), the addition of a basal insulin, such as insulin glargine, to existing oral therapy can help patients attain recommended glycaemic control targets, including haemoglobin A(1c) (HbA(1c)) <7% and fasting blood glucose <5." | ( Raccah, D, 2008) |
| "The insulin treatment in type 2 diabetes mellitus (DM 2) is an explosive subject within health economics." | ( Fritsche, A, 2008) |
| "In animal models, treatment of type 2 diabetes mellitus rats with BBR lowered fasting blood glucose and fasting serum insulin, increased insulin sensitivity, and elevated InsR mRNA as well as PKC activity in the liver." | ( Jiang, JD; Kong, WJ; Li, ZR; Pan, HN; Shan, N; Si, SY; Song, DQ; Wang, YM; Wei, J; Xue, R; Yang, P; You, XF; Zhang, H; Zhao, LX; Zhao, W; Zhou, ZX, 2009) |
| "Known treatments of type 2 diabetes mellitus have limitations such as weight gain, and hypoglycaemias." | ( Verspohl, EJ, 2009) |
| "LSG is an effective adjunct in the treatment of type 2 diabetes mellitus in obese individuals." | ( Shah, PS; Shah, SS; Todkar, JS, 2010) |
| "A 65-year-old woman had been treated for type 2 diabetes mellitus, familial hypercholesterolemia and old myocardial infarction." | ( Miyamori, I; Suzuki, J; Takahashi, S; Zenimaru, Y, 2009) |
| "Sulphonylureas are widely used in the treatment of type 2 diabetes mellitus (T2DM)." | ( Heikkilä, P; Huupponen, R; Laine, K; Tirkkonen, T, 2010) |
| "Pioglitazone treatment in type 2 diabetes mellitus produced significant improvements in glycaemic control, plasma lipids, blood pressure and inflammation." | ( Alemdar, R; Aydin, M; Basar, C; Caglar, O; Ordu, S; Ozhan, H; Yalcin, S; Yazici, M, 2010) |
| "Pioglitazone treatment in type 2 diabetes mellitus produced significant improvements in measures of glycaemic control and diastolic ventricular function." | ( Alemdar, R; Aydin, M; Basar, C; Caglar, O; Ordu, S; Ozhan, H; Yalcin, S; Yazici, M, 2010) |
| "Metformin is widely used for the treatment of type 2 diabetes mellitus." | ( Arora, M; Day, RO; Doogue, MP; Duong, JK; Furlong, TJ; Graham, GG; Greenfield, JR; Greenup, LC; Kirkpatrick, CM; Punt, J; Ray, JE; Timmins, P; Williams, KM, 2011) |
| "Metformin is widely used for the treatment of type 2 diabetes mellitus." | ( Bober, J; Grzybowska, M; Olszewska, M, 2011) |
| "Primary goals in the treatment of type 2 diabetes mellitus (T2DM) include lowering blood glucose levels sufficiently to prevent micro- and macrovascular complications while limiting side effects, such as hypoglycemia and excessive weight gain." | ( Niswender, KD, 2011) |
| "Overall, 1121 patients treated for type 2 diabetes mellitus by 134 general practitioners were enrolled in this representative, national, cross-sectional survey and were followed retrospectively from the start of diabetes treatment." | ( Brändle, M; Gerber, PA; Keller, U; Lehmann, R; Spirk, D; Thoenes, M, 2011) |
| "Metformin represents the cornerstone of treatment for type 2 diabetes mellitus." | ( Maltezos, E; Mikhailidis, DP; Papanas, N, 2012) |
| "As it relates to specific treatment of type 2 diabetes mellitus, clinicians have traditionally initiated lifestyle intervention and progressed therapy using various drug treatments first as monotherapy and then as combination therapy throughout the course of the disease." | ( Cefalu, WT, 2012) |
| "Most of the drugs available to treat type 2 diabetes mellitus (T2DM) act either in the pancreas by increasing insulin secretion or in tissues such as the liver or muscle by improving insulin sensitivity." | ( Donato, J, 2012) |
| "The safety of insulin in the treatment of type 2 diabetes mellitus (T2DM) has recently undergone scrutiny." | ( Currie, CJ; Evans, M; Morgan, CL; Peters, JR; Poole, CD, 2013) |
| "One vital therapeutic approach for the treatment of type 2 diabetes mellitus is the use of agents that can decrease postprandial hyperglycaemia by inhibiting carbohydrate digesting enzymes." | ( Ahmad, M; Ali, RB; Asmawi, MZ; Atangwho, IJ; Kuar, N; Mahmud, R, 2013) |
| "RE is intended for use for the treatment of type 2 diabetes mellitus (T2DM) as monotherapy and in combination with existing therapies." | ( Dobbins, RL; Hussey, EK; James, CD; Kapur, A; O'Connor-Semmes, R; Polli, JW; Rafferty, B; Tao, W, 2013) |
| "Sitagliptin has been widely used in the treatment of type 2 diabetes mellitus (T2DM); however, the therapeutic efficacy of sitagliptin remains inconclusive in randomized controlled studies on T2DM in which metformin has served as a control." | ( Du, Q; Liang, YY; Wang, YJ; Wu, B; Yang, S; Zhao, YY, 2013) |
| "Exenatide has been widely used for the treatment of type 2 diabetes mellitus." | ( Cai, Y; Huang, X; Liu, Z; Ma, L; Tao, A; Wei, L; Yuan, W, 2013) |
| "It has already been approved for the treatment of type 2 diabetes mellitus, but its underlying mechanisms of action are not fully understood." | ( Wang, D; Wang, Y; Xiang, D; Yuan, YX; Zhu, ZQ, 2014) |
| "These attributes make GLP-1 agonists a treatment option in type 2 diabetes mellitus (T2DM)." | ( Bolli, GB; Monnier, L; Owens, DR, 2013) |
| "MTT was applied to previously untreated Type 2 Diabetes Mellitus (T2DM) subjects." | ( Fujioka, Y; Inoue, K; Izawa, S; Kato, M; Matsuzawa, K; Nakanishi, R; Ohkura, H; Ohkura, T; Shiochi, H; Sumi, K; Taniguchi, S; Yamamoto, K; Yamamoto, N, 2013) |
| "Current strategies for the treatment of type 2 diabetes mellitus promote individualized plans to achieve target glucose levels on a patient-by-patient basis while minimizing treatment related risks." | ( Corathers, SD; Peavie, S; Salehi, M, 2013) |
| "Metformin is an established first-line treatment for type 2 diabetes mellitus (T2DM) patients, but intensification of oral anti-diabetes therapy is usually required over time." | ( Bader, G; Dworak, M; Göke, R; Gruenberger, JB, 2014) |
| "Recent advances in therapies for the treatment of type 2 diabetes mellitus (T2DM) have led to the development of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), which, unlike insulin and sulphonylurea, are effective, with a low risk of hypoglycaemia." | ( Bolli, GB; Owens, DR, 2014) |
| "Oral antihyperglycemic drugs used to treat type 2 diabetes mellitus (T2DM) vary in safety and tolerability." | ( Davidson, JA, 2014) |
| "GLP-1 mimetics are used for the treatment of type 2 diabetes mellitus." | ( Brock, B; Gejl, M; Gjedde, A; Rungby, J, 2014) |
| "Several drugs are available for the treatment of type 2 diabetes mellitus (T2DM), but few patients achieve and maintain glycaemic control without weight gain and hypoglycaemias." | ( Pafili, K; Papanas, N, 2014) |
| "Metformin is considered first-line treatment for type 2 diabetes mellitus." | ( Ahmedani, BK; González Burchard, E; Lanfear, DE; Padhukasahasram, B; Peterson, EL; Wells, KE; Williams, LK, 2014) |
| "FGF-21 is a potential candidate for the treatment of type 2 diabetes mellitus." | ( Li, D; Liu, M; Qi, J; Ren, G; Sun, G; Wu, Y; Ye, X; Yu, D; Zhao, J; Zhu, S, 2013) |
| "Established treatments for type 2 diabetes mellitus (T2DM) have side effects that limit their use in specific populations." | ( Barnett, AH, 2015) |
| "Liraglutide has been widely used in the treatment of type 2 diabetes mellitus (T2DM), however, the results of a number of randomized placebo-controlled trials on the effects of liraglutide for the treatment of T2DM have varied." | ( Du, Q; Han, P; Wang, YJ; Yang, S; Zhao, YY, 2014) |
| "In the treatment of type 2 diabetes mellitus, we found that berberine with lifestyle intervention tended to lower the level of FPG, PPG and HbA1c than lifestyle intervention alone or placebo; the same as berberine combined with oral hypoglycaemics to the same hypoglycaemics; but there was no statistical significance between berberine and oral hypoglycaemics." | ( Dong, F; Fan, J; Lan, J; Sun, G; Yan, Z; Zhao, Y; Zheng, W, 2015) |
| "Published guidelines for treatment of type 2 diabetes mellitus (T2DM) agree on initial pharmacotherapy." | ( Baltz, JC; Bouchard, JR; Lian, J; Meah, YA; Moretz, DC; Slabaugh, SL; Stacy, JN; Xu, Y, 2015) |
| "In the treatment of type 2 diabetes mellitus (T2DM), a relatively new class of oral agents inhibits sodium-glucose cotransporter 2 (SGLT2), reducing reabsorption of filtered glucose and increasing urinary glucose excretion." | ( Dailey, G, 2015) |
| "Metformin is a widely used drug in the treatment of type 2 diabetes mellitus (T2DM)." | ( Bettencourt, N; Fontes-Carvalho, R; Gama, V; Ladeiras-Lopes, R; Leite-Moreira, A; Sampaio, F, 2015) |
| "This antihyperglycemic treatment for type 2 diabetes mellitus (DM) has attracted increased clinical attention not only for its antihyperglycemic action but also for its potential extrapancreatic effects." | ( Hieshima, K; Jinnouchi, H; Jinnouchi, T; Kajiwara, K; Kurinami, N; Matsui, K; Miyamoto, F; Sugiyama, S; Suzuki, T; Yoshida, A, 2015) |
| "32 normal and 75 patients with untreated type 2 diabetes mellitus were enrolled in this study." | ( Ilyas, S; Saboor, M, 2015) |
| "It may be a potential target for the treatment of type 2 diabetes mellitus and lipid disorders." | ( Jiang, Q; Liu, SN; Peng, J; Shen, ZF, 2015) |
| "Small peptides are approved as treatments for type 2 diabetes mellitus and may have utility in metabolic diseases." | ( Chism, JP; Gruenloh, CJ; Johnson, SL; Lin, J; Nunez, DJ; Vlasakakis, G; Yao, X, 2015) |
| "In statin-treated men with type 2 diabetes mellitus, ERN decreased plasma Lp(a) concentrations by decreasing the production of apo(a) and Lp(a)-apoB-100." | ( Barrett, PH; Chan, DC; Hamilton, SJ; Marcovina, SM; McCormick, SP; Ooi, EM; Pang, J; Tenneti, VS; Watts, GF, 2015) |
| "It is widely used for the treatment of type 2 diabetes mellitus, and administered by subcutaneous injection once daily." | ( Flint, A; Ingwersen, SH; Jacobsen, LV; Olsen, AK, 2016) |
| "In the treatment of type 2 diabetes mellitus, it is very important to develop therapeutics with prolonged circulation half-life." | ( Chen, X; Gao, S; Jacobson, O; Kiesewetter, DO; Lang, L; Liu, Y; Ma, Q; Ma, Y; Wang, G; Zhang, H; Zhu, L, 2016) |
| "Anti-hyperglycemic treatments for type 2 diabetes mellitus that induce hyperinsulinemia (i." | ( De Souza, A; Khawaja, KI; Masud, F; Saif, MW, 2016) |
| "Incretin-based therapies in the treatment of type 2 diabetes mellitus are associated with significant improvements in glycemic control, which are accompanied by a beneficial impact on atherosclerosis." | ( Basiak, M; Belowski, D; Bołdys, A; Bułdak, RJ; Bułdak, Ł; Machnik, G; Okopień, B; Łabuzek, K, 2016) |
| "Metformin is a basic drug used for the treatment of type 2 diabetes mellitus." | ( Borbély, Z, 2016) |
| "Metformin is a biguanide used in the treatment of type 2 diabetes mellitus and obesity." | ( Arenas, M; Cabre, N; Camps, J; Garcia-Heredia, A; Hernandez-Aguilera, A; Joven, J; Luciano-Mateo, F, 2016) |
| "Metformin is a first-line drug for treating type 2 diabetes mellitus, yet its mechanism remains only partially understood and controversial." | ( Chen, QT; Liu, T; Liu, ZQ; Luo, DQ; Song, XM; Teng, JT; Zhou, K, 2016) |
| "Biguanides are a drug of choice for the treatment of type 2 diabetes mellitus." | ( Fujita, M; Godo, S; Kudo, D; Kushimoto, S; Nomura, R; Shimokawa, H; Yoshida, Y, 2017) |
| "GKAs offer a novel approach for the treatment of Type 2 Diabetes Mellitus (T2DM) and as such have garnered much attention." | ( Addona, G; Berger, JP; Campbell, B; Chen, HS; Chen, Z; Eiermann, GJ; Elowe, NH; Farrer, BT; Feng, W; Fu, Q; Kats-Kagan, R; Kavana, M; Lin, S; Malkani, S; McMasters, DR; Mitra, K; Myers, RW; Pachanski, MJ; Parmee, ER; Tong, X; Trujillo, ME; Xu, J; Xu, L; Zhang, B; Zhang, F; Zhang, R, 2017) |
| "However, their comparative efficacy in treating type 2 diabetes mellitus (T2DM) in class I obese patients specifically in Indian has not been studied yet." | ( Bhandari, M; Kumar, R; Mathur, W; Mishra, A, 2017) |
| "Choices for the treatment of type 2 diabetes mellitus (T2DM) have multiplied as our understanding of the underlying pathophysiologic defects has evolved." | ( Thrasher, J, 2017) |
| "exendin-4, are used for the treatment of type 2 diabetes mellitus." | ( Cai, Y; Culhane, KJ; DeVree, BT; Liu, Y; Sunahara, RK; Yan, ECY; Yang, Y, 2017) |
| "Metformin treatment for type 2 diabetes mellitus (T2DM) can be limited by gastrointestinal (GI) adverse events (AEs), resulting in treatment discontinuation." | ( Feng, B; Ji, L; Li, Q; Li, W; Li, X; Li, Y; Liang, L; Liang, Z; Lin, M; Lin, S; Liu, J; Liu, Y; Luo, Y; Ma, L; Ma, T; Qu, S; Song, W; Wang, J; Xi, S; Xu, H; Yang, J; Yang, Y; Zeng, J; Zhu, D, 2018) |
| "Metformin constitutes first-line treatment of type 2 diabetes mellitus." | ( Aharaz, A; Beck-Nielsen, H; Hallas, J; Henriksen, DP; Lassen, AT; Pottegård, A, 2018) |
| "To provide a more effective treatment of type 2 diabetes mellitus (T2DM), this study aims to compare different efficacies of six kinds of hypoglycemic drugs based on metformin, including glimepiride, pioglitazone, exenatide, glibenclamide, rosiglitazone, and vildagliptin, in T2DM by a network meta-analysis that were verified by randomized-controlled trials (RCTs)." | ( Chen, SH; Liu, XN; Peng, Y; Sun, QY, 2019) |
| "As the next generation for the treatment of type 2 diabetes mellitus (T2DM), GPR119 agonist has been intensively studied by pharmaceutical companies and a lot of patents have been applied by them." | ( Matsumoto, K; Shimada, T; Yoshitomi, T, 2018) |
| "Pharmacotherapy used to treat type 2 diabetes mellitus (T2DM) is facing a paradigm shift in clinical practice with recent cardiovascular (CV) outcome trials having a substantial impact on drug prescription with treatment having a more tailored approach." | ( De Ponti, F; Marchesini, G; Mazzotti, A; Poluzzi, E; Raschi, E, 2018) |
| "Liraglutide is now the first-line treatment for type 2 diabetes mellitus (T2DM) with promise, according to recent reports, to mitigate the fatty degeneration of the liver." | ( Du, HM; Feng, PP; Gong, JP; Li, Z; Zhao, ZB; Zhu, W, 2019) |
| "Metformin is first-line treatment of type 2 diabetes mellitus and reduces cardiovascular events in patients with insulin resistance and type 2 diabetes." | ( Brøsen, K; Feddersen, S; Gormsen, LC; Grønbaek, H; Hamilton-Dutoit, SJ; Heebøll, S; Jakobsen, S; Jessen, N; Munk, OL; Pedersen, SB; Sundelin, EIO; Vendelbo, MH, 2019) |
| "Metformin (MET) is used as first-line treatment for type 2 diabetes mellitus but has been shown to have pleiotropic effects that have expanded its use to various conditions." | ( Le, S; Lee, GC, 2019) |
| "Metformin is commonly used for the treatment of type 2 diabetes mellitus." | ( Ham, YR; Jeong, WJ; Oh, SK; Ryu, S; Son, SH; You, YH, 2019) |
| "Metformin is used for the treatment of type 2 diabetes mellitus and has shown therapeutic effects in preclinical models of other pathologies, such as cancer and autoimmune diseases." | ( Caserta, CA; Lefoulon, F; Marcucci, F; Romeo, E; Rumio, C, 2020) |
| "Metformin is the first-line treatment for type 2 diabetes mellitus (T2DM), but many patients either cannot tolerate it or cannot achieve glycemic control with metformin alone, so treatment with other glucose-lowering agents in combination with metformin is frequently required." | ( Alva, H; Aravind, SR; Asirvatham, A; Balamurugan, R; Barkate, H; Chawla, M; Dharmalingam, M; Gaikwad, R; Goyal, R; Kadam, P; Katare, S; Kodgule, R; Mohan, B; Paramesh, S; Pendse, A; Shembalkar, J; Suryawanshi, S; Tandon, M; Thacker, H; Vaidyanathan, S, 2020) |
| "Exenatide is widely used in the treatment of type 2 diabetes mellitus (T2DM) because of its established effect on lowering glucose and promotion of weight loss." | ( Li, X; Ling, H; Lu, Q; Lv, D; Wang, T; Wang, X; Yin, X; Zhang, F, 2020) |
| "Amongst newer agents available for treatment of type 2 diabetes mellitus (T2DM), sodium-glucose cotransporter-2 (SGLT2) inhibitors have garnered much attention in contemporary clinical practice due to observed benefits on cardiovascular and kidney outcomes among patients with T2DM, as reported in large randomized controlled trials (RCT)." | ( Chertow, GM; Jardine, MJ; Mahaffey, KW; Rhee, JJ, 2020) |
| "Empagliflozin is approved to treat adults with type 2 diabetes mellitus (T2DM) insufficiently controlled by diet and exercise." | ( Clark, D; Iliev, H; Kaspers, S; Kinduryte Schorling, O; Lee, J; Zwiener, I, 2020) |
| "Metformin is the drug of choice in the treatment of type 2 diabetes mellitus." | ( Bolívar, S; Mendoza, X; Mendoza-Torres, E; Noriega, L; Ortega, S; Osorio, E; Rosales, W, 2021) |
| "Sulfonylureas are commonly used to treat type 2 diabetes mellitus." | ( Bilker, WB; Brensinger, CM; Dawwas, GK; Dhopeshwarkar, N; Flory, JH; Gagne, JJ; Hennessy, S; Leonard, CE; Soprano, SE, 2020) |
| "paliurus), has the ability to treat type 2 diabetes mellitus (T2DM), but cannot be digested by our digestive system." | ( Chen, H; Wang, D; Wang, W; Wu, N; Yan, L; Yao, Y, 2020) |
| "Metformin has benefit as a first-line treatment for type 2 diabetes mellitus." | ( Cho, YY; Kang, MJ; Kim, SW; Lee, BW; Lee, S; Lee, YH; Song, SO; Suh, SH; You, JH, 2020) |
| "Metformin is the drug of choice in the treatment of type 2 diabetes mellitus." | ( Gregorová, J; Kovačič, M; Linhartová, A; Murínová, I, 2020) |
| "Metformin as first-line treatment in type 2 diabetes mellitus (T2 D) shows benefits in terms of reducing cardiovascular events, but the risk of a lactic acidosis as a serious adverse event especially in patients with decreased renal function is still relevant." | ( Eisert, A; Freitag, M; Masur, S, 2021) |
| "Metformin has been used to treat patients with type 2 diabetes mellitus (T2DM), and animal and clinical studies have reported therapeutic effects of metformin in Alzheimer's disease (AD)." | ( Ando, Y; Inoue, Y; Masuda, T; Misumi, Y; Ueda, M, 2021) |
| "A promising approach for treating type 2 diabetes mellitus (T2DM) is to target the Peroxisome Proliferator-Activated Receptor γ (PPARγ) transcription factor, which regulates the expression of proteins critical for T2DM." | ( Bruning, JB; Frkic, RL; Richter, K, 2021) |
| "Current drugs for treating type 2 diabetes mellitus (T2DM) are based on the use of gastrointestinal hormones." | ( Kaneko, S, 2021) |
| "Current drugs for treating type 2 diabetes mellitus (T2DM) are based on the use of gastrointestinal hormones." | ( Kaneko, S, 2021) |
| "The number of adults treated for type 2 diabetes mellitus increased from 1,867 (2." | ( Im, YJ; Jin, HY; Kim, EY; Kim, YJ; Lee, KA; Park, TS, 2021) |
| "GLP-1 receptor agonists approved for treating Type 2 diabetes mellitus and obesity have received attention as a potential anti-addiction treatment." | ( Fink-Jensen, A; Klausen, MK; Thomsen, M; Wortwein, G, 2022) |
| "The therapeutic arsenal for treating type 2 diabetes mellitus (T2DM) has been enriched recently with the inclusion of type 1 glucagon-like peptide (GLP-1)." | ( Mandarim-de-Lacerda, CA; Spezani, R, 2022) |
| "Biguanide is an ideal drug for the treatment of type 2 diabetes mellitus." | ( Jimura, F; Kachi, N; Tamaki, H; Tsushima, H, 2022) |
| "Metformin is the first-line drug to treat type 2 diabetes mellitus." | ( Carpinelli, AR; Lucena, CF; Muscara, MN; Teixeira, SA; Valle, MMR; Vilas-Boas, EA, 2022) |
| "metformin monotherapy in the treatment of type 2 diabetes mellitus (T2DM)." | ( Cao, L; Ding, Y; Dong, F; Li, Y; Lin, M; Lin, S; Liu, Y; Qu, Y, 2022) |
| "Metformin is a widely used drug for the treatment of type 2 diabetes mellitus with a known ability to lower blood glucose levels." | ( Fernandez, F; Landis, D; Nugent, K; Sutter, A, 2022) |
| "Tight control of glycemia is a major treatment goal for type 2 diabetes mellitus (T2DM)." | ( Beguinot, F; Botti, G; Cabaro, S; Collina, F; Formisano, P; Leone, A; Longo, M; Miele, C; Napoli, R; Nicolò, A; Nigro, C; Panarese, I; Prevenzano, I, 2022) |
| "Metformin is the first-line treatment used for type 2 diabetes mellitus for more than 60 years." | ( Claisse, G; Crepet, F; Delavenne, X; Demaretz, L; Fanton-D'Andon, C; Gonzalo, P; Herda, A; Launay, M; Mariat, C; Marin, C, 2022) |
| "Metformin is a first-line drug for treating type 2 diabetes mellitus (T2DM) and one of the most commonly prescribed drugs in the world." | ( Fei, E; Li, N; Zhou, T, 2022) |
| "Semaglutide was used to treat type 2 diabetes mellitus (T2DM) combined with NAFLD mice for 12 weeks." | ( Fang, P; Hu, K; Kong, D; Li, L; Li, R; She, D; Xu, W; Xue, Y; Ye, Z; Zhang, K; Zhou, Y; Zong, G, 2022) |
| "Metformin is at the forefront of the treatment of type 2 diabetes mellitus (DM2)." | ( Rahman, F; Tuba, S, 2022) |
| "Semaglutide was approved for treatment of type 2 diabetes mellitus (T2DM) and chronic weight management in obesity or overweight adults." | ( Ding, Y; He, X; Liu, Y; Shu, Y; Wu, P; Zhang, Q, 2022) |
| "Metformin is the first-line oral treatment for type 2 diabetes mellitus and is prescribed to more than 150 million people worldwide." | ( Andersson, AM; Kjær, KH; Kristensen, DM; Lindahl-Jacobsen, R; Mathiesen, ER; Skakkebæk, NE; Tavlo, M, 2022) |
| "Metformin is widely used to treat type 2 diabetes mellitus (T2DM) individuals." | ( Jayaram, P; Mallya, S; Nagri, SK; Prabhu, NB; Rai, PS; Sharma, AR; Umakanth, S; Vohra, M, 2023) |
| "Metformin is widely used to treat type 2 diabetes mellitus (T2DM) individuals." | ( Jayaram, P; Mallya, S; Nagri, SK; Prabhu, NB; Rai, PS; Sharma, AR; Umakanth, S; Vohra, M, 2023) |
| "Metformin is a drug for treating type 2 diabetes mellitus (T2DM)." | ( Feng, H; Fu, D; He, L; Huang, Y; Li, A; Li, J; Liu, Y; Zhao, H, 2023) |
| "Exenatide is a peptide used to treat type 2 diabetes mellitus." | ( Bryniarski, MA; Campos-Bilderback, SB; Chaves, LD; Fraser-McArthur, J; Molitoris, BA; Morris, ME; Ruszaj, DM; Sandoval, RM; Yacoub, R; Yee, BM, 2023) |
| "A 76-year-old woman undergoing insulin treatment for type 2 diabetes mellitus at our hospital was diagnosed with Clostridium difficile infection (CDI)." | ( Obata, K; Yamashita, S, 2023) |
| "In the treatment of type 2 diabetes mellitus (T2DM), comprehensive management of multiple risk factors, such as blood glucose, body weight, and lipids, is important to prevent disease progression." | ( Goto, T; Iijima, H; Inoue, K; Kawada, T; Kawarasaki, S; Nomura, W; Sawazaki, H; Takahashi, H, 2023) |
| "Drugs currently used to treat type 2 diabetes mellitus may have mechanisms of action that are relevant to the prevention and treatment of sarcopenia, for those with type 2 diabetes and those without diabetes." | ( Granic, A; Pearson, E; Robinson, SM; Sayer, AA; Witham, MD, 2023) |
| "PYY is a potential treatment for type 2 diabetes mellitus (T2DM) because of its ability to delay gastric emptying, reduce appetite, decrease weight, and lower blood glucose." | ( Binbin, G; Chen, W; Jing, H; Lidan, S; Qiang, Z, 2023) |
| "α-Glucosidase inhibition is an approved treatment for type 2 diabetes mellitus (T2DM)." | ( Bayati, B; Emamgholipour, Z; Faramarzi, MA; Firoozpour, L; Foroumadi, A; Hekmati, M; Hosseini, FS; Moghadam, MS; Mojtabavi, S; Peytam, F; Sadat-Ebrahimi, SE; Tehrani, MB, 2023) |
| "Metformin is commonly used for the treatment of type 2 diabetes mellitus." | ( Huang, R; Sun, W, 2023) |
| Drug | Indicated | Relationship Strength | Studies | Trials |
|---|
| acetylcarnitine | 0 | medium | 14 | 4 |
| dinitrochlorobenzene | 0 | low | 1 | 0 |
| alpha-hydroxyglutarate | 0 | low | 1 | 0 |
| 2,3-diphosphoglycerate | 0 | medium | 14 | 1 |
| 2-keto-4-methylvalerate | 0 | medium | 14 | 1 |
| protocatechuic acid | 0 | low | 5 | 0 |
| 3-hydroxyanthranilic acid | 0 | low | 2 | 0 |
| 3-hydroxyisobutyric acid | 0 | low | 3 | 0 |
| 3-hydroxykynurenine | 0 | low | 1 | 0 |
| acetoacetic acid | 0 | medium | 21 | 3 |
| phosphoserine | 0 | low | 12 | 0 |
| 3-phenylpropionic acid | 0 | low | 3 | 0 |
| n-carbamoyl-beta-alanine | 0 | low | 1 | 0 |
| gamma-aminobutyric acid | 0 | medium | 59 | 7 |
| 4-hydroxyphenylacetic acid | 0 | low | 2 | 0 |
| aminolevulinic acid | 0 | medium | 6 | 2 |
| 5-hydroxytryptophan | 0 | medium | 3 | 1 |
| acetic acid | 0 | medium | 26 | 6 |
| acetaldehyde | 0 | medium | 10 | 2 |
| acetone | 0 | medium | 25 | 1 |
| adenine | 0 | medium | 34 | 3 |
| agmatine | 0 | low | 5 | 0 |
| allantoin | 0 | medium | 4 | 2 |
| curdlan | 0 | low | 1 | 0 |
| ammonium hydroxide | 0 | medium | 15 | 4 |
| anthranilic acid | 0 | low | 1 | 0 |
| quinacrine | 0 | medium | 5 | 1 |
| beta-alanine | 0 | medium | 21 | 2 |
| benzene | 0 | medium | 2 | 1 |
| benzoic acid | 0 | low | 4 | 0 |
| betaine | 0 | medium | 36 | 7 |
| butyraldehyde | 0 | low | 1 | 0 |
| 2,3-butylene glycol | 0 | low | 1 | 0 |
| 1-butanol | 0 | low | 5 | 0 |
| butyric acid | 0 | medium | 16 | 2 |
| cadaverine | 0 | low | 3 | 0 |
| carbamates | 0 | medium | 267 | 102 |
| carbon monoxide | 0 | medium | 20 | 2 |
| aminooxyacetic acid | 0 | low | 1 | 0 |
| carnitine | 0 | medium | 137 | 33 |
| catechol | 0 | low | 4 | 0 |
| methane | 0 | medium | 10 | 2 |
| choline | 0 | medium | 48 | 7 |
| aconitic acid | 0 | low | 1 | 0 |
| citric acid, anhydrous | 0 | medium | 24 | 5 |
| chlorine | 0 | medium | 22 | 3 |
| hydrochloric acid | 0 | low | 1 | 0 |
| coumarin | 0 | low | 4 | 0 |
| salicylic acid | 0 | low | 17 | 0 |
| 3-cresol | 0 | low | 1 | 0 |
| 4-hydroxyphenylglyoxylic acid | 0 | low | 1 | 0 |
| octane | 0 | low | 3 | 0 |
| phloroglucinol | 0 | low | 5 | 0 |
| 2,3-diaminopropionic acid | 0 | low | 1 | 0 |
| gallic acid | 0 | medium | 20 | 1 |
| 4-nitrophenylphosphate | 0 | low | 1 | 0 |
| octanoic acid | 0 | medium | 5 | 2 |
| hydrogen sulfide | 0 | medium | 30 | 1 |
| 3-hydroxybutyric acid | 0 | medium | 96 | 22 |
| n(1)-methylnicotinamide | 0 | medium | 5 | 1 |
| guaiacol | 0 | low | 3 | 0 |
| hippuric acid | 0 | medium | 6 | 1 |
| 2-aminoadipic acid | 0 | low | 9 | 0 |
| methylmalonic acid | 0 | medium | 8 | 1 |
| n(g),n(g')-dimethyl-l-arginine | 0 | medium | 93 | 20 |
| malic acid | 0 | low | 6 | 0 |
| 3,4-dihydroxyphenylacetic acid | 0 | medium | 4 | 1 |
| aminocaproic acid | 0 | low | 2 | 0 |
| dibenzofuran | 0 | medium | 2 | 1 |
| creatine | 0 | medium | 67 | 12 |
| cytosine | 0 | medium | 28 | 1 |
| lactic acid | 0 | medium | 284 | 40 |
| diacetyl | 0 | low | 1 | 0 |
| dihydroxyacetone phosphate | 0 | low | 2 | 0 |
| dihydroxyacetone | 0 | medium | 4 | 1 |
| dimethylglycine | 0 | medium | 5 | 3 |
| dimethylamine | 0 | low | 1 | 0 |
| dimethyl sulfoxide | 0 | low | 5 | 0 |
| ethanolamine | 0 | low | 4 | 0 |
| formaldehyde | 0 | medium | 10 | 1 |
| gamma-butyrobetaine | 0 | low | 2 | 0 |
| hexachlorocyclohexane | 0 | low | 3 | 0 |
| glycine | 0 | medium | 127 | 16 |
| glyceraldehyde | 0 | low | 13 | 0 |
| glycerol | 0 | medium | 164 | 45 |
| alpha-glycerophosphoric acid | 0 | low | 7 | 0 |
| glycolaldehyde | 0 | low | 1 | 0 |
| glycolic acid | 0 | low | 1 | 0 |
| glyoxylic acid | 0 | low | 3 | 0 |
| glycocyamine | 0 | low | 1 | 0 |
| hydrogen cyanide | 0 | low | 1 | 0 |
| hydrogen carbonate | 0 | medium | 41 | 5 |
| dalteparin | 0 | medium | 9 | 1 |
| histamine | 0 | medium | 13 | 2 |
| hydrogen | 0 | medium | 26 | 8 |
| hydroquinone | 0 | low | 3 | 0 |
| imidazole | 0 | low | 3 | 0 |
| indole | 0 | medium | 3 | 1 |
| indole-3-acetaldehyde | 0 | low | 1 | 0 |
| indoleacetic acid | 0 | low | 1 | 0 |
| iodine | 0 | medium | 28 | 2 |
| dihydroxyphenylalanine | 0 | low | 1 | 0 |
| kynurenine | 0 | medium | 21 | 1 |
| pipecolic acid | 0 | low | 2 | 0 |
| 2,3,4,5-tetrahydroxypentanal | 0 | low | 1 | 0 |
| lipoamide | 0 | low | 1 | 0 |
| racemethionine | 0 | low | 3 | 0 |
| pyruvaldehyde | 0 | medium | 112 | 14 |
| methanol | 0 | medium | 18 | 1 |
| phytic acid | 0 | medium | 11 | 2 |
| inositol | 0 | medium | 191 | 70 |
| melatonin | 0 | medium | 141 | 11 |
| naphthalene | 0 | low | 1 | 0 |
| naringenin | 0 | low | 1 | 0 |
| nickel | 0 | medium | 13 | 1 |
| niacinamide | 0 | medium | 118 | 9 |
| nitrates | 0 | medium | 109 | 25 |
| nitric acid | 0 | low | 1 | 0 |
| nitroxyl | 0 | medium | 2 | 1 |
| nitrites | 0 | medium | 92 | 18 |
| nitrous oxide | 0 | low | 6 | 0 |
| hydroxide ion | 0 | low | 2 | 0 |
| hydroxypyruvic acid | 0 | low | 2 | 0 |
| orotic acid | 0 | low | 1 | 0 |
| oxalic acid | 0 | low | 2 | 0 |
| oxamic acid | 0 | low | 3 | 0 |
| 4-aminobenzoic acid | 0 | low | 4 | 0 |
| palmitic acid | 0 | medium | 156 | 9 |
| pentachlorophenol | 0 | low | 1 | 0 |
| phenanthrene | 0 | low | 1 | 0 |
| phenol | 0 | low | 3 | 0 |
| phenylacetic acid | 0 | low | 3 | 0 |
| phenethylamine | 0 | low | 1 | 0 |
| phosphoric acid | 0 | low | 1 | 0 |
| phosphoenolpyruvate | 0 | medium | 9 | 1 |
| phosphorylcholine | 0 | low | 9 | 0 |
| phosphorylethanolamine | 0 | low | 2 | 0 |
| phthalic acid | 0 | low | 19 | 0 |
| picolinic acid | 0 | medium | 36 | 11 |
| porphobilinogen | 0 | low | 2 | 0 |
| diphosphoric acid | 0 | low | 1 | 0 |
| pqq cofactor | 0 | low | 2 | 0 |
| propylene glycol | 0 | medium | 2 | 1 |
| 1-propanol | 0 | medium | 6 | 3 |
| propionic acid | 0 | medium | 12 | 2 |
| purine | 0 | low | 6 | 0 |
| putrescine | 0 | low | 2 | 0 |
| pyrazinamide | 0 | medium | 9 | 1 |
| pyrazole | 0 | low | 1 | 0 |
| pyridoxal phosphate | 0 | medium | 11 | 3 |
| pyridoxamine | 0 | medium | 13 | 3 |
| pyrogallol | 0 | low | 1 | 0 |
| pyruvic acid | 0 | medium | 54 | 3 |
| quinolinic acid | 0 | low | 2 | 0 |
| dimethyl sulfide | 0 | low | 1 | 0 |
| thiosulfates | 0 | low | 10 | 0 |
| sarcosine | 0 | medium | 8 | 3 |
| selenic acid | 0 | low | 4 | 0 |
| selenious acid | 0 | low | 2 | 0 |
| spermidine | 0 | low | 6 | 0 |
| spermine | 0 | low | 4 | 0 |
| succinic acid | 0 | medium | 16 | 3 |
| sulfur dioxide | 0 | medium | 4 | 1 |
| thiamine | 0 | medium | 52 | 18 |
| thymine | 0 | low | 19 | 0 |
| toluene | 0 | medium | 3 | 1 |
| trimethyloxamine | 0 | medium | 34 | 4 |
| trimethylamine | 0 | medium | 6 | 1 |
| tryptamine | 0 | low | 1 | 0 |
| uracil | 0 | medium | 205 | 84 |
| uric acid | 0 | medium | 652 | 69 |
| vanillin | 0 | low | 3 | 0 |
| xanthine | 0 | medium | 9 | 1 |
| isocitric acid | 0 | low | 1 | 0 |
| 4-iodo-2,5-dimethoxyphenylisopropylamine | 0 | low | 1 | 0 |
| 2-(6-(4-chlorophenoxy)hexyl)oxirane-2-carboxylic acid | 0 | low | 1 | 0 |
| ibotenic acid | 0 | low | 1 | 0 |
| normetanephrine | 0 | low | 3 | 0 |
| vanilmandelic acid | 0 | low | 1 | 0 |
| menthol | 0 | low | 2 | 0 |
| 1,2-dimethylhydrazine | 0 | low | 1 | 0 |
| 1,3-dipropyl-8-cyclopentylxanthine | 0 | low | 1 | 0 |
| pk 11195 | 0 | low | 1 | 0 |
| 1-(3-chlorophenyl)piperazine | 0 | low | 3 | 0 |
| 1-anilino-8-naphthalenesulfonate | 0 | medium | 215 | 25 |
| 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine | 0 | low | 1 | 0 |
| 14,15-epoxy-5,8,11-eicosatrienoic acid | 0 | low | 2 | 0 |
| n-(3-(aminomethyl)benzyl)acetamidine | 0 | low | 1 | 0 |
| 2,4,5-trichlorophenoxyacetic acid | 0 | low | 2 | 0 |
| 2,4-dichlorophenoxyacetic acid | 0 | low | 2 | 0 |
| 2,4-dinitrophenol | 0 | low | 6 | 0 |
| zopolrestat | 0 | medium | 3 | 1 |
| 3,4-methylenedioxyamphetamine | 0 | low | 3 | 0 |
| amitrole | 0 | low | 1 | 0 |
| 3-aminobenzamide | 0 | low | 2 | 0 |
| tramiprosate | 0 | low | 2 | 0 |
| 3-bromo-7-nitroindazole | 0 | low | 1 | 0 |
| 3-nitropropionic acid | 0 | low | 1 | 0 |
| 4-aminopyridine | 0 | low | 1 | 0 |
| 4-diphenylacetoxy-1,1-dimethylpiperidinium | 0 | low | 1 | 0 |
| homovanillic acid | 0 | low | 1 | 0 |
| phenytoin | 0 | medium | 8 | 3 |
| 5,8,11,14-eicosatetraynoic acid | 0 | low | 1 | 0 |
| 5-dimethylamiloride | 0 | low | 1 | 0 |
| 5-hydroxydecanoate | 0 | low | 1 | 0 |
| hydroxyindoleacetic acid | 0 | low | 5 | 0 |
| 5-iodo-2-(oxaloamino)benzoic acid | 0 | low | 1 | 0 |
| oxyquinoline | 0 | low | 1 | 0 |
| tacrine | 0 | low | 1 | 0 |
| 2,2'-azobis(2-amidinopropane) | 0 | low | 3 | 0 |
| acebutolol | 0 | medium | 1 | 1 |
| acemetacin | 0 | low | 1 | 0 |
| acephate | 0 | low | 1 | 0 |
| acetazolamide | 0 | medium | 12 | 4 |
| acetohexamide | 0 | low | 2 | 0 |
| acetyl-dl-leucine | 0 | low | 1 | 0 |
| adrenic acid | 0 | low | 1 | 0 |
| albendazole | 0 | medium | 6 | 3 |
| albuterol | 0 | medium | 4 | 1 |
| alendronate | 0 | medium | 18 | 4 |
| alfuzosin | 0 | low | 1 | 0 |
| alprazolam | 0 | medium | 2 | 1 |
| alrestatin | 0 | low | 1 | 0 |
| am 251 | 0 | low | 3 | 0 |
| am 580 | 0 | low | 1 | 0 |
| aminoglutethimide | 0 | low | 1 | 0 |
| pimagedine | 0 | medium | 30 | 1 |
| p-aminohippuric acid | 0 | low | 7 | 0 |
| theophylline | 0 | low | 5 | 0 |
| 2-aminothiazole | 0 | low | 1 | 0 |
| amiodarone | 0 | medium | 9 | 1 |
| dan 2163 | 0 | medium | 1 | 1 |
| amitriptyline | 0 | medium | 4 | 3 |
| amlexanox | 0 | medium | 2 | 1 |
| amobarbital | 0 | low | 1 | 0 |
| amosulalol | 0 | low | 1 | 0 |
| amoxapine | 0 | low | 1 | 0 |
| antipyrine | 0 | medium | 16 | 5 |
| acetovanillone | 0 | low | 7 | 0 |
| arecoline | 0 | low | 5 | 0 |
| arotinolol | 0 | low | 1 | 0 |
| atenolol | 0 | medium | 72 | 41 |
| atrazine | 0 | low | 4 | 0 |
| azathioprine | 0 | medium | 17 | 2 |
| azelaic acid | 0 | low | 1 | 0 |
| azosemide | 0 | low | 1 | 0 |
| aztreonam | 0 | low | 1 | 0 |
| baclofen | 0 | low | 1 | 0 |
| 2,2-bis(4-glycidyloxyphenyl)propane | 0 | low | 2 | 0 |
| bay-k-8644 | 0 | low | 4 | 0 |
| bencyclane | 0 | medium | 1 | 1 |
| bendroflumethiazide | 0 | medium | 6 | 4 |
| benzamide | 0 | low | 4 | 0 |
| benzbromarone | 0 | low | 5 | 0 |
| benzo(a)pyrene | 0 | medium | 5 | 1 |
| benzothiazide | 0 | medium | 2 | 1 |
| benzyl isothiocyanate | 0 | low | 1 | 0 |
| bepridil | 0 | medium | 1 | 1 |
| diminazene | 0 | low | 2 | 0 |
| betaxolol | 0 | medium | 1 | 1 |
| bay h 4502 | 0 | low | 1 | 0 |
| bisindolylmaleimide i | 0 | low | 3 | 0 |
| bisoprolol | 0 | medium | 17 | 5 |
| brotizolam | 0 | low | 1 | 0 |
| bu 224 | 0 | low | 1 | 0 |
| buflomedil | 0 | medium | 6 | 4 |
| buformin | 0 | medium | 10 | 1 |
| bunazosin | 0 | medium | 2 | 1 |
| bupivacaine | 0 | medium | 4 | 1 |
| busulfan | 0 | low | 1 | 0 |
| cacodylic acid | 0 | low | 2 | 0 |
| calmidazolium | 0 | low | 1 | 0 |
| camostat | 0 | low | 2 | 0 |
| camphor, (+-)-isomer | 0 | low | 1 | 0 |
| carbamazepine | 0 | medium | 8 | 1 |
| carteolol | 0 | low | 3 | 0 |
| carbonyl cyanide m-chlorophenyl hydrazone | 0 | medium | 6 | 1 |
| cefuroxime | 0 | low | 5 | 0 |
| celecoxib | 0 | medium | 6 | 1 |
| celiprolol | 0 | low | 1 | 0 |
| cetirizine | 0 | low | 1 | 0 |
| cetyltrimethylammonium ion | 0 | low | 1 | 0 |
| chelerythrine | 0 | low | 1 | 0 |
| chlorambucil | 0 | low | 1 | 0 |
| chloroquine | 0 | medium | 17 | 2 |
| chlorpheniramine | 0 | low | 1 | 0 |
| chlorpromazine | 0 | low | 2 | 0 |
| chlorpyrifos | 0 | low | 1 | 0 |
| chlorzoxazone | 0 | low | 3 | 0 |
| cifenline | 0 | low | 1 | 0 |
| ciclopirox | 0 | low | 2 | 0 |
| ciglitazone | 0 | low | 14 | 0 |
| cilostamide | 0 | low | 1 | 0 |
| cilostazol | 0 | medium | 50 | 21 |
| cimetidine | 0 | medium | 9 | 3 |
| eucalyptol | 0 | low | 1 | 0 |
| ciprofibrate | 0 | medium | 6 | 3 |
| ciprofloxacin | 0 | medium | 34 | 2 |
| cirazoline | 0 | low | 2 | 0 |
| cisapride | 0 | medium | 7 | 2 |
| citalopram | 0 | medium | 9 | 3 |
| clenbuterol | 0 | low | 1 | 0 |
| clofibrate | 0 | medium | 10 | 2 |
| clofibric acid | 0 | medium | 54 | 8 |
| clomipramine | 0 | low | 3 | 0 |
| clonazepam | 0 | low | 2 | 0 |
| clonidine | 0 | medium | 31 | 10 |
| 4-cresol | 0 | low | 3 | 0 |
| cyclopenthiazide | 0 | medium | 1 | 1 |
| cyclopentolate | 0 | low | 1 | 0 |
| cyproheptadine | 0 | low | 1 | 0 |
| dantrolene | 0 | low | 2 | 0 |
| dapi | 0 | low | 2 | 0 |
| dapsone | 0 | low | 12 | 0 |
| debrisoquin | 0 | medium | 3 | 1 |
| decanoic acid | 0 | low | 2 | 0 |
| deferiprone | 0 | low | 2 | 0 |
| deferoxamine | 0 | medium | 15 | 3 |
| dephostatin | 0 | low | 2 | 0 |
| nonivamide | 0 | low | 1 | 0 |
| amphetamine | 0 | low | 2 | 0 |
| diazepam | 0 | medium | 3 | 1 |
| diazinon | 0 | low | 2 | 0 |
| dibutyl phthalate | 0 | low | 3 | 0 |
| diclofenac | 0 | medium | 12 | 7 |
| dichlorodiphenyl dichloroethylene | 0 | low | 22 | 0 |
| ddt | 0 | low | 9 | 0 |
| dichlorvos | 0 | low | 1 | 0 |
| diethylcarbamazine | 0 | low | 2 | 0 |
| pentetic acid | 0 | medium | 6 | 1 |
| dilazep | 0 | medium | 3 | 1 |
| dimethadione | 0 | low | 1 | 0 |
| diphenhydramine | 0 | medium | 2 | 1 |
| diphenyleneiodonium | 0 | low | 2 | 0 |
| dipyridamole | 0 | medium | 35 | 7 |
| disopyramide | 0 | low | 4 | 0 |
| disulfiram | 0 | low | 3 | 0 |
| valproic acid | 0 | medium | 14 | 3 |
| racemetirosine | 0 | low | 1 | 0 |
| thiorphan | 0 | low | 2 | 0 |
| 2,3-dimethoxy-1,4-naphthoquinone | 0 | low | 1 | 0 |
| domperidone | 0 | medium | 5 | 2 |
| doxazosin | 0 | medium | 33 | 13 |
| econazole | 0 | low | 1 | 0 |
| embelin | 0 | low | 2 | 0 |
| emodin | 0 | medium | 6 | 1 |
| endosulfan | 0 | low | 1 | 0 |
| enflurane | 0 | low | 1 | 0 |
| eperisone | 0 | medium | 1 | 1 |
| erythrosine | 0 | low | 18 | 0 |
| ether | 0 | low | 4 | 0 |
| ethoxyquin | 0 | low | 1 | 0 |
| eicosapentaenoic acid ethyl ester | 0 | medium | 23 | 6 |
| etidronate | 0 | medium | 3 | 1 |
| brl 42810 | 0 | low | 1 | 0 |
| famotidine | 0 | low | 1 | 0 |
| carbonyl cyanide p-trifluoromethoxyphenylhydrazone | 0 | low | 3 | 0 |
| fendiline | 0 | low | 1 | 0 |
| fenfluramine | 0 | medium | 54 | 28 |
| fenoldopam | 0 | low | 2 | 0 |
| berotek | 0 | low | 2 | 0 |
| fentanyl | 0 | low | 4 | 0 |
| fenthion | 0 | low | 1 | 0 |
| fenvalerate | 0 | low | 1 | 0 |
| fexofenadine | 0 | low | 1 | 0 |
| flecainide | 0 | low | 1 | 0 |
| fluconazole | 0 | medium | 27 | 2 |
| flucytosine | 0 | low | 1 | 0 |
| fluphenazine | 0 | low | 2 | 0 |
| flumazenil | 0 | low | 7 | 0 |
| flunitrazepam | 0 | medium | 1 | 1 |
| fluorouracil | 0 | medium | 15 | 1 |
| fluoxetine | 0 | medium | 29 | 11 |
| fluphenazine depot | 0 | low | 2 | 0 |
| fluspirilene | 0 | low | 1 | 0 |
| flutamide | 0 | low | 4 | 0 |
| fomepizole | 0 | low | 1 | 0 |
| foscarnet | 0 | low | 1 | 0 |
| gabapentin | 0 | medium | 18 | 3 |
| gabexate | 0 | low | 3 | 0 |
| gentamicin | 0 | medium | 18 | 1 |
| 2,5-dihydroxybenzoic acid | 0 | low | 1 | 0 |
| glimepiride | 0 | medium | 543 | 284 |
| glutaral | 0 | low | 1 | 0 |
| glyphosate | 0 | low | 3 | 0 |
| go 6976 | 0 | low | 1 | 0 |
| guaifenesin | 0 | low | 3 | 0 |
| guanfacine | 0 | medium | 6 | 2 |
| guanidine | 0 | medium | 4 | 1 |
| 1-(5-isoquinolinesulfonyl)-2-methylpiperazine | 0 | medium | 7 | 1 |
| fasudil | 0 | medium | 7 | 1 |
| haloperidol | 0 | medium | 8 | 1 |
| hexamethonium | 0 | low | 1 | 0 |
| beta-thujaplicin | 0 | low | 1 | 0 |
| ethidium | 0 | low | 1 | 0 |
| hydroxyurea | 0 | low | 3 | 0 |
| hydroxyzine | 0 | low | 3 | 0 |
| hypericin | 0 | low | 2 | 0 |
| ibudilast | 0 | medium | 2 | 2 |
| ibuprofen | 0 | low | 6 | 0 |
| lidocaine | 0 | medium | 13 | 5 |
| idebenone | 0 | low | 2 | 0 |
| imipramine | 0 | medium | 3 | 1 |
| indirubin-3'-monoxime | 0 | low | 1 | 0 |
| indomethacin | 0 | medium | 21 | 4 |
| iodixanol | 0 | low | 1 | 0 |
| iohexol | 0 | medium | 12 | 1 |
| iopromide | 0 | low | 2 | 0 |
| iothalamic acid | 0 | medium | 6 | 2 |
| indolepropionic acid | 0 | medium | 7 | 1 |
| ipriflavone | 0 | low | 1 | 0 |
| 1-methyl-3-isobutylxanthine | 0 | low | 10 | 0 |
| isoflurane | 0 | medium | 16 | 3 |
| isoniazid | 0 | medium | 15 | 2 |
| 2-propanol | 0 | medium | 21 | 3 |
| propyphenazone | 0 | low | 1 | 0 |
| isoproterenol | 0 | low | 41 | 0 |
| isradipine | 0 | medium | 12 | 11 |
| itopride | 0 | medium | 1 | 1 |
| nsc 664704 | 0 | low | 1 | 0 |
| ketamine | 0 | medium | 6 | 1 |
| ketanserin | 0 | medium | 8 | 2 |
| ketoprofen | 0 | medium | 2 | 1 |
| ketorolac | 0 | low | 2 | 0 |
| ketotifen | 0 | medium | 1 | 1 |
| khellin | 0 | low | 2 | 0 |
| kinetin | 0 | low | 1 | 0 |
| kynurenic acid | 0 | low | 5 | 0 |
| labetalol | 0 | medium | 4 | 1 |
| lamotrigine | 0 | low | 1 | 0 |
| lansoprazole | 0 | medium | 5 | 1 |
| beta-lapachone | 0 | low | 1 | 0 |
| lauric acid | 0 | medium | 2 | 1 |
| leflunomide | 0 | low | 1 | 0 |
| letrozole | 0 | medium | 3 | 1 |
| lg 100268 | 0 | low | 4 | 0 |
| loperamide | 0 | low | 3 | 0 |
| lorazepam | 0 | low | 1 | 0 |
| loxoprofen | 0 | medium | 1 | 1 |
| 2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one | 0 | low | 16 | 0 |
| malathion | 0 | low | 1 | 0 |
| manidipine | 0 | medium | 19 | 14 |
| maprotiline | 0 | low | 1 | 0 |
| mazindol | 0 | medium | 1 | 1 |
| edaravone | 0 | medium | 5 | 1 |
| mebendazole | 0 | low | 3 | 0 |
| mefenamic acid | 0 | medium | 1 | 1 |
| memantine | 0 | medium | 9 | 3 |
| meperidine | 0 | low | 1 | 0 |
| mephenytoin | 0 | medium | 1 | 1 |
| mepivacaine | 0 | low | 1 | 0 |
| merbromin | 0 | low | 1 | 0 |
| mesalamine | 0 | low | 1 | 0 |
| methadone | 0 | medium | 4 | 1 |
| methazolamide | 0 | medium | 2 | 1 |
| nocodazole | 0 | low | 1 | 0 |
| methyl salicylate | 0 | medium | 1 | 1 |
| methylphenidate | 0 | low | 2 | 0 |
| metoclopramide | 0 | medium | 10 | 3 |
| metronidazole | 0 | medium | 30 | 8 |
| metyrapone | 0 | medium | 7 | 1 |
| mianserin | 0 | medium | 3 | 1 |
| miconazole | 0 | medium | 5 | 1 |
| midodrine | 0 | low | 1 | 0 |
| milrinone | 0 | medium | 1 | 1 |
| mirtazapine | 0 | medium | 2 | 1 |
| modafinil | 0 | low | 1 | 0 |
| molsidomine | 0 | low | 2 | 0 |
| moxisylyte | 0 | low | 1 | 0 |
| entinostat | 0 | low | 1 | 0 |
| myristicin | 0 | low | 1 | 0 |
| w 12 | 0 | medium | 2 | 1 |
| ethylmaleimide | 0 | low | 2 | 0 |
| clorgyline | 0 | low | 1 | 0 |
| deoxyepinephrine | 0 | medium | 1 | 1 |
| apnea | 0 | medium | 2 | 1 |
| nafamostat | 0 | low | 3 | 0 |
| activins | 0 | medium | 17 | 1 |
| nefazodone | 0 | low | 2 | 0 |
| neostigmine | 0 | low | 2 | 0 |
| nevirapine | 0 | low | 1 | 0 |
| nicardipine | 0 | medium | 15 | 7 |
| niclosamide | 0 | low | 8 | 0 |
| nifedipine | 0 | medium | 82 | 41 |
| nilvadipine | 0 | medium | 5 | 4 |
| nimodipine | 0 | medium | 3 | 1 |
| nisoldipine | 0 | medium | 19 | 11 |
| nitrendipine | 0 | medium | 20 | 14 |
| nitroglycerin | 0 | medium | 69 | 25 |
| norfenefrine | 0 | low | 1 | 0 |
| norfloxacin | 0 | low | 2 | 0 |
| nortriptyline | 0 | medium | 2 | 1 |
| ns 1619 | 0 | low | 1 | 0 |
| n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide | 0 | low | 2 | 0 |
| o(6)-benzylguanine | 0 | medium | 1 | 1 |
| octopamine | 0 | low | 2 | 0 |
| ofloxacin | 0 | medium | 11 | 1 |
| olprinone | 0 | low | 1 | 0 |
| ondansetron | 0 | medium | 1 | 1 |
| oxonic acid | 0 | low | 1 | 0 |
| oxidopamine | 0 | low | 2 | 0 |
| benoxinate | 0 | low | 1 | 0 |
| oxybutynin | 0 | medium | 9 | 3 |
| aminosalicylic acid | 0 | low | 1 | 0 |
| quinone | 0 | low | 1 | 0 |
| 4-nitrophenylacetic acid | 0 | low | 1 | 0 |
| palmidrol | 0 | medium | 4 | 1 |
| pamidronate | 0 | medium | 4 | 1 |
| papaverine | 0 | medium | 9 | 1 |
| patulin | 0 | low | 1 | 0 |
| pd 98059 | 0 | low | 10 | 0 |
| pentamidine | 0 | low | 2 | 0 |
| pentobarbital | 0 | low | 1 | 0 |
| pentoxifylline | 0 | medium | 40 | 21 |
| perhexiline | 0 | low | 4 | 0 |
| phenacetin | 0 | low | 1 | 0 |
| phenobarbital | 0 | medium | 9 | 3 |
| phenolsulfonphthalein | 0 | low | 3 | 0 |
| phentermine | 0 | medium | 23 | 4 |
| 4-phenylbutyric acid | 0 | low | 10 | 0 |
| oxophenylarsine | 0 | low | 1 | 0 |
| phenylbutazone | 0 | low | 3 | 0 |
| phenylmethylsulfonyl fluoride | 0 | low | 1 | 0 |
| phloretin | 0 | low | 7 | 0 |
| moxonidine | 0 | medium | 11 | 3 |
| picotamide | 0 | medium | 4 | 3 |
| pifithrin | 0 | low | 1 | 0 |
| pinacidil | 0 | low | 2 | 0 |
| pindolol | 0 | medium | 2 | 1 |
| piperazine | 0 | low | 4 | 0 |
| piracetam | 0 | low | 3 | 0 |
| pirenzepine | 0 | medium | 20 | 3 |
| piribedil | 0 | medium | 1 | 1 |
| potassium chloride | 0 | low | 19 | 0 |
| potassium iodide | 0 | low | 3 | 0 |
| 4-aminobenzoic acid | 0 | low | 2 | 0 |
| pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid | 0 | low | 1 | 0 |
| praziquantel | 0 | low | 3 | 0 |
| prazosin | 0 | medium | 15 | 4 |
| primaquine | 0 | low | 1 | 0 |
| probucol | 0 | medium | 35 | 11 |
| procainamide | 0 | low | 2 | 0 |
| procaine | 0 | low | 1 | 0 |
| procarbazine | 0 | low | 1 | 0 |
| proglumide | 0 | medium | 1 | 1 |
| propafenone | 0 | medium | 2 | 1 |
| proxymetacaine | 0 | low | 1 | 0 |
| propofol | 0 | medium | 17 | 4 |
| propranolol | 0 | medium | 23 | 5 |
| propyl gallate | 0 | low | 1 | 0 |
| protopine | 0 | low | 1 | 0 |
| protoporphyrin ix | 0 | low | 1 | 0 |
| pyridinolcarbamate | 0 | low | 1 | 0 |
| pyrimethamine | 0 | medium | 1 | 1 |
| resorcinol | 0 | low | 1 | 0 |
| rimantadine | 0 | low | 1 | 0 |
| risperidone | 0 | medium | 40 | 3 |
| ritanserin | 0 | low | 2 | 0 |
| ro 31-8220 | 0 | low | 2 | 0 |
| 4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone | 0 | low | 1 | 0 |
| rofecoxib | 0 | medium | 2 | 1 |
| rolipram | 0 | low | 1 | 0 |
| ropinirole | 0 | low | 1 | 0 |
| s-methylisothiopseudouronium | 0 | low | 1 | 0 |
| saccharin | 0 | medium | 9 | 2 |
| sanguinarine | 0 | low | 1 | 0 |
| sarpogrelate | 0 | medium | 13 | 7 |
| sb 202190 | 0 | low | 1 | 0 |
| suberoyl bis-hydroxamic acid | 0 | low | 1 | 0 |
| sebacic acid | 0 | medium | 3 | 1 |
| carbamylhydrazine | 0 | low | 2 | 0 |
| sevoflurane | 0 | medium | 10 | 1 |
| sibutramine | 0 | medium | 68 | 29 |
| linsidomine | 0 | low | 2 | 0 |
| sodium fluoride | 0 | medium | 5 | 1 |
| risedronic acid | 0 | low | 2 | 0 |
| sotalol | 0 | low | 1 | 0 |
| ponalrestat | 0 | medium | 7 | 6 |
| stearic acid | 0 | medium | 13 | 3 |
| imatinib | 0 | low | 1 | 0 |
| vorinostat | 0 | low | 1 | 0 |
| succinylcholine | 0 | low | 4 | 0 |
| sulfacetamide | 0 | low | 1 | 0 |
| sulfamerazine | 0 | low | 2 | 0 |
| sulfamethazine | 0 | medium | 3 | 1 |
| sulfamethoxazole | 0 | low | 2 | 0 |
| sulfanilamide | 0 | low | 1 | 0 |
| sulfaphenazole | 0 | low | 2 | 0 |
| sulfasalazine | 0 | low | 4 | 0 |
| sulfobromophthalein | 0 | low | 3 | 0 |
| sulpiride | 0 | medium | 6 | 1 |
| suramin | 0 | low | 2 | 0 |
| gatifloxacin | 0 | medium | 7 | 1 |
| tazarotene | 0 | low | 1 | 0 |
| 1,4-bis(2-(3,5-dichloropyridyloxy))benzene | 0 | low | 1 | 0 |
| tegafur | 0 | low | 1 | 0 |
| temozolomide | 0 | medium | 3 | 1 |
| terbutaline | 0 | low | 3 | 0 |
| terfenadine | 0 | low | 2 | 0 |
| tetraethylammonium | 0 | low | 3 | 0 |
| krypton | 0 | medium | 1 | 1 |
| thalidomide | 0 | medium | 4 | 2 |
| theobromine | 0 | low | 5 | 0 |
| thioridazine | 0 | low | 1 | 0 |
| thiotepa | 0 | low | 1 | 0 |
| thiram | 0 | low | 1 | 0 |
| ticlopidine | 0 | medium | 105 | 33 |
| tilorone | 0 | low | 1 | 0 |
| tinidazole | 0 | low | 1 | 0 |
| tioconazole | 0 | low | 1 | 0 |
| tolmetin | 0 | low | 1 | 0 |
| n,n,n',n'-tetrakis(2-pyridylmethyl)ethylenediamine | 0 | low | 1 | 0 |
| tranexamic acid | 0 | low | 2 | 0 |
| trapidil | 0 | medium | 1 | 1 |
| trazodone | 0 | low | 1 | 0 |
| triazolam | 0 | low | 2 | 0 |
| trichlormethiazide | 0 | medium | 2 | 1 |
| triclosan | 0 | low | 2 | 0 |
| trientine | 0 | medium | 3 | 1 |
| trifluoperazine | 0 | low | 1 | 0 |
| trigonelline | 0 | low | 11 | 0 |
| trimethoprim | 0 | low | 1 | 0 |
| troglitazone | 0 | medium | 354 | 107 |
| tropicamide | 0 | medium | 4 | 1 |
| thenoyltrifluoroacetone | 0 | low | 2 | 0 |
| tyramine | 0 | low | 3 | 0 |
| urapidil | 0 | medium | 2 | 2 |
| 5-methylurapidil | 0 | low | 1 | 0 |
| urethane | 0 | low | 1 | 0 |
| vinca | 0 | low | 1 | 0 |
| wb 4101 | 0 | low | 1 | 0 |
| pirinixic acid | 0 | low | 14 | 0 |
| xanthurenic acid | 0 | low | 4 | 0 |
| ici 204,219 | 0 | low | 1 | 0 |
| fr 74366 | 0 | low | 1 | 0 |
| zinc chloride | 0 | medium | 2 | 1 |
| zolpidem | 0 | medium | 4 | 1 |
| zonisamide | 0 | low | 2 | 0 |
| zopiclone | 0 | low | 1 | 0 |
| mitomycin | 0 | low | 2 | 0 |
| corticosterone | 0 | medium | 58 | 1 |
| estriol | 0 | low | 1 | 0 |
| phentolamine | 0 | low | 9 | 0 |
| sorbitol | 0 | medium | 114 | 37 |
| alloxan | 0 | medium | 39 | 1 |
| thymidine | 0 | low | 13 | 0 |
| benzimidazole | 0 | low | 3 | 0 |
| hydroxyproline | 0 | low | 20 | 0 |
| thyroxine | 0 | medium | 117 | 10 |
| methacetin | 0 | low | 1 | 0 |
| carbachol | 0 | low | 15 | 0 |
| norethindrone acetate | 0 | medium | 6 | 5 |
| spironolactone | 0 | medium | 84 | 36 |
| prednisolone acetate | 0 | low | 1 | 0 |
| aldosterone | 0 | medium | 165 | 46 |
| penicillamine | 0 | low | 2 | 0 |
| tetrahydrocortisol | 0 | medium | 3 | 2 |
| tetrahydrocortisone | 0 | low | 1 | 0 |
| estrone | 0 | low | 14 | 0 |
| fluprednisolone | 0 | low | 1 | 0 |
| methylprednisolone acetate | 0 | medium | 5 | 3 |
| oxandrolone | 0 | low | 1 | 0 |
| androsterone | 0 | low | 1 | 0 |
| dehydroepiandrosterone | 0 | medium | 58 | 7 |
| penicillin g | 0 | medium | 7 | 1 |
| pilocarpine | 0 | low | 5 | 0 |
| dimethylphenylpiperazinium iodide | 0 | low | 1 | 0 |
| triiodothyronine | 0 | medium | 79 | 6 |
| diethylnitrosamine | 0 | low | 3 | 0 |
| carbon tetrachloride | 0 | low | 3 | 0 |
| alanine | 0 | medium | 172 | 16 |
| serine | 0 | medium | 87 | 1 |
| aspartic acid | 0 | medium | 53 | 1 |
| allyl isothiocyanate | 0 | low | 2 | 0 |
| cyanides | 0 | low | 1 | 0 |
| physostigmine | 0 | low | 2 | 0 |
| sucrose | 0 | medium | 153 | 32 |
| chlordan | 0 | low | 4 | 0 |
| tubocurarine | 0 | low | 2 | 0 |
| apomorphine | 0 | medium | 2 | 1 |
| aminopyrine | 0 | low | 2 | 0 |
| methyltestosterone | 0 | low | 1 | 0 |
| tetrabenazine | 0 | medium | 8 | 1 |
| adenosine diphosphate | 0 | medium | 83 | 11 |
| uridine | 0 | medium | 6 | 1 |
| uridine monophosphate | 0 | low | 1 | 0 |
| uridine diphosphate | 0 | low | 6 | 0 |
| bromodeoxyuridine | 0 | low | 8 | 0 |
| galactose | 0 | medium | 25 | 5 |
| carbostyril | 0 | medium | 19 | 1 |
| phenylephrine | 0 | medium | 44 | 3 |
| levodopa | 0 | low | 7 | 0 |
| edetic acid | 0 | medium | 18 | 3 |
| phenylethyl alcohol | 0 | low | 7 | 0 |
| phlorhizin | 0 | low | 66 | 0 |
| adenosine monophosphate | 0 | low | 48 | 0 |
| methicillin | 0 | low | 4 | 0 |
| 4-deoxypyridoxine | 0 | low | 1 | 0 |
| cloxacillin | 0 | low | 4 | 0 |
| methylene blue | 0 | medium | 7 | 4 |
| bretylium tosylate | 0 | low | 1 | 0 |
| methacholine chloride | 0 | medium | 7 | 1 |
| dimethylnitrosamine | 0 | low | 1 | 0 |
| androstenedione | 0 | medium | 14 | 1 |
| uridine triphosphate | 0 | low | 3 | 0 |
| methionine | 0 | medium | 78 | 3 |
| phenylalanine | 0 | medium | 227 | 80 |
| desoxycorticosterone | 0 | low | 5 | 0 |
| colchicine | 0 | medium | 19 | 3 |
| cytidine | 0 | low | 3 | 0 |
| cytidine triphosphate | 0 | low | 1 | 0 |
| strophanthidin | 0 | low | 1 | 0 |
| oxacillin | 0 | low | 1 | 0 |
| cycloheximide | 0 | low | 3 | 0 |
| ficusin | 0 | low | 1 | 0 |
| egtazic acid | 0 | low | 2 | 0 |
| chloroform | 0 | low | 2 | 0 |
| fluocinolone acetonide | 0 | low | 2 | 0 |
| norethindrone | 0 | medium | 14 | 11 |
| 17-alpha-hydroxyprogesterone | 0 | medium | 5 | 1 |
| tubercidin | 0 | low | 2 | 0 |
| ampicillin | 0 | low | 8 | 0 |
| mannitol | 0 | medium | 13 | 1 |
| cytarabine | 0 | low | 2 | 0 |
| ornithine | 0 | medium | 17 | 3 |
| asparagine | 0 | medium | 16 | 1 |
| histidine | 0 | medium | 26 | 3 |
| medroxyprogesterone acetate | 0 | medium | 16 | 6 |
| valine | 0 | medium | 172 | 60 |
| threonine | 0 | low | 50 | 0 |
| alizarin | 0 | low | 1 | 0 |
| cordycepin | 0 | low | 3 | 0 |
| tryptophan | 0 | medium | 91 | 4 |
| isoleucine | 0 | medium | 48 | 3 |
| ethylene | 0 | medium | 1 | 1 |
| acetylene | 0 | low | 2 | 0 |
| methylamine | 0 | low | 2 | 0 |
| boranes | 0 | medium | 1 | 1 |
| propane | 0 | low | 1 | 0 |
| ethylamine | 0 | low | 1 | 0 |
| acetonitrile | 0 | low | 2 | 0 |
| carbon disulfide | 0 | medium | 1 | 1 |
| ethylene oxide | 0 | low | 1 | 0 |
| propylene oxide | 0 | low | 2 | 0 |
| tert-butylhydroperoxide | 0 | low | 4 | 0 |
| trichloroacetic acid | 0 | low | 3 | 0 |
| perflutren | 0 | medium | 1 | 1 |
| triamcinolone acetonide | 0 | medium | 45 | 17 |
| phencyclidine | 0 | medium | 8 | 2 |
| divinyl sulfone | 0 | low | 1 | 0 |
| tromethamine | 0 | medium | 4 | 2 |
| quinic acid | 0 | low | 2 | 0 |
| 3-mercaptopropionic acid | 0 | low | 1 | 0 |
| pentaerythritol tetranitrate | 0 | low | 1 | 0 |
| isoprene | 0 | medium | 4 | 1 |
| acrylamide | 0 | low | 1 | 0 |
| chloroacetamide | 0 | low | 1 | 0 |
| acrylic acid | 0 | medium | 2 | 1 |
| isobutyric acid | 0 | low | 1 | 0 |
| methacrylamide | 0 | low | 1 | 0 |
| dichloroacetic acid | 0 | low | 4 | 0 |
| pantothenic acid | 0 | low | 2 | 0 |
| bisphenol a | 0 | medium | 64 | 2 |
| bis(4-hydroxyphenyl)sulfone | 0 | low | 4 | 0 |
| taurocholic acid | 0 | low | 6 | 0 |
| rhodamine b | 0 | medium | 3 | 1 |
| pyridoxic acid | 0 | low | 3 | 0 |
| methylprednisolone | 0 | medium | 39 | 6 |
| rotenone | 0 | low | 4 | 0 |
| phthalimide | 0 | low | 1 | 0 |
| propoxycaine | 0 | low | 1 | 0 |
| fluorene | 0 | low | 1 | 0 |
| carbazole | 0 | low | 2 | 0 |
| isosorbide dinitrate | 0 | medium | 7 | 2 |
| penicillanic acid | 0 | low | 9 | 0 |
| D-arabinopyranose | 0 | low | 1 | 0 |
| xylitol | 0 | medium | 9 | 1 |
| n-vinyl-2-pyrrolidinone | 0 | medium | 5 | 1 |
| anthranilamide | 0 | low | 1 | 0 |
| picric acid | 0 | low | 1 | 0 |
| thymol | 0 | low | 1 | 0 |
| 2-phenylphenol | 0 | medium | 1 | 1 |
| xanthone | 0 | low | 1 | 0 |
| quinoxalines | 0 | medium | 15 | 4 |
| quinoline | 0 | low | 4 | 0 |
| isatin | 0 | low | 1 | 0 |
| 2-naphthylamine | 0 | low | 1 | 0 |
| tolonium chloride | 0 | low | 1 | 0 |
| diphenyl | 0 | low | 5 | 0 |
| xanthenes | 0 | low | 6 | 0 |
| propylparaben | 0 | medium | 4 | 1 |
| butylparaben | 0 | low | 1 | 0 |
| bis(1-piperidylthiocarbonyl)disulfide | 0 | low | 1 | 0 |
| monosulfiram | 0 | low | 1 | 0 |
| benzothiophene | 0 | low | 2 | 0 |
| benzothiazole | 0 | low | 1 | 0 |
| dilactide | 0 | low | 3 | 0 |
| 4-butyrolactone | 0 | low | 4 | 0 |
| 2,4-di-tert-butylphenol | 0 | low | 1 | 0 |
| 2,4-dinitroaniline | 0 | low | 1 | 0 |
| furaldehyde | 0 | medium | 6 | 1 |
| pyrrolidonecarboxylic acid | 0 | medium | 13 | 1 |
| trehalose | 0 | medium | 9 | 1 |
| methylparaben | 0 | low | 2 | 0 |
| ethylbenzene | 0 | medium | 2 | 1 |
| styrene | 0 | low | 2 | 0 |
| 4-vinylpyridine | 0 | low | 1 | 0 |
| benzylamine | 0 | low | 3 | 0 |
| phenylhydrazine | 0 | low | 1 | 0 |
| quinuclidines | 0 | low | 2 | 0 |
| cyclamic acid | 0 | low | 1 | 0 |
| triclocarban | 0 | low | 1 | 0 |
| pyridostigmine bromide | 0 | medium | 3 | 3 |
| 4-benzylphenol | 0 | low | 1 | 0 |
| 4-bromophenyl phenyl ether | 0 | low | 1 | 0 |
| boric acid | 0 | medium | 1 | 1 |
| ethyl bromoacetate | 0 | medium | 1 | 1 |
| caprolactam | 0 | medium | 1 | 1 |
| citronellal | 0 | low | 1 | 0 |
| dimethyl succinate | 0 | low | 6 | 0 |
| epichlorohydrin | 0 | medium | 14 | 4 |
| acrolein | 0 | low | 7 | 0 |
| allylamine | 0 | medium | 57 | 18 |
| acrylonitrile | 0 | medium | 1 | 1 |
| allyl alcohol | 0 | low | 1 | 0 |
| glyoxal | 0 | medium | 21 | 1 |
| 2-methylpentane | 0 | low | 1 | 0 |
| methyl malonate | 0 | medium | 1 | 1 |
| 3,5-xylenol | 0 | low | 1 | 0 |
| cyclohexanol | 0 | medium | 8 | 2 |
| 4-methylmorpholine | 0 | low | 1 | 0 |
| pentane | 0 | low | 2 | 0 |
| pyrroles | 0 | medium | 314 | 158 |
| thiophenes | 0 | medium | 296 | 93 |
| isopropyl myristate | 0 | medium | 1 | 1 |
| cyclohexene | 0 | low | 2 | 0 |
| piperidine | 0 | low | 1 | 0 |
| morpholine | 0 | low | 1 | 0 |
| behenic acid | 0 | low | 4 | 0 |
| phenformin | 0 | medium | 47 | 8 |
| propylene | 0 | low | 1 | 0 |
| triphenyl phosphate | 0 | low | 2 | 0 |
| linalyl acetate | 0 | low | 1 | 0 |
| tetradifon | 0 | low | 1 | 0 |
| diethylhexyl phthalate | 0 | medium | 10 | 1 |
| maltol | 0 | low | 4 | 0 |
| hexachlorobenzene | 0 | low | 3 | 0 |
| framycetin | 0 | medium | 1 | 1 |
| tetralin | 0 | low | 1 | 0 |
| dianisidine | 0 | low | 1 | 0 |
| dibenzoylmethane | 0 | low | 1 | 0 |
| ethyl-p-hydroxybenzoate | 0 | low | 1 | 0 |
| dibenzothiazyl disulfide | 0 | low | 1 | 0 |
| cyclopentanone | 0 | low | 1 | 0 |
| vanillic acid | 0 | low | 3 | 0 |
| suramin sodium | 0 | low | 1 | 0 |
| pyrazolanthrone | 0 | low | 6 | 0 |
| iodoantipyrine | 0 | low | 1 | 0 |
| meglumine | 0 | medium | 8 | 2 |
| iodohippuric acid | 0 | low | 2 | 0 |
| uridine diphosphate glucose | 0 | low | 10 | 0 |
| 1-naphthylamine | 0 | medium | 1 | 1 |
| syringaldehyde | 0 | low | 1 | 0 |
| 2-naphthol | 0 | medium | 1 | 1 |
| dextrothyroxine | 0 | low | 1 | 0 |
| shikimic acid | 0 | low | 1 | 0 |
| nitrilotriacetic acid | 0 | low | 1 | 0 |
| protocatechualdehyde | 0 | low | 1 | 0 |
| citronellol | 0 | medium | 1 | 1 |
| ethyl acetate | 0 | low | 8 | 0 |
| guanidine carboxamide | 0 | low | 2 | 0 |
| 2-hydroxypyridine | 0 | low | 1 | 0 |
| hexanoic acid | 0 | low | 2 | 0 |
| monomethylarsonic acid | 0 | low | 1 | 0 |
| pregnenolone | 0 | low | 3 | 0 |
| 3-o-methylglucose | 0 | medium | 26 | 4 |
| copper phthalocyanine | 0 | low | 1 | 0 |
| diphenhydramine hydrochloride | 0 | medium | 3 | 1 |
| nafcillin | 0 | low | 1 | 0 |
| 1,2-dihydroxybenzene-3,5-disulfonic acid disodium salt | 0 | low | 1 | 0 |
| potassium cyanide | 0 | medium | 1 | 1 |
| cycloguanil | 0 | low | 1 | 0 |
| dydrogesterone | 0 | low | 3 | 0 |
| catechin | 0 | medium | 88 | 9 |
| thiamine pyrophosphate | 0 | medium | 4 | 2 |
| homoarginine | 0 | low | 2 | 0 |
| perylene | 0 | low | 2 | 0 |
| quinazolines | 0 | medium | 150 | 46 |
| acridines | 0 | low | 2 | 0 |
| indazoles | 0 | medium | 8 | 1 |
| benzofuran | 0 | low | 1 | 0 |
| benzoxazoles | 0 | medium | 17 | 2 |
| azulene | 0 | low | 1 | 0 |
| adamantane | 0 | medium | 649 | 233 |
| cyclopentane | 0 | medium | 9 | 2 |
| isoxazoles | 0 | medium | 21 | 1 |
| oxazoles | 0 | medium | 79 | 26 |
| thiazoles | 0 | medium | 810 | 165 |
| 1,2,4-triazole | 0 | low | 1 | 0 |
| pyrimidine | 0 | low | 4 | 0 |
| pyrazines | 0 | medium | 586 | 222 |
| nitroblue tetrazolium | 0 | medium | 8 | 1 |
| methylphenazonium methosulfate | 0 | low | 1 | 0 |
| ephedrine | 0 | low | 1 | 0 |
| hydrazine | 0 | medium | 9 | 3 |
| thiocyanate | 0 | low | 1 | 0 |
| chlormadinone acetate | 0 | medium | 1 | 1 |
| benzoylarginine-2-naphthylamide | 0 | low | 1 | 0 |
| paraoxon | 0 | low | 4 | 0 |
| dexamethasone 21-phosphate | 0 | medium | 3 | 1 |
| evans blue | 0 | low | 2 | 0 |
| monocrotaline | 0 | low | 2 | 0 |
| testosterone enanthate | 0 | low | 2 | 0 |
| aminophylline | 0 | medium | 3 | 1 |
| azacitidine | 0 | low | 1 | 0 |
| triflusal | 0 | medium | 2 | 1 |
| 6-aminonicotinamide | 0 | low | 1 | 0 |
| perfluorooctanoic acid | 0 | medium | 9 | 1 |
| perfluorodecanoic acid | 0 | low | 2 | 0 |
| carbutamide | 0 | low | 1 | 0 |
| glymidine | 0 | low | 1 | 0 |
| perflexane | 0 | low | 1 | 0 |
| aminoimidazole carboxamide | 0 | medium | 36 | 2 |
| kynuramine | 0 | low | 1 | 0 |
| betamethasone | 0 | medium | 12 | 2 |
| fluorometholone | 0 | low | 1 | 0 |
| cyproterone acetate | 0 | medium | 4 | 1 |
| lithocholic acid | 0 | low | 7 | 0 |
| 2-aminopurine | 0 | low | 1 | 0 |
| cyanogen | 0 | low | 1 | 0 |
| hydantoins | 0 | medium | 7 | 1 |
| fluorobenzenes | 0 | medium | 68 | 33 |
| homocystine | 0 | medium | 5 | 2 |
| propiolic acid | 0 | low | 1 | 0 |
| methylguanidine | 0 | low | 1 | 0 |
| limestone | 0 | medium | 6 | 3 |
| oxamide | 0 | low | 1 | 0 |
| chenodeoxycholic acid | 0 | medium | 18 | 3 |
| glycocholic acid | 0 | low | 1 | 0 |
| fusarium | 0 | low | 7 | 0 |
| boldine | 0 | low | 1 | 0 |
| rhein | 0 | low | 5 | 0 |
| osthol | 0 | low | 1 | 0 |
| reticulin | 0 | low | 1 | 0 |
| cytisine | 0 | low | 3 | 0 |
| bicuculline | 0 | low | 2 | 0 |
| flavanone | 0 | low | 1 | 0 |
| thymoquinone | 0 | medium | 5 | 1 |
| 1,4-benzodioxan | 0 | low | 1 | 0 |
| indoline | 0 | low | 1 | 0 |
| isomaltose | 0 | medium | 14 | 8 |
| carvacrol | 0 | low | 4 | 0 |
| 4-hydroxyphenylethanol | 0 | low | 3 | 0 |
| caprolactone | 0 | low | 1 | 0 |
| azetidine | 0 | low | 1 | 0 |
| isovaleric acid | 0 | low | 1 | 0 |
| alpha-aminopyridine | 0 | medium | 23 | 6 |
| thiazolidines | 0 | medium | 113 | 37 |
| margaric acid | 0 | low | 4 | 0 |
| arachidic acid | 0 | low | 3 | 0 |
| cyanogen bromide | 0 | low | 1 | 0 |
| oleanolic acid | 0 | medium | 61 | 13 |
| hematoxylin | 0 | low | 9 | 0 |
| podophyllotoxin | 0 | low | 2 | 0 |
| noramidopyrine | 0 | medium | 1 | 1 |
| hesperidin | 0 | medium | 18 | 4 |
| medroxyprogesterone | 0 | medium | 4 | 2 |
| androstenediol | 0 | low | 1 | 0 |
| dihydrotestosterone | 0 | medium | 12 | 4 |
| luminol | 0 | medium | 4 | 2 |
| pyridoxamine dihydrochloride | 0 | medium | 2 | 2 |
| flavone | 0 | low | 1 | 0 |
| gluconic acid | 0 | medium | 3 | 1 |
| copper gluconate | 0 | medium | 5 | 1 |
| azomycin | 0 | medium | 4 | 1 |
| uridine diphosphate n-acetylglucosamine | 0 | low | 6 | 0 |
| syringic acid | 0 | low | 1 | 0 |
| thiamine monophosphate | 0 | low | 1 | 0 |
| tropolone | 0 | low | 1 | 0 |
| 4,6-dinitro-o-cresol | 0 | low | 1 | 0 |
| methamphetamine | 0 | low | 2 | 0 |
| uranyl acetate | 0 | low | 1 | 0 |
| butyramide | 0 | low | 1 | 0 |
| maleimide | 0 | low | 2 | 0 |
| muscone | 0 | medium | 1 | 1 |
| malondialdehyde | 0 | medium | 395 | 90 |
| myristic acid | 0 | low | 10 | 0 |
| trinitrobenzenesulfonic acid | 0 | low | 1 | 0 |
| eosine yellowish-(ys) | 0 | medium | 10 | 1 |
| resazurin | 0 | low | 1 | 0 |
| 1-naphthylisothiocyanate | 0 | low | 1 | 0 |
| hematoporphyrin | 0 | low | 1 | 0 |
| neutral red | 0 | low | 1 | 0 |
| lithium carbonate | 0 | low | 5 | 0 |
| glycylglycine | 0 | low | 1 | 0 |
| lignoceric acid | 0 | low | 3 | 0 |
| 18-hydroxycorticosterone | 0 | low | 3 | 0 |
| glycerylphosphorylcholine | 0 | medium | 5 | 2 |
| 2-hydroxybutyric acid | 0 | medium | 8 | 1 |
| malachite green | 0 | low | 1 | 0 |
| congo red | 0 | low | 5 | 0 |
| 3-hydroxyflavone | 0 | medium | 28 | 7 |
| diphenylamine | 0 | medium | 2 | 1 |
| allyl sulfide | 0 | low | 1 | 0 |
| megestrol acetate | 0 | low | 2 | 0 |
| 2,2-dimethylbutyric acid | 0 | low | 1 | 0 |
| glycopyrrolate | 0 | medium | 4 | 1 |
| methyl pyruvate | 0 | low | 2 | 0 |
| galactitol | 0 | medium | 1 | 1 |
| 2-anthramine | 0 | low | 1 | 0 |
| 4-carboxybenzaladehyde | 0 | low | 1 | 0 |
| ethylurea | 0 | low | 1 | 0 |
| 4-hydroxypyridine | 0 | low | 1 | 0 |
| c.i. 42510 | 0 | low | 4 | 0 |
| Berberine chloride (TN) | 0 | low | 2 | 0 |
| clopamide | 0 | low | 1 | 0 |
| erythromycin | 0 | medium | 14 | 4 |
| isocaproic acid | 0 | low | 1 | 0 |
| dehydroepiandrosterone sulfate | 0 | medium | 55 | 7 |
| mannoheptulose | 0 | low | 4 | 0 |
| homoserine | 0 | low | 1 | 0 |
| 2-piperidone | 0 | medium | 29 | 19 |
| hempa | 0 | low | 1 | 0 |
| methylnitrosourea | 0 | low | 1 | 0 |
| dodecanedioic acid | 0 | medium | 5 | 2 |
| diphenyliodonium | 0 | low | 1 | 0 |
| ethylnitrosourea | 0 | low | 3 | 0 |
| 4-nitrophenyl acetate | 0 | low | 1 | 0 |
| ethyl gallate | 0 | low | 1 | 0 |
| diphenyl disulfide | 0 | low | 1 | 0 |
| benzoylarginine nitroanilide | 0 | low | 1 | 0 |
| diphenoxylate | 0 | low | 1 | 0 |
| hexafluoroisopropanol | 0 | low | 3 | 0 |
| deoxycytidine | 0 | medium | 11 | 1 |
| deoxyuridine | 0 | low | 2 | 0 |
| canrenone | 0 | medium | 2 | 2 |
| cytidine diphosphate choline | 0 | low | 1 | 0 |
| pentadecanoic acid | 0 | low | 6 | 0 |
| heptachlor epoxide | 0 | low | 1 | 0 |
| endosulfan sulfate | 0 | low | 1 | 0 |
| deoxycytidine monophosphate | 0 | low | 2 | 0 |
| ethambutol | 0 | medium | 8 | 1 |
| nicotinamide mononucleotide | 0 | low | 2 | 0 |
| tetramethylpyrazine | 0 | low | 5 | 0 |
| decabromobiphenyl ether | 0 | low | 1 | 0 |
| 3,4-dihydroxyacetophenone | 0 | low | 1 | 0 |
| calcium peroxide | 0 | medium | 1 | 1 |
| durapatite | 0 | medium | 3 | 1 |
| manganese dioxide | 0 | medium | 1 | 1 |
| zinc oxide | 0 | medium | 9 | 2 |
| arsenic trioxide | 0 | low | 3 | 0 |
| sorbitan monostearate | 0 | low | 1 | 0 |
| vancomycin | 0 | medium | 25 | 2 |
| glycyrrhizic acid | 0 | medium | 10 | 1 |
| d-alpha tocopherol | 0 | medium | 283 | 98 |
| tocopherols | 0 | medium | 17 | 6 |
| 3,5-di-tert-butyl-4-hydroxybenzoic acid | 0 | low | 1 | 0 |
| 1,2-epoxyhexane | 0 | medium | 1 | 1 |
| pseudouridine | 0 | low | 2 | 0 |
| selenomethionine | 0 | low | 7 | 0 |
| vincamine | 0 | low | 2 | 0 |
| methyl tert-butyl ether | 0 | low | 1 | 0 |
| laudanosine | 0 | low | 1 | 0 |
| norfenfluramine | 0 | low | 1 | 0 |
| ethyldimethylaminopropyl carbodiimide | 0 | low | 2 | 0 |
| tetrachloroisophthalonitrile | 0 | medium | 1 | 1 |
| s,n,n'-tripropylthiocarbamate | 0 | medium | 31 | 7 |
| 2-tert-butylhydroquinone | 0 | low | 3 | 0 |
| amiloride | 0 | medium | 10 | 4 |
| pimozide | 0 | low | 1 | 0 |
| 2,2'-dithiobis(5-nitropyridine) | 0 | low | 1 | 0 |
| azetidyl-2-carboxylic acid | 0 | medium | 10 | 7 |
| diallyl disulfide | 0 | low | 1 | 0 |
| mofebutazone | 0 | low | 1 | 0 |
| phenethyl isothiocyanate | 0 | medium | 2 | 1 |
| fluorescein | 0 | medium | 18 | 1 |
| fast green fcf | 0 | low | 1 | 0 |
| heneicosanoic acid | 0 | low | 1 | 0 |
| methylprednisolone hemisuccinate | 0 | low | 2 | 0 |
| thioflavin t | 0 | low | 18 | 0 |
| flupenthixol | 0 | low | 1 | 0 |
| fucose | 0 | low | 2 | 0 |
| cme-carbodiimide | 0 | low | 1 | 0 |
| sulfur hexafluoride | 0 | low | 4 | 0 |
| uridine diphosphate glucuronic acid | 0 | low | 1 | 0 |
| acadesine | 0 | low | 5 | 0 |
| n,n-dimethylacrylamide | 0 | low | 1 | 0 |
| squaric acid | 0 | low | 1 | 0 |
| uridine diphosphate galactose | 0 | low | 1 | 0 |
| stavudine | 0 | medium | 3 | 1 |
| hydroxyhexamide | 0 | low | 1 | 0 |
| 2,2-bis(bromomethyl)-1,3-propanediol | 0 | low | 1 | 0 |
| fluorescein-5-isothiocyanate | 0 | low | 4 | 0 |
| sabinene | 0 | medium | 28 | 6 |
| mannose | 0 | medium | 16 | 3 |
| dithiothreitol | 0 | medium | 2 | 1 |
| megestrol | 0 | low | 1 | 0 |
| phenoxyacetic acid | 0 | low | 4 | 0 |
| carbonates | 0 | low | 7 | 0 |
| l 451167 | 0 | low | 1 | 0 |
| monomethyl phthalate | 0 | low | 1 | 0 |
| mono-(2-ethylhexyl)phthalate | 0 | low | 1 | 0 |
| fructosamine | 0 | medium | 373 | 108 |
| vantocil | 0 | low | 3 | 0 |
| ethyl maltol | 0 | low | 1 | 0 |
| metanephrine | 0 | low | 3 | 0 |
| trimetazidine | 0 | medium | 24 | 10 |
| buthionine sulfoximine | 0 | low | 4 | 0 |
| norleucine | 0 | low | 5 | 0 |
| floxacillin | 0 | low | 5 | 0 |
| vidarabine | 0 | low | 1 | 0 |
| iodinated glycerol | 0 | low | 12 | 0 |
| laurolitsine | 0 | low | 1 | 0 |
| diazoline | 0 | low | 1 | 0 |
| mebhydroline | 0 | low | 1 | 0 |
| n-methylaspartate | 0 | low | 4 | 0 |
| diformyl dapsone | 0 | low | 1 | 0 |
| iridium | 0 | medium | 2 | 1 |
| lanthanum | 0 | medium | 1 | 1 |
| manganese | 0 | medium | 36 | 2 |
| mercury | 0 | medium | 12 | 1 |
| molybdenum | 0 | medium | 10 | 1 |
| palladium | 0 | low | 2 | 0 |
| platinum | 0 | low | 3 | 0 |
| rhenium | 0 | low | 3 | 0 |
| ruthenium | 0 | medium | 4 | 1 |
| silver | 0 | medium | 15 | 5 |
| technetium | 0 | medium | 9 | 3 |
| terbium | 0 | low | 1 | 0 |
| thulium | 0 | medium | 1 | 1 |
| titanium | 0 | medium | 26 | 4 |
| tungsten | 0 | low | 1 | 0 |
| argon | 0 | medium | 3 | 1 |
| cadmium | 0 | low | 36 | 0 |
| cerium | 0 | low | 1 | 0 |
| chromium | 0 | medium | 143 | 31 |
| erbium | 0 | medium | 1 | 1 |
| europium | 0 | low | 2 | 0 |
| gadolinium | 0 | medium | 11 | 1 |
| gold | 0 | medium | 26 | 1 |
| uranium | 0 | medium | 2 | 1 |
| vanadium | 0 | medium | 31 | 2 |
| ytterbium | 0 | medium | 2 | 1 |
| yttrium | 0 | medium | 2 | 2 |
| zirconium | 0 | low | 3 | 0 |
| magnesium sulfate | 0 | low | 6 | 0 |
| acetylglucosamine | 0 | low | 36 | 0 |
| galactosamine | 0 | medium | 3 | 2 |
| phosphoric acid, trisodium salt | 0 | medium | 1 | 1 |
| perchloric acid | 0 | low | 1 | 0 |
| sodium nitrate | 0 | medium | 7 | 2 |
| hypochlorous acid | 0 | low | 4 | 0 |
| camptothecin | 0 | medium | 7 | 1 |
| ferric chloride | 0 | low | 1 | 0 |
| ferrous sulfate | 0 | low | 3 | 0 |
| barium sulfate | 0 | low | 2 | 0 |
| zinc sulfate | 0 | medium | 6 | 3 |
| sodium sulfate | 0 | medium | 1 | 1 |
| tricalcium phosphate | 0 | medium | 7 | 1 |
| copper sulfate | 0 | low | 3 | 0 |
| tungstate | 0 | low | 3 | 0 |
| sodium thiosulfate | 0 | low | 9 | 0 |
| calcium sulfate | 0 | low | 2 | 0 |
| deuterium | 0 | medium | 31 | 6 |
| fluorine | 0 | low | 2 | 0 |
| chlorine | 0 | low | 1 | 0 |
| deuterium oxide | 0 | low | 3 | 0 |
| galactose | 0 | medium | 23 | 4 |
| poloxalene | 0 | low | 1 | 0 |
| phosphoryl chloride | 0 | low | 1 | 0 |
| ozone | 0 | medium | 36 | 6 |
| ferric sulfate | 0 | low | 1 | 0 |
| radon | 0 | low | 2 | 0 |
| chromium sulfate | 0 | low | 1 | 0 |
| sodium selenite | 0 | medium | 5 | 1 |
| cadmium chloride | 0 | low | 1 | 0 |
| 4-chloro-7-nitrobenzofurazan | 0 | low | 6 | 0 |
| camphoroquinone | 0 | low | 1 | 0 |
| trolamine salicylate | 0 | medium | 54 | 2 |
| stanozolol | 0 | low | 3 | 0 |
| rhamnose | 0 | low | 4 | 0 |
| clodronic acid | 0 | low | 2 | 0 |
| ammonium chloride | 0 | low | 4 | 0 |
| tricalcium silicate | 0 | low | 1 | 0 |
| titanium dioxide | 0 | medium | 5 | 2 |
| sodium tungstate(vi) | 0 | low | 1 | 0 |
| tris(1,3-dichloro-2-propyl)phosphate | 0 | low | 2 | 0 |
| tiletamine hydrochloride | 0 | low | 5 | 0 |
| phytanic acid | 0 | low | 2 | 0 |
| rutamarin | 0 | low | 1 | 0 |
| cephalexin | 0 | medium | 1 | 1 |
| cromolyn sodium | 0 | low | 1 | 0 |
| isosorbide-5-mononitrate | 0 | medium | 3 | 1 |
| tetradecanoylphorbol acetate | 0 | medium | 34 | 2 |
| sodium bisulfide | 0 | low | 5 | 0 |
| fluorides | 0 | medium | 5 | 1 |
| chromium | 0 | medium | 2 | 1 |
| 1-deoxynojirimycin | 0 | medium | 111 | 52 |
| iodine | 0 | low | 4 | 0 |
| osmium tetroxide | 0 | low | 1 | 0 |
| daunorubicin | 0 | low | 1 | 0 |
| phosphotyrosine | 0 | low | 23 | 0 |
| carbimazole | 0 | low | 1 | 0 |
| bromocriptine | 0 | medium | 51 | 11 |
| zingerone | 0 | low | 1 | 0 |
| phenyl acetate | 0 | medium | 65 | 15 |
| cetylpyridinium chloride anhydrous | 0 | medium | 59 | 4 |
| 4-chlorophenyl methyl sulfide | 0 | low | 1 | 0 |
| pyrrolidine | 0 | low | 9 | 0 |
| triamcinolone | 0 | medium | 12 | 3 |
| fludrocortisone | 0 | low | 2 | 0 |
| pregnanolone | 0 | low | 2 | 0 |
| butylated hydroxytoluene | 0 | low | 1 | 0 |
| pyrene | 0 | low | 1 | 0 |
| isothiuronium | 0 | low | 1 | 0 |
| benzonidazole | 0 | low | 1 | 0 |
| 4-methoxyamphetamine | 0 | medium | 24 | 3 |
| du-21220 | 0 | low | 1 | 0 |
| 8-bromo cyclic adenosine monophosphate | 0 | low | 4 | 0 |
| transferrin | 0 | medium | 83 | 9 |
| androstane-3,17-diol | 0 | low | 1 | 0 |
| alkenes | 0 | low | 10 | 0 |
| calcium oxalate | 0 | low | 9 | 0 |
| glutamic acid | 0 | medium | 70 | 3 |
| glucaric acid | 0 | low | 5 | 0 |
| azoxymethane | 0 | low | 5 | 0 |
| cefazolin | 0 | low | 7 | 0 |
| sodium azide | 0 | low | 3 | 0 |
| azides | 0 | low | 6 | 0 |
| adenosine diphosphate ribose | 0 | low | 4 | 0 |
| halofenate | 0 | low | 1 | 0 |
| amoxicillin | 0 | medium | 21 | 11 |
| timolol | 0 | low | 2 | 0 |
| indoramin | 0 | medium | 1 | 1 |
| penfluridol | 0 | low | 1 | 0 |
| tramadol | 0 | medium | 5 | 2 |
| vanadyl sulfate | 0 | medium | 8 | 6 |
| oxovanadium iv | 0 | low | 4 | 0 |
| nicergoline | 0 | low | 1 | 0 |
| gallium citrate | 0 | medium | 1 | 1 |
| tetrahydrocannabivarin 9 | 0 | medium | 1 | 1 |
| oxcarbazepine | 0 | medium | 3 | 1 |
| s-adenosylmethionine | 0 | medium | 53 | 6 |
| zidovudine | 0 | medium | 2 | 1 |
| acetylgalactosamine | 0 | low | 1 | 0 |
| pcb 118 | 0 | low | 1 | 0 |
| 4-vinyl-2,6-dimethoxyphenol | 0 | low | 1 | 0 |
| 4-hydroxyphenylglycine, (s)-isomer | 0 | low | 1 | 0 |
| 3,4,3',4'-tetrachlorobiphenyl | 0 | low | 1 | 0 |
| paclitaxel | 0 | medium | 24 | 4 |
| fluchloralin | 0 | medium | 2 | 1 |
| etoposide | 0 | low | 4 | 0 |
| substance p | 0 | medium | 25 | 3 |
| acetosulfame | 0 | medium | 3 | 1 |
| dobutamine | 0 | medium | 26 | 4 |
| 2,4,5,2',4',5'-hexachlorobiphenyl | 0 | low | 5 | 0 |
| ribavirin | 0 | medium | 21 | 2 |
| lentinan | 0 | low | 1 | 0 |
| amikacin | 0 | medium | 9 | 1 |
| phorbol 12,13-dibutyrate | 0 | low | 2 | 0 |
| fluorescamine | 0 | low | 1 | 0 |
| cephradine | 0 | low | 1 | 0 |
| agent orange | 0 | low | 3 | 0 |
| methyldopa | 0 | low | 1 | 0 |
| levobunolol | 0 | low | 1 | 0 |
| vecuronium bromide | 0 | medium | 4 | 1 |
| ng-nitroarginine methyl ester | 0 | medium | 51 | 2 |
| permethrin | 0 | low | 3 | 0 |
| chlorodiphenyl (54% chlorine) | 0 | low | 1 | 0 |
| decamethrin | 0 | low | 1 | 0 |
| pirfenidone | 0 | medium | 5 | 1 |
| 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid | 0 | low | 2 | 0 |
| 1-carboxyglutamic acid | 0 | low | 2 | 0 |
| desogestrel | 0 | low | 2 | 0 |
| etofylline clofibrate | 0 | low | 2 | 0 |
| 3,3',5,5'-tetramethylbenzidine | 0 | low | 1 | 0 |
| meglitinide | 0 | medium | 49 | 3 |
| muzolimine | 0 | medium | 1 | 1 |
| phosphopantothenic acid | 0 | low | 1 | 0 |
| nitazoxanide | 0 | low | 3 | 0 |
| sufentanil | 0 | low | 1 | 0 |
| acarbose | 0 | low | 10 | 0 |
| satranidazole | 0 | medium | 1 | 1 |
| epirubicin | 0 | medium | 4 | 2 |
| desflurane | 0 | low | 4 | 0 |
| enkephalin, methionine | 0 | medium | 5 | 1 |
| idarubicin | 0 | low | 2 | 0 |
| dihydroalprenolol | 0 | low | 1 | 0 |
| 2,2',4,4',5-pentachlorodiphenyl ether | 0 | low | 1 | 0 |
| propiconazole | 0 | medium | 13 | 1 |
| nitrosobis(2-oxopropyl)amine | 0 | low | 2 | 0 |
| piperacillin | 0 | low | 9 | 0 |
| paroxetine | 0 | medium | 9 | 4 |
| pirogliride | 0 | low | 1 | 0 |
| bopindolol | 0 | medium | 1 | 1 |
| progabide | 0 | low | 1 | 0 |
| cefoperazone | 0 | low | 2 | 0 |
| staurosporine | 0 | low | 2 | 0 |
| salsoline | 0 | low | 1 | 0 |
| 4-(n-methyl-n-nitrosamino)-1-(3-pyridyl)-1-butanone | 0 | low | 1 | 0 |
| nicorandil | 0 | medium | 3 | 1 |
| colforsin | 0 | medium | 22 | 3 |
| encainide | 0 | low | 1 | 0 |
| buserelin | 0 | low | 2 | 0 |
| nedocromil | 0 | medium | 1 | 1 |
| pimonidazole | 0 | low | 1 | 0 |
| cefaclor anhydrous | 0 | medium | 1 | 1 |
| pefloxacin | 0 | low | 1 | 0 |
| octenidine | 0 | low | 7 | 0 |
| fomesafen | 0 | medium | 49 | 4 |
| fenoxycarb | 0 | low | 3 | 0 |
| miglustat | 0 | low | 2 | 0 |
| tripamide | 0 | medium | 1 | 1 |
| cefotetan | 0 | low | 1 | 0 |
| lovastatin | 0 | medium | 48 | 23 |
| tolrestat | 0 | medium | 12 | 9 |
| ethyl 2-(5-(4-chlorophenyl)pentyl)oxiran-2-carboxylate | 0 | low | 1 | 0 |
| idazoxan | 0 | medium | 3 | 1 |
| pravastatin | 0 | medium | 101 | 45 |
| cabergoline | 0 | medium | 5 | 2 |
| atomoxetine hydrochloride | 0 | low | 1 | 0 |
| quinapril | 0 | medium | 16 | 8 |
| raloxifene hydrochloride | 0 | medium | 15 | 4 |
| mifepristone | 0 | medium | 13 | 3 |
| itraconazole | 0 | medium | 18 | 2 |
| gusperimus | 0 | low | 2 | 0 |
| cilazapril, anhydrous | 0 | medium | 12 | 6 |
| salmeterol xinafoate | 0 | medium | 1 | 1 |
| fura-2 | 0 | low | 7 | 0 |
| finasteride | 0 | low | 1 | 0 |
| imiquimod | 0 | low | 5 | 0 |
| lisofylline | 0 | medium | 1 | 1 |
| n 0437, (-)-isomer | 0 | low | 1 | 0 |
| fadrozole | 0 | low | 1 | 0 |
| esmolol | 0 | low | 1 | 0 |
| sabeluzole | 0 | medium | 2 | 1 |
| loxiglumide | 0 | medium | 1 | 1 |
| aromasil | 0 | low | 1 | 0 |
| englitazone | 0 | low | 4 | 0 |
| zileuton | 0 | low | 1 | 0 |
| mibefradil | 0 | low | 2 | 0 |
| bromfenac | 0 | low | 1 | 0 |
| gemcitabine | 0 | medium | 9 | 1 |
| technetium tc 99m mertiatide | 0 | medium | 3 | 2 |
| aripiprazole | 0 | low | 14 | 0 |
| remifentanil | 0 | low | 2 | 0 |
| lamivudine | 0 | medium | 1 | 1 |
| duloxetine hydrochloride | 0 | low | 11 | 0 |
| irinotecan | 0 | low | 4 | 0 |
| ibandronic acid | 0 | medium | 2 | 1 |
| ziprasidone | 0 | low | 5 | 0 |
| 3-iodobenzylguanidine | 0 | medium | 40 | 4 |
| simendan | 0 | medium | 3 | 1 |
| darglitazone | 0 | medium | 3 | 1 |
| adefovir dipivoxil | 0 | low | 1 | 0 |
| emtricitabine | 0 | medium | 3 | 2 |
| tirofiban | 0 | low | 2 | 0 |
| capecitabine | 0 | low | 3 | 0 |
| adenosine | 0 | medium | 87 | 18 |
| safranal | 0 | low | 3 | 0 |
| ferric citrate | 0 | low | 1 | 0 |
| 3-n-butylphthalide | 0 | low | 2 | 0 |
| gadolinium chloride | 0 | low | 1 | 0 |
| nitrogen trioxide | 0 | low | 1 | 0 |
| monoammonium molybdate | 0 | low | 1 | 0 |
| vanadates | 0 | medium | 35 | 3 |
| acridine orange | 0 | low | 2 | 0 |
| isothiocyanic acid | 0 | low | 2 | 0 |
| potassium phosphate | 0 | low | 1 | 0 |
| caloreen | 0 | medium | 9 | 5 |
| colestipol | 0 | low | 3 | 0 |
| venlafaxine hydrochloride | 0 | medium | 4 | 1 |
| trazodone hydrochloride | 0 | medium | 53 | 22 |
| 3,4,5,3',4'-pentachlorobiphenyl | 0 | low | 2 | 0 |
| nelfinavir | 0 | medium | 2 | 1 |
| tromantadine | 0 | low | 1 | 0 |
| glucose, (beta-d)-isomer | 0 | medium | 1,736 | 520 |
| anisodamine | 0 | medium | 2 | 1 |
| simvastatin acid | 0 | low | 1 | 0 |
| dihydrochalcone | 0 | low | 1 | 0 |
| chloroquine diphosphate | 0 | low | 2 | 0 |
| 2',7'-dichlorofluorescein | 0 | low | 1 | 0 |
| ursolic acid | 0 | low | 11 | 0 |
| n-methylnicotinamide | 0 | low | 1 | 0 |
| 3-aminoisobutyric acid | 0 | low | 5 | 0 |
| iodonitrotetrazolium | 0 | low | 1 | 0 |
| xanthosine | 0 | low | 2 | 0 |
| 1,5-anhydroglucitol | 0 | medium | 104 | 24 |
| norharman | 0 | low | 1 | 0 |
| thiazolyl blue | 0 | low | 3 | 0 |
| 3-methylhistidine | 0 | low | 1 | 0 |
| betulinic acid | 0 | low | 5 | 0 |
| arctigenin | 0 | low | 3 | 0 |
| baicalin | 0 | medium | 8 | 1 |
| plerixafor | 0 | medium | 6 | 1 |
| oseltamivir | 0 | low | 2 | 0 |
| allicin | 0 | low | 1 | 0 |
| 5-methylcytosine | 0 | low | 6 | 0 |
| n-acetylaspartic acid | 0 | low | 15 | 0 |
| 25-hydroxycholesterol | 0 | low | 1 | 0 |
| 6-sulfatoxymelatonin | 0 | low | 7 | 0 |
| norvaline | 0 | low | 1 | 0 |
| 10,10'-dimethyl-9,9'-biacridinium | 0 | low | 1 | 0 |
| aica ribonucleotide | 0 | medium | 34 | 2 |
| salvin | 0 | low | 2 | 0 |
| testosterone undecanoate | 0 | medium | 20 | 12 |
| metaperiodate | 0 | low | 1 | 0 |
| lissamine rhodamine b | 0 | low | 1 | 0 |
| 1,2,3,4,6-pentakis-O-galloyl-beta-D-glucose | 0 | low | 2 | 0 |
| fluorophosphate | 0 | low | 1 | 0 |
| fructose-1-phosphate | 0 | low | 1 | 0 |
| 2-deoxy-2,3-dehydro-n-acetylneuraminic acid | 0 | low | 1 | 0 |
| pyrrolidine dithiocarbamate | 0 | low | 6 | 0 |
| peroxynitric acid | 0 | low | 2 | 0 |
| glutathione disulfide | 0 | medium | 22 | 4 |
| secoisolariciresinol | 0 | low | 2 | 0 |
| hypusine | 0 | low | 1 | 0 |
| cephalosporin c | 0 | low | 10 | 0 |
| propazole | 0 | low | 1 | 0 |
| lathosterol | 0 | medium | 8 | 1 |
| rutecarpine | 0 | low | 1 | 0 |
| tretoquinol | 0 | low | 1 | 0 |
| etofibrate | 0 | medium | 3 | 1 |
| glipalamide | 0 | medium | 1 | 1 |
| mci-196 | 0 | medium | 16 | 5 |
| lercanidipine | 0 | medium | 11 | 9 |
| web 2086 | 0 | low | 1 | 0 |
| goralatide | 0 | medium | 2 | 1 |
| azelnidipine | 0 | medium | 10 | 7 |
| raxofelast | 0 | medium | 1 | 1 |
| methacycline | 0 | medium | 9 | 1 |
| bergenin | 0 | low | 2 | 0 |
| boron nitride | 0 | low | 1 | 0 |
| dexfenfluramine | 0 | low | 3 | 0 |
| xenon radioisotopes | 0 | low | 5 | 0 |
| naphthalimides | 0 | low | 2 | 0 |
| salicylhydroxamic acid | 0 | low | 1 | 0 |
| benzeneboronic acid | 0 | low | 1 | 0 |
| synthalin a | 0 | low | 1 | 0 |
| 1,7-phenanthroline | 0 | medium | 3 | 2 |
| pyrrolo(1,2-a)quinoxaline | 0 | low | 1 | 0 |
| 1h-imidazo(4,5-b)pyridine | 0 | low | 1 | 0 |
| triazoles | 0 | medium | 560 | 179 |
| 1h-tetrazole | 0 | low | 1 | 0 |
| 1,2,4-triazine | 0 | low | 2 | 0 |
| guanidinopropionic acid | 0 | low | 1 | 0 |
| perfluorohexanesulfonic acid | 0 | low | 2 | 0 |
| perfluoro-n-nonanoic acid | 0 | low | 1 | 0 |
| isocoumarins | 0 | low | 2 | 0 |
| djenkolic acid | 0 | low | 1 | 0 |
| phenylacetylglycine | 0 | low | 1 | 0 |
| flindersine | 0 | low | 1 | 0 |
| delphinidin | 0 | low | 2 | 0 |
| ibopamine | 0 | medium | 1 | 1 |
| methyl 2-tetradecylglycidate | 0 | low | 1 | 0 |
| fluorodeoxyglucose f18 | 0 | medium | 119 | 24 |
| sertraline | 0 | medium | 14 | 6 |
| rilmenidine | 0 | medium | 3 | 3 |
| zoledronic acid | 0 | medium | 7 | 1 |
| brinzolamide | 0 | low | 1 | 0 |
| midaglizole | 0 | low | 6 | 0 |
| artemether | 0 | low | 1 | 0 |
| glycine amide | 0 | low | 1 | 0 |
| beta-hydroxyisovaleric acid | 0 | low | 1 | 0 |
| phenylpropiolic acid | 0 | low | 1 | 0 |
| fructose-6-phosphate | 0 | low | 6 | 0 |
| dracorhodin | 0 | low | 1 | 0 |
| malvidin chloride | 0 | low | 1 | 0 |
| 2,3-diaminonaphthalene | 0 | low | 1 | 0 |
| tyrosyltyrosine | 0 | low | 5 | 0 |
| monoethyl succinate | 0 | low | 3 | 0 |
| 5-imidazolepropionic acid | 0 | medium | 8 | 2 |
| 5-hydroxymethylcytosine | 0 | low | 3 | 0 |
| 1,2-benzisoxazole | 0 | low | 1 | 0 |
| cloridarol | 0 | low | 1 | 0 |
| n-methylscopolamine | 0 | low | 2 | 0 |
| cromakalim | 0 | low | 3 | 0 |
| dapoxetine | 0 | medium | 1 | 1 |
| dexrazoxane | 0 | medium | 2 | 2 |
| masoprocol | 0 | low | 5 | 0 |
| diflorasone | 0 | low | 1 | 0 |
| trichlorosucrose | 0 | medium | 11 | 6 |
| voriconazole | 0 | medium | 16 | 1 |
| rexigen | 0 | low | 1 | 0 |
| mepindolol | 0 | low | 1 | 0 |
| glyclopyramide | 0 | low | 1 | 0 |
| alacepril | 0 | low | 2 | 0 |
| nipradilol | 0 | low | 1 | 0 |
| efaroxan | 0 | low | 2 | 0 |
| perindoprilat | 0 | medium | 2 | 2 |
| acemannan | 0 | low | 1 | 0 |
| terlipressin | 0 | low | 1 | 0 |
| tiemonium iodide | 0 | low | 1 | 0 |
| tritoqualine | 0 | medium | 1 | 1 |
| ubenimex | 0 | low | 1 | 0 |
| fagomine | 0 | low | 1 | 0 |
| hesperetin | 0 | low | 9 | 0 |
| magnolol | 0 | low | 3 | 0 |
| honokiol | 0 | low | 7 | 0 |
| sesamin | 0 | low | 4 | 0 |
| betulin | 0 | low | 1 | 0 |
| hernandezine | 0 | low | 1 | 0 |
| nobiletin | 0 | low | 2 | 0 |
| mesoporphyrin ix | 0 | low | 1 | 0 |
| picropodophyllin | 0 | low | 1 | 0 |
| grepafloxacin | 0 | low | 1 | 0 |
| berberrubine | 0 | low | 1 | 0 |
| 1h-benzotriazole-5-carboxylic acid | 0 | low | 1 | 0 |
| xylenol orange | 0 | low | 2 | 0 |
| magnoflorine | 0 | low | 1 | 0 |
| calpeptin | 0 | low | 2 | 0 |
| dauricine | 0 | low | 1 | 0 |
| panaxadiol | 0 | low | 2 | 0 |
| 2,5-anhydromannitol | 0 | low | 1 | 0 |
| corilagin | 0 | low | 2 | 0 |
| sakuranetin | 0 | low | 1 | 0 |
| bilobalide | 0 | low | 1 | 0 |
| panaxatriol | 0 | low | 1 | 0 |
| arjunolic acid | 0 | low | 2 | 0 |
| maslinic acid | 0 | low | 2 | 0 |
| carbohydrazide | 0 | low | 1 | 0 |
| oxazolidin-2-one | 0 | medium | 8 | 1 |
| ceric oxide | 0 | low | 1 | 0 |
| phenylsulfate | 0 | low | 1 | 0 |
| perfluorooctane sulfonic acid | 0 | medium | 5 | 1 |
| c.i. direct red 80 | 0 | low | 1 | 0 |
| 4-aminobenzamide | 0 | low | 1 | 0 |
| 6-carboxyfluorescein | 0 | low | 2 | 0 |
| 1-pyrenebutyrate | 0 | low | 1 | 0 |
| bendamustine hydrochloride | 0 | low | 2 | 0 |
| perfluoroundecanoic acid | 0 | low | 2 | 0 |
| monomethyl succinate | 0 | low | 3 | 0 |
| rivastigmine | 0 | low | 1 | 0 |
| glyceryl 1,2-dinitrate | 0 | low | 1 | 0 |
| mono-n-octyl phthalate | 0 | low | 1 | 0 |
| n-hydroxysuccinimide | 0 | low | 2 | 0 |
| 3,7-dimethyl-7-octen-1-ol | 0 | low | 1 | 0 |
| cryptolepine | 0 | medium | 1 | 1 |
| 2-bromopalmitate | 0 | low | 2 | 0 |
| bexarotene | 0 | low | 4 | 0 |
| s20098 | 0 | medium | 3 | 2 |
| 1-ethyl-2-benzimidazolinone | 0 | low | 3 | 0 |
| 3,4-dihydroxyphenylethanol | 0 | low | 5 | 0 |
| iridium oxide | 0 | medium | 1 | 1 |
| 4-phenylbutylamine | 0 | low | 1 | 0 |
| eriocitrin | 0 | low | 2 | 0 |
| clarithromycin | 0 | medium | 21 | 8 |
| 3-bromo-4,5-dihydroxybenzaldehyde | 0 | low | 1 | 0 |
| we 201 | 0 | low | 3 | 0 |
| stearoyl alpha-lysolecithin | 0 | low | 2 | 0 |
| coenzyme a | 0 | low | 8 | 0 |
| loganin | 0 | low | 2 | 0 |
| gentiopicroside | 0 | low | 1 | 0 |
| d-glucitol, 6-o-alpha-d-glucopyranosyl-, mixture with 1-o-alpha-d-glucopyranosyl-d-mannitol | 0 | medium | 1 | 1 |
| kampirone | 0 | low | 1 | 0 |
| mebeverine | 0 | medium | 5 | 1 |
| nicotine | 0 | medium | 40 | 6 |
| nsc-172755 | 0 | low | 9 | 0 |
| bromophenophos | 0 | low | 1 | 0 |
| fibrinogen | 0 | medium | 350 | 62 |
| 17-alpha-hydroxypregnenolone | 0 | low | 2 | 0 |
| beta-eudesmol | 0 | low | 1 | 0 |
| aucubin | 0 | low | 3 | 0 |
| equol | 0 | low | 6 | 0 |
| 7-ketocholesterol | 0 | medium | 11 | 2 |
| 2-tyrosine | 0 | medium | 2 | 1 |
| fluocinolone | 0 | low | 1 | 0 |
| 6-phosphogluconic acid | 0 | low | 1 | 0 |
| inermin | 0 | low | 1 | 0 |
| homocysteine | 0 | medium | 338 | 61 |
| alpha,beta-methyleneadenosine 5'-triphosphate | 0 | low | 1 | 0 |
| methylglucoside | 0 | low | 2 | 0 |
| salsolinol | 0 | low | 2 | 0 |
| gliquidone | 0 | medium | 26 | 5 |
| acetylsalicylic acid lysinate | 0 | medium | 4 | 1 |
| cadusafos | 0 | low | 1 | 0 |
| taraxerol | 0 | low | 2 | 0 |
| succinyl-coenzyme a | 0 | low | 1 | 0 |
| lupenone | 0 | low | 2 | 0 |
| phenylacetylglutamine | 0 | low | 3 | 0 |
| 3-aminobenzeneboronic acid | 0 | low | 1 | 0 |
| mci 9038 | 0 | low | 2 | 0 |
| lopinavir | 0 | medium | 5 | 1 |
| gamma-tocopherol | 0 | medium | 6 | 3 |
| orotidine | 0 | low | 1 | 0 |
| annatto | 0 | low | 1 | 0 |
| arginine methyl ester | 0 | low | 1 | 0 |
| firefly luciferin | 0 | low | 2 | 0 |
| 4-nitrophenyl alpha-glucoside | 0 | low | 3 | 0 |
| droxidopa | 0 | low | 1 | 0 |
| glutamic acid dimethyl ester | 0 | low | 2 | 0 |
| glycidyl nitrate | 0 | low | 3 | 0 |
| isohumulone | 0 | medium | 2 | 1 |
| stearoyl-coenzyme a | 0 | low | 2 | 0 |
| 6-paradol | 0 | low | 1 | 0 |
| pyrroline | 0 | low | 2 | 0 |
| diprotin a | 0 | low | 4 | 0 |
| glucuronic acid | 0 | medium | 12 | 3 |
| 2,2',4,4'-tetrabromodiphenyl ether | 0 | low | 3 | 0 |
| prolamins | 0 | low | 2 | 0 |
| 1-methylguanosine | 0 | low | 1 | 0 |
| 5-iodotubercidin | 0 | low | 3 | 0 |
| benzoylphenylalanine | 0 | low | 2 | 0 |
| 1,3,4-oxadiazole | 0 | low | 2 | 0 |
| s-(2,4-dinitrophenyl)glutathione | 0 | low | 1 | 0 |
| 2,5-dihydroxypyridine | 0 | medium | 1 | 1 |
| diosgenin | 0 | low | 8 | 0 |
| isosteviol | 0 | low | 4 | 0 |
| malabaricone c | 0 | low | 1 | 0 |
| arctiin | 0 | low | 2 | 0 |
| aminomalonic acid | 0 | low | 1 | 0 |
| sesamolin | 0 | low | 1 | 0 |
| n-methyladenosine | 0 | low | 6 | 0 |
| 2-amino-4-phenylbutyric acid | 0 | low | 1 | 0 |
| 2,3-bis(4-hydroxyphenyl)-propionitrile | 0 | low | 1 | 0 |
| lanthionine | 0 | low | 3 | 0 |
| cobalt | 0 | low | 15 | 0 |
| fulvestrant | 0 | low | 1 | 0 |
| hydrogen sulfite | 0 | low | 1 | 0 |
| yttrium radioisotopes | 0 | medium | 1 | 1 |
| mizoribine | 0 | low | 1 | 0 |
| enkephalin, d-penicillamine (2,5)- | 0 | low | 2 | 0 |
| u 73122 | 0 | low | 3 | 0 |
| vitamin b 6 | 0 | medium | 19 | 4 |
| 1,4-dihydropyridine | 0 | medium | 5 | 4 |
| imipenem, anhydrous | 0 | low | 7 | 0 |
| s-nitrosoglutathione | 0 | low | 1 | 0 |
| diacetyldichlorofluorescein | 0 | low | 1 | 0 |
| 1-(2-(3-(4-methoxyphenyl)propoxy)-4-methoxyphenylethyl)-1h-imidazole | 0 | low | 1 | 0 |
| 1,n(6)-ethenoadenine | 0 | medium | 1 | 1 |
| paxilline | 0 | low | 2 | 0 |
| prolinedithiocarbamate | 0 | low | 1 | 0 |
| fructose 2,6-diphosphate | 0 | low | 5 | 0 |
| dihydrorhodamine 123 | 0 | low | 1 | 0 |
| pyridinoline | 0 | low | 4 | 0 |
| deoxypyridinoline | 0 | medium | 13 | 1 |
| fura-2-am | 0 | low | 2 | 0 |
| ((18)O)water | 0 | low | 3 | 0 |
| indobufen | 0 | medium | 1 | 1 |
| thiamethoxam | 0 | medium | 1 | 1 |
| 4-hydroxydebrisoquin | 0 | low | 1 | 0 |
| cv 3988 | 0 | medium | 1 | 1 |
| propionylcarnitine | 0 | medium | 9 | 5 |
| 1,1-dimethylheptyl-11-hydroxytetrahydrocannabinol | 0 | low | 1 | 0 |
| fr 139317 | 0 | low | 1 | 0 |
| hypotaurine | 0 | low | 1 | 0 |
| l-pyroglutamyl-l-histidyl-3,3-dimethylprolinamide | 0 | low | 3 | 0 |
| tryptoline | 0 | low | 1 | 0 |
| geniposide | 0 | low | 10 | 0 |
| procyanidin | 0 | medium | 32 | 1 |
| sr 95531 | 0 | low | 1 | 0 |
| dityrosine | 0 | low | 2 | 0 |
| epicatechin gallate | 0 | low | 3 | 0 |
| ecopipam | 0 | medium | 2 | 1 |
| deguelin | 0 | low | 1 | 0 |
| fingolimod hydrochloride | 0 | medium | 9 | 1 |
| parinaric acid | 0 | low | 1 | 0 |
| n(g)-iminoethylornithine | 0 | low | 2 | 0 |
| triptolide | 0 | low | 1 | 0 |
| ramosetron | 0 | low | 1 | 0 |
| cobaltiprotoporphyrin | 0 | low | 5 | 0 |
| cafestol | 0 | low | 7 | 0 |
| proanthocyanidin | 0 | low | 4 | 0 |
| parthenolide | 0 | low | 2 | 0 |
| benzamil | 0 | medium | 1 | 1 |
| cotinine-n-oxide | 0 | low | 1 | 0 |
| schizandrin b | 0 | low | 2 | 0 |
| 1-hexadecyl-2-acetyl-glycero-3-phosphocholine | 0 | medium | 15 | 3 |
| 5-acetylamino-6-formylamino-3-methyluracil | 0 | medium | 1 | 1 |
| deoxyglucose | 0 | medium | 211 | 27 |
| 3-chloro-L-tyrosine | 0 | low | 1 | 0 |
| anserine | 0 | low | 1 | 0 |
| 6-methyl-2-ethyl-3-hydroxypyridine | 0 | medium | 2 | 1 |
| precirol | 0 | low | 1 | 0 |
| 1-phenyl-2-decanoylamino-3-morpholino-1-propanol | 0 | low | 1 | 0 |
| 2,3-bis(3'-hydroxybenzyl)butyrolactone | 0 | low | 3 | 0 |
| homoorientin | 0 | medium | 1 | 1 |
| kahweol | 0 | low | 4 | 0 |
| valerates | 0 | low | 5 | 0 |
| selenomethylselenocysteine | 0 | low | 1 | 0 |
| 3-deoxyglucosone | 0 | medium | 19 | 3 |
| higenamine | 0 | low | 1 | 0 |
| thromboxanes | 0 | medium | 18 | 6 |
| opc 21268 | 0 | medium | 2 | 1 |
| tanshinone | 0 | low | 4 | 0 |
| 1-(carboxymethylthio)tetradecane | 0 | medium | 3 | 1 |
| geraniin | 0 | low | 1 | 0 |
| 10-n-nonylacridinium orange | 0 | low | 1 | 0 |
| amarogentin | 0 | low | 1 | 0 |
| 3'-o-(4-benzoyl)benzoyladenosine 5'-triphosphate | 0 | low | 2 | 0 |
| panipenem-betamipron | 0 | low | 1 | 0 |
| sc 58125 | 0 | low | 1 | 0 |
| stachydrine | 0 | low | 2 | 0 |
| sophocarpine | 0 | low | 1 | 0 |
| 2-aminobicyclo(2,2,1)heptane-2-carboxylic acid | 0 | low | 2 | 0 |
| perospirone | 0 | low | 1 | 0 |
| chymosin | 0 | low | 1 | 0 |
| nitroaspirin | 0 | medium | 1 | 1 |
| asiatic acid | 0 | low | 3 | 0 |
| 1-(6-hydroxy-2-isopropenyl-1-benzofuran-5-yl)-1-ethanone | 0 | low | 1 | 0 |
| s-(3-hydroxypropyl)cysteine n-acetate | 0 | low | 1 | 0 |
| efonidipine | 0 | medium | 2 | 2 |
| lithospermate b | 0 | low | 1 | 0 |
| sr 48692 | 0 | low | 1 | 0 |
| dioscin | 0 | low | 3 | 0 |
| iodofiltic acid | 0 | medium | 4 | 1 |
| caprylates | 0 | medium | 17 | 4 |
| tris(2-carboxyethyl)phosphine | 0 | medium | 1 | 1 |
| s-lactoylglutathione | 0 | low | 1 | 0 |
| muricholic acid | 0 | low | 2 | 0 |
| k 76 carboxylic acid | 0 | low | 1 | 0 |
| pramipexole | 0 | medium | 3 | 1 |
| mosapride | 0 | medium | 5 | 3 |
| pentosidine | 0 | medium | 59 | 9 |
| emeriamine | 0 | low | 2 | 0 |
| hydroxypropylmethylcellulose acetate succinate | 0 | low | 1 | 0 |
| methylthio-adp | 0 | low | 1 | 0 |
| 2-n-(4-(1-azitrifluoroethyl)benzoyl)-1,3-bis-(mannos-4-yloxy)-2-propylamine | 0 | low | 1 | 0 |
| phytosphingosine | 0 | low | 2 | 0 |
| delta-hydroxylysylnorleucine | 0 | low | 1 | 0 |
| luzindole | 0 | low | 2 | 0 |
| brl 35135 | 0 | low | 1 | 0 |
| 2-formyl-5-(hydroxymethyl)pyrrole-1-norleucine | 0 | low | 4 | 0 |
| 5-(dimethylamino)-n-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide | 0 | low | 1 | 0 |
| glucitollysine | 0 | low | 2 | 0 |
| emoxypine succinate | 0 | medium | 6 | 2 |
| saccharolactone | 0 | low | 1 | 0 |
| florox reagent | 0 | low | 1 | 0 |
| pyroglutamyl-histidyl-glycine | 0 | low | 1 | 0 |
| inositol cyclic phosphate | 0 | low | 1 | 0 |
| astragaloside a | 0 | low | 9 | 0 |
| celastrol | 0 | low | 7 | 0 |
| procyanidin b2 | 0 | low | 3 | 0 |
| aromadedrin | 0 | low | 1 | 0 |
| peroxynitrous acid | 0 | medium | 16 | 1 |
| cyclopropanol | 0 | low | 2 | 0 |
| fullerene c60 | 0 | low | 3 | 0 |
| imatinib mesylate | 0 | medium | 22 | 1 |
| tazobactam | 0 | low | 3 | 0 |
| gefitinib | 0 | medium | 4 | 1 |
| 3,5-diiodothyronine | 0 | low | 1 | 0 |
| dimyristoylphosphatidylserine | 0 | low | 1 | 0 |
| 2,3-bis(3'-hydroxybenzyl)butane-1,4-diol | 0 | low | 2 | 0 |
| cdp ethanolamine | 0 | low | 1 | 0 |
| 7 alpha-hydroxy-4-cholesten-3-one | 0 | medium | 2 | 1 |
| galactosyl-(1-3)galactose | 0 | low | 1 | 0 |
| c & b metabond | 0 | low | 2 | 0 |
| cgp 42112a | 0 | low | 1 | 0 |
| deltorphin ii, ala(2)- | 0 | low | 1 | 0 |
| phenylalanyl-leucyl-phenylalanyl-glutaminyl-prolyl-glutaminyl-arginyl-phenylalaninamide | 0 | low | 1 | 0 |
| n(6)-carboxymethyllysine | 0 | medium | 69 | 11 |
| angiotensin ii, des-phe(8)- | 0 | low | 14 | 0 |
| 2-chloro-n(6)cyclopentyladenosine | 0 | low | 1 | 0 |
| 5,5'-bis(8-(phenylamino)-1-naphthalenesulfonate) | 0 | low | 1 | 0 |
| n,n-dimethylarginine | 0 | medium | 93 | 20 |
| dihydrotetrabenazine | 0 | low | 2 | 0 |
| cyclic adp-ribose | 0 | low | 5 | 0 |
| 3-(2,2,2-trimethylhydrazine)propionate | 0 | medium | 4 | 2 |
| interleukin-1beta (163-171) | 0 | low | 1 | 0 |
| n(omega)-hydroxyarginine | 0 | low | 1 | 0 |
| 1,9-dimethylmethylene blue | 0 | low | 1 | 0 |
| bq 610 | 0 | low | 1 | 0 |
| hydroxycitric acid | 0 | medium | 2 | 1 |
| statine | 0 | medium | 1 | 1 |
| 4-(alpha-(4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl)-n,n-diethylbenzamide | 0 | low | 1 | 0 |
| alanylglutamine | 0 | medium | 2 | 2 |
| gamma-glutamylcysteine | 0 | low | 2 | 0 |
| naadp | 0 | low | 1 | 0 |
| 3-carboxy-4-methyl-5-propyl-2-furanpropionic acid | 0 | medium | 7 | 1 |
| dehydroalanine | 0 | low | 1 | 0 |
| 5,5'-dihydroxylysylnorleucine | 0 | low | 1 | 0 |
| proanthocyanidin a2 | 0 | low | 1 | 0 |
| swertisin | 0 | low | 2 | 0 |
| tetrahydrocurcumin | 0 | low | 7 | 0 |
| garenoxacin | 0 | low | 1 | 0 |
| eriodictyol 7-glucuronide | 0 | low | 1 | 0 |
| glucogallin | 0 | low | 1 | 0 |
| 2-pyrazinoylguanidine | 0 | medium | 3 | 1 |
| 1-o-myristoyl-2-acetyl-glycerol | 0 | low | 1 | 0 |
| 8-oxo-dado | 0 | low | 1 | 0 |
| glycerophosphoinositol 4,5-bisphosphate | 0 | low | 4 | 0 |
| n-methylisoindigotin | 0 | low | 1 | 0 |
| glicentin | 0 | low | 2 | 0 |
| lvv-hemorphin-7 | 0 | low | 1 | 0 |
| vv-hemorphin-7 | 0 | low | 2 | 0 |
| 6-chloropenicillanic acid s-sulfoxide | 0 | low | 1 | 0 |
| lavendustin c6 | 0 | low | 1 | 0 |
| methotrexate | 0 | medium | 28 | 3 |
| 1-diphosphoinositol pentakisphosphate | 0 | low | 1 | 0 |
| n-formyl-13-dihydrocarminomycin | 0 | low | 2 | 0 |
| ci 924 | 0 | low | 1 | 0 |
| 1,4-dideoxy-1,4-iminoarabinitol | 0 | low | 3 | 0 |
| s-4-bromobenzylglutathione cyclopentyl diester | 0 | low | 1 | 0 |
| ad 5075 | 0 | low | 1 | 0 |
| dihydroethidium | 0 | low | 1 | 0 |
| cyanidin | 0 | low | 2 | 0 |
| tamsulosin | 0 | low | 3 | 0 |
| sorbitol 3-phosphate | 0 | medium | 1 | 1 |
| sulbactam | 0 | low | 3 | 0 |
| diphenyl-1-pyrenylphosphine | 0 | medium | 1 | 1 |
| fructose 3-phosphate | 0 | medium | 3 | 1 |
| olmesartan medoxomil | 0 | medium | 21 | 12 |
| cercosporamide | 0 | low | 1 | 0 |
| 10-methyl spiro(4.5)dec-6-en-6-carboxylic acid | 0 | medium | 1 | 1 |
| 4-diethoxyphosphorylmethyl-n-(4-bromo-2-cyanophenyl)benzamide | 0 | low | 1 | 0 |
| 4b,5,9b,10-tetrahydroindeno(1,2-b)indole | 0 | low | 1 | 0 |
| 3-((2'-carboxybiphenyl-4-yl)methyl)-2-cyclopropyl-7-methyl-3h-imidazo(4,5-b)pyridine | 0 | low | 2 | 0 |
| 14-fluoro-6-thiaheptadecanoic acid | 0 | low | 1 | 0 |
| sl 84.0418 | 0 | low | 1 | 0 |
| n',n''-diacetylspermine | 0 | low | 1 | 0 |
| omega-n-methylarginine | 0 | medium | 39 | 14 |
| hemorphin 7 | 0 | low | 1 | 0 |
| abiraterone | 0 | low | 1 | 0 |
| ivabradine | 0 | medium | 5 | 2 |
| 2,7,8-trimethyl-2-(beta-carboxyethyl)-6-hydroxychroman | 0 | low | 1 | 0 |
| risarestat | 0 | medium | 1 | 1 |
| leucinal | 0 | low | 1 | 0 |
| febuxostat | 0 | medium | 9 | 3 |
| carbapenems | 0 | medium | 5 | 2 |
| n-acetylgalactosaminuronic acid | 0 | low | 1 | 0 |
| triiodothyronine | 0 | low | 2 | 0 |
| aspartame | 0 | medium | 15 | 5 |
| calcium borate | 0 | medium | 1 | 1 |
| xylose | 0 | medium | 13 | 4 |
| beta-lactams | 0 | medium | 4 | 1 |
| tx 3301 | 0 | medium | 1 | 1 |
| n-nitrosoallyl-2,3-dihydroxypropylamine | 0 | low | 1 | 0 |
| perrhenate | 0 | low | 1 | 0 |
| phenyldiazene | 0 | low | 1 | 0 |
| proline | 0 | medium | 109 | 13 |
| cucurbitaceae | 0 | medium | 15 | 3 |
| 3,3',4'-trihydroxyflavone | 0 | low | 1 | 0 |
| isodibut | 0 | medium | 2 | 1 |
| sdz 51641 | 0 | low | 1 | 0 |
| docetaxel anhydrous | 0 | medium | 2 | 1 |
| perifosine | 0 | low | 1 | 0 |
| diquafosol | 0 | medium | 4 | 1 |
| peptide elongation factor 2 | 0 | low | 1 | 0 |
| levofloxacin | 0 | medium | 12 | 1 |
| ertapenem | 0 | low | 2 | 0 |
| 3-deoxyglucose | 0 | low | 2 | 0 |
| nepafenac | 0 | medium | 1 | 1 |
| cariporide | 0 | low | 2 | 0 |
| mk 767 | 0 | low | 4 | 0 |
| diaminoguanidine | 0 | low | 1 | 0 |
| evodiamine | 0 | low | 1 | 0 |
| phenyl di-n-pentylphosphinate | 0 | low | 1 | 0 |
| 2-chloro-2-deoxyglucose | 0 | low | 1 | 0 |
| sorbitol 6-phosphate | 0 | low | 1 | 0 |
| histidylproline | 0 | low | 1 | 0 |
| imidazole-4-carboxamide | 0 | low | 1 | 0 |
| 1,2-diamino-4,5-dimethoxybenzene | 0 | low | 1 | 0 |
| mn(iii) 5,10,15,20-tetrakis(n-methylpyridinium-2-yl)porphyrin | 0 | low | 3 | 0 |
| as 3201 | 0 | medium | 5 | 4 |
| borneo | 0 | low | 1 | 0 |
| jtt 501 | 0 | low | 2 | 0 |
| bazedoxifene | 0 | low | 3 | 0 |
| 4-methoxyhonokiol | 0 | low | 2 | 0 |
| kolaviron | 0 | low | 3 | 0 |
| desmethylcarvedilol | 0 | low | 1 | 0 |
| atractylenolide iii | 0 | low | 1 | 0 |
| naproxen | 0 | medium | 4 | 2 |
| cinacalcet | 0 | low | 5 | 0 |
| ertiprotafib | 0 | medium | 4 | 1 |
| hydroxyl radical | 0 | medium | 10 | 1 |
| lubiprostone | 0 | medium | 1 | 1 |
| methyl 5-aminolevulinate | 0 | low | 1 | 0 |
| satavaptan | 0 | low | 1 | 0 |
| atazanavir sulfate | 0 | medium | 1 | 1 |
| olmesartan | 0 | medium | 68 | 30 |
| rhodioloside | 0 | low | 5 | 0 |
| malvidin | 0 | low | 2 | 0 |
| torcetrapib | 0 | medium | 4 | 1 |
| atrasentan | 0 | medium | 31 | 14 |
| o-desmethylindomethacin | 0 | low | 1 | 0 |
| singlet oxygen | 0 | medium | 5 | 1 |
| peroxymonosulfate | 0 | medium | 1 | 1 |
| fidarestat | 0 | medium | 2 | 1 |
| aloesin | 0 | low | 1 | 0 |
| cryptotanshinone | 0 | low | 1 | 0 |
| fenton's reagent | 0 | low | 1 | 0 |
| ar-turmerone | 0 | low | 1 | 0 |
| aldosterone 18-glucuronide | 0 | low | 1 | 0 |
| isoflavanone | 0 | medium | 2 | 1 |
| gamma-glu-asp | 0 | low | 1 | 0 |
| leonurine | 0 | low | 1 | 0 |
| 3,5-dihydroxyphenylpropionic acid | 0 | low | 1 | 0 |
| ag 3-5 | 0 | low | 1 | 0 |
| isovitexin | 0 | low | 1 | 0 |
| monodansylthiacadaverine | 0 | low | 2 | 0 |
| glyceollin | 0 | low | 1 | 0 |
| platycodin d | 0 | low | 1 | 0 |
| malabaricone b | 0 | low | 1 | 0 |
| asenapine | 0 | low | 1 | 0 |
| 2-deoxy-2-fluoroglucopyranosyl fluoride | 0 | low | 1 | 0 |
| lysyl-arginyl-alanyl-lysyl-alanyl-lysyl-threonyl-threonyl-lysyl-lysyl-arginine | 0 | low | 1 | 0 |
| m 16209 | 0 | low | 2 | 0 |
| sdz wag-994 | 0 | low | 1 | 0 |
| 4-trifluoromethylsalicylic acid | 0 | low | 1 | 0 |
| methylinositol | 0 | medium | 9 | 4 |
| epsilon-n-methyllysine | 0 | low | 1 | 0 |
| 3,3',5-triiodothyronamine | 0 | low | 1 | 0 |
| lauroyl-coenzyme a | 0 | low | 1 | 0 |
| 4'-galactooligosaccharide | 0 | medium | 1 | 1 |
| avasimibe | 0 | low | 1 | 0 |
| technetium tc 99m pentetate | 0 | medium | 15 | 3 |
| n-valyltryptophan | 0 | low | 1 | 0 |
| lanthanum carbonate | 0 | medium | 1 | 1 |
| boswellic acid | 0 | low | 1 | 0 |
| symmetric dimethylarginine | 0 | medium | 16 | 2 |
| n,n-di-n-propylserotonin | 0 | medium | 1 | 1 |
| varenicline | 0 | medium | 5 | 2 |
| farglitazar | 0 | medium | 5 | 1 |
| 5-hydroxyhexanoic acid | 0 | medium | 2 | 1 |
| n,n'-bis(salicylideneamino)ethane-manganese(ii) | 0 | low | 2 | 0 |
| angiotensin ii | 0 | medium | 218 | 40 |
| 3-methyladenosine | 0 | low | 1 | 0 |
| campesterol | 0 | medium | 12 | 5 |
| ly 79771 | 0 | low | 1 | 0 |
| gr 144053 | 0 | low | 1 | 0 |
| n-formylmethionyl-methionyl-phenylalanine | 0 | low | 1 | 0 |
| atropine | 0 | medium | 21 | 2 |
| lignin | 0 | medium | 2 | 1 |
| ropivacaine | 0 | medium | 6 | 1 |
| sb 203580 | 0 | low | 6 | 0 |
| sb 216763 | 0 | low | 2 | 0 |
| zm 241385 | 0 | low | 1 | 0 |
| erlotinib hydrochloride | 0 | low | 5 | 0 |
| 4'-o-methylepigallocatechin | 0 | low | 1 | 0 |
| lu 135252 | 0 | low | 2 | 0 |
| organophosphonates | 0 | medium | 20 | 1 |
| dialuric acid | 0 | low | 1 | 0 |
| cacalol | 0 | low | 1 | 0 |
| psyllium | 0 | medium | 22 | 8 |
| scutellarin | 0 | low | 5 | 0 |
| dioxiram | 0 | low | 1 | 0 |
| dihydroresveratrol | 0 | medium | 2 | 1 |
| glycitin | 0 | low | 1 | 0 |
| cirsimaritin | 0 | low | 2 | 0 |
| loureirin b | 0 | low | 1 | 0 |
| mk 912 | 0 | medium | 1 | 1 |
| ternatin heptapeptide | 0 | low | 1 | 0 |
| 4-nitro-3-dimethylaminopropiophenone | 0 | medium | 5 | 1 |
| bis(diazo)benzidine | 0 | low | 1 | 0 |
| n(delta)-acetylornithine | 0 | low | 1 | 0 |
| 6-dodecyl-2-methoxy-1,4-benzoquinone | 0 | low | 1 | 0 |
| 4-carboxyphenylglyoxal | 0 | low | 1 | 0 |
| 2-oxo-3-deoxygalactonic acid | 0 | low | 1 | 0 |
| n(2)-(gamma-d-glutamyl)-meso-2,2'-diaminopimelic acid | 0 | low | 1 | 0 |
| depsidomycin | 0 | low | 1 | 0 |
| cadmium metallothionein | 0 | low | 1 | 0 |
| glucovance | 0 | medium | 22 | 6 |
| mcc-555 | 0 | low | 3 | 0 |
| dronedarone | 0 | low | 1 | 0 |
| ramelteon | 0 | low | 2 | 0 |
| lapatinib | 0 | low | 1 | 0 |
| bmy 7378 | 0 | low | 1 | 0 |
| darunavir | 0 | low | 1 | 0 |
| deferasirox | 0 | low | 1 | 0 |
| dabigatran | 0 | medium | 9 | 1 |
| sorafenib | 0 | low | 9 | 0 |
| telmisartan, hydrochlorothiazide drug combination | 0 | medium | 1 | 1 |
| alagebrium | 0 | low | 3 | 0 |
| succinobucol | 0 | medium | 2 | 1 |
| lenalidomide | 0 | medium | 3 | 1 |
| solifenacin succinate | 0 | low | 2 | 0 |
| alanyl-glutamyl-aspartyl-glycine | 0 | low | 1 | 0 |
| cholic acid | 0 | medium | 8 | 2 |
| sitosterol, (3beta)-isomer | 0 | low | 2 | 0 |
| erythritol | 0 | medium | 6 | 1 |
| deoxycholic acid | 0 | medium | 9 | 2 |
| delrin | 0 | low | 1 | 0 |
| estradiol 3-benzoate | 0 | low | 1 | 0 |
| cortisone | 0 | medium | 27 | 2 |
| isoflupredone acetate | 0 | low | 1 | 0 |
| cholesterol alpha-oxide | 0 | low | 1 | 0 |
| cellulose triacetate | 0 | medium | 1 | 1 |
| 3-nitrotyrosine | 0 | medium | 74 | 13 |
| 5-hydroxymethylfurfural | 0 | medium | 6 | 1 |
| sodium sulfide | 0 | low | 1 | 0 |
| stigmastanol | 0 | medium | 3 | 2 |
| lanosterol | 0 | medium | 2 | 1 |
| benzofurans | 0 | medium | 71 | 16 |
| 5-hydroxymethyl-1,2,3,4-cyclohexanetetrol | 0 | low | 1 | 0 |
| withaferin a | 0 | low | 1 | 0 |
| esi-05 | 0 | low | 1 | 0 |
| wortmannin | 0 | low | 20 | 0 |
| 2-oxindole | 0 | low | 1 | 0 |
| malabaricone a | 0 | low | 1 | 0 |
| withanolides | 0 | low | 3 | 0 |
| sorbinil | 0 | medium | 7 | 4 |
| 3,4-dihydroxyphenylpropionic acid | 0 | medium | 2 | 1 |
| erianin | 0 | low | 1 | 0 |
| trimethoprim, sulfamethoxazole drug combination | 0 | medium | 17 | 1 |
| taurochenodeoxycholic acid | 0 | low | 11 | 0 |
| bortezomib | 0 | medium | 5 | 1 |
| ritonavir | 0 | medium | 10 | 1 |
| Bardoxolone | 0 | medium | 2 | 1 |
| bardoxolone methyl | 0 | medium | 24 | 14 |
| n,n-dimethyl-n-(18f)fluoromethyl-2-hydroxyethylammonium | 0 | low | 1 | 0 |
| dihydropyridines | 0 | medium | 68 | 46 |
| povidone-iodine | 0 | medium | 5 | 2 |
| permanganate | 0 | medium | 1 | 1 |
| leupeptins | 0 | low | 3 | 0 |
| carboplatin | 0 | medium | 9 | 1 |
| lithium chloride | 0 | low | 4 | 0 |
| s-adenosylhomocysteine | 0 | low | 2 | 0 |
| glyceraldehyde 3-phosphate | 0 | low | 1 | 0 |
| glycogen | 0 | medium | 379 | 17 |
| sorbose | 0 | low | 4 | 0 |
| arabinose | 0 | low | 7 | 0 |
| n-acetylneuraminic acid | 0 | medium | 64 | 4 |
| fibrin | 0 | medium | 42 | 2 |
| bradykinin | 0 | medium | 38 | 7 |
| amylopectin | 0 | low | 2 | 0 |
| glucosamine | 0 | medium | 82 | 31 |
| glucosamine 6-phosphate | 0 | low | 1 | 0 |
| elastin | 0 | low | 13 | 0 |
| carnosine | 0 | medium | 31 | 11 |
| mevalonic acid | 0 | medium | 11 | 2 |
| naringenin | 0 | low | 19 | 0 |
| epiglucan | 0 | medium | 35 | 8 |
| diaminopimelic acid | 0 | low | 2 | 0 |
| oxytocin | 0 | medium | 25 | 3 |
| laminaran | 0 | low | 1 | 0 |
| d-tagatose | 0 | medium | 9 | 3 |
| pantetheine | 0 | low | 2 | 0 |
| dithioerythritol | 0 | low | 1 | 0 |
| theanine | 0 | low | 2 | 0 |
| inositol 1,4,5-trisphosphate | 0 | low | 7 | 0 |
| cysteinylglycine | 0 | medium | 2 | 1 |
| ouabain | 0 | medium | 23 | 2 |
| salicin | 0 | low | 1 | 0 |
| scopolin | 0 | low | 1 | 0 |
| casein hydrolysate | 0 | medium | 4 | 1 |
| stachyose | 0 | low | 1 | 0 |
| taxifolin | 0 | low | 7 | 0 |
| isomaltulose | 0 | medium | 11 | 6 |
| desmosterol | 0 | low | 2 | 0 |
| alpha-aminobutyric acid | 0 | low | 1 | 0 |
| pentostatin | 0 | low | 1 | 0 |
| nicotinamide-beta-riboside | 0 | low | 1 | 0 |
| 5-o-methyl-myo-inositol | 0 | low | 1 | 0 |
| n-glycolylneuraminic acid | 0 | low | 1 | 0 |
| nitroarginine | 0 | low | 13 | 0 |
| 1-kestose | 0 | low | 1 | 0 |
| trimethyllysine | 0 | low | 1 | 0 |
| inositol 3-phosphate | 0 | medium | 3 | 1 |
| 1-o-indol-3-ylacetylglucose | 0 | low | 1 | 0 |
| adenosine 5'-o-(3-thiotriphosphate) | 0 | low | 1 | 0 |
| dehydroascorbic acid | 0 | low | 6 | 0 |
| cortodoxone | 0 | low | 1 | 0 |
| eriodictyol | 0 | low | 2 | 0 |
| arbutin | 0 | low | 1 | 0 |
| fructans | 0 | low | 5 | 0 |
| cellulase | 0 | low | 1 | 0 |
| psicose, (d)-isomer | 0 | medium | 11 | 3 |
| quinidine | 0 | low | 2 | 0 |
| meropenem | 0 | medium | 8 | 1 |
| griseofulvin | 0 | low | 1 | 0 |
| monensin | 0 | low | 1 | 0 |
| digitoxin | 0 | low | 3 | 0 |
| saquinavir | 0 | low | 3 | 0 |
| pentazocine | 0 | low | 1 | 0 |
| rocuronium | 0 | low | 5 | 0 |
| hyperforin | 0 | low | 1 | 0 |
| abacavir | 0 | low | 2 | 0 |
| netilmicin | 0 | medium | 2 | 1 |
| mometasone furoate | 0 | low | 1 | 0 |
| linezolid | 0 | medium | 9 | 1 |
| phalloidine | 0 | low | 2 | 0 |
| indican | 0 | low | 12 | 0 |
| cyanidin 3-o-beta-d-glucopyranoside | 0 | low | 1 | 0 |
| ryanodine | 0 | low | 1 | 0 |
| ginsenoside re | 0 | medium | 5 | 1 |
| ginsenoside rg1 | 0 | low | 7 | 0 |
| notoginsenoside r1 | 0 | low | 1 | 0 |
| stevioside | 0 | medium | 10 | 2 |
| genipin | 0 | low | 2 | 0 |
| naringin | 0 | low | 7 | 0 |
| swertiamarin | 0 | low | 4 | 0 |
| ochratoxin a | 0 | low | 1 | 0 |
| theasinensin a | 0 | low | 1 | 0 |
| tecomine | 0 | low | 1 | 0 |
| vicenin ii | 0 | low | 1 | 0 |
| lusianthridin | 0 | low | 1 | 0 |
| gingerol | 0 | low | 5 | 0 |
| hinokinin | 0 | low | 1 | 0 |
| alpha bitter acid | 0 | low | 1 | 0 |
| lignans | 0 | medium | 40 | 2 |
| acriflavine | 0 | low | 1 | 0 |
| temocaprilat | 0 | low | 1 | 0 |
| bq 123 | 0 | medium | 12 | 2 |
| n-formylmethionine leucyl-phenylalanine | 0 | medium | 15 | 1 |
| teprotide | 0 | low | 1 | 0 |
| sodium arsenite | 0 | low | 2 | 0 |
| mepirodipine | 0 | medium | 3 | 3 |
| temocapril hydrochloride | 0 | medium | 12 | 6 |
| erythromycin ethylsuccinate | 0 | low | 1 | 0 |
| vinpocetine | 0 | low | 3 | 0 |
| tibolone | 0 | medium | 7 | 2 |
| sultamicillin | 0 | medium | 2 | 1 |
| betadex | 0 | medium | 6 | 1 |
| sucrose octasulfate | 0 | medium | 2 | 1 |
| maleic acid | 0 | low | 1 | 0 |
| acetyl coenzyme a | 0 | low | 17 | 0 |
| e-z cinnamic acid | 0 | low | 6 | 0 |
| ergosterol | 0 | low | 2 | 0 |
| trichostatin a | 0 | low | 3 | 0 |
| cp 320626 | 0 | low | 1 | 0 |
| 2-(oxaloamino)benzoic acid | 0 | low | 1 | 0 |
| tretinoin | 0 | medium | 18 | 1 |
| arachidonic acid | 0 | medium | 97 | 12 |
| alpha-cyclodextrin | 0 | medium | 2 | 2 |
| farnesol | 0 | low | 2 | 0 |
| 3-hydroxy-3-methylglutaryl-coenzyme a | 0 | low | 3 | 0 |
| retinol | 0 | medium | 99 | 12 |
| cyanoginosin lr | 0 | low | 1 | 0 |
| docosahexaenoate | 0 | low | 1 | 0 |
| palmitoleic acid | 0 | low | 24 | 0 |
| oleic acid | 0 | medium | 74 | 9 |
| tacrolimus | 0 | medium | 60 | 6 |
| ferulic acid | 0 | medium | 23 | 2 |
| pectins | 0 | medium | 18 | 2 |
| cerivastatin | 0 | medium | 17 | 11 |
| cocaine | 0 | medium | 20 | 4 |
| eicosapentaenoic acid | 0 | medium | 141 | 50 |
| thapsigargin | 0 | low | 26 | 0 |
| mycophenolic acid | 0 | medium | 20 | 1 |
| mupirocin | 0 | low | 2 | 0 |
| clindamycin | 0 | medium | 15 | 2 |
| gw 409544 | 0 | low | 2 | 0 |
| keratan sulfate | 0 | low | 1 | 0 |
| gw 6471 | 0 | low | 1 | 0 |
| lycopene | 0 | medium | 26 | 6 |
| fosfomycin | 0 | medium | 3 | 1 |
| zithromax | 0 | medium | 10 | 2 |
| adenylosuccinate | 0 | low | 1 | 0 |
| formycin | 0 | low | 2 | 0 |
| valine-pyrrolidide | 0 | low | 1 | 0 |
| geranylgeranyl pyrophosphate | 0 | low | 2 | 0 |
| drf 2725 | 0 | medium | 6 | 3 |
| obeticholic acid | 0 | medium | 5 | 1 |
| gw 3965 | 0 | low | 3 | 0 |
| t0901317 | 0 | medium | 10 | 1 |
| epothilone b | 0 | low | 2 | 0 |
| n-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)urea | 0 | low | 1 | 0 |
| y 27632 | 0 | low | 4 | 0 |
| adenosine-5'-(n-ethylcarboxamide) | 0 | low | 3 | 0 |
| prostaglandin d2 | 0 | medium | 8 | 1 |
| diethylstilbestrol | 0 | low | 2 | 0 |
| epothilone a | 0 | low | 1 | 0 |
| 7-n-butyl-6-(4'-hydroxyphenyl)-5h-pyrrolo(2,3b)pyrazine | 0 | low | 1 | 0 |
| 6-bromoindirubin-3'-oxime | 0 | low | 1 | 0 |
| cp-640186 | 0 | low | 1 | 0 |
| alitretinoin | 0 | low | 2 | 0 |
| h 89 | 0 | low | 8 | 0 |
| imidazolidines | 0 | medium | 21 | 8 |
| aclarubicin | 0 | low | 1 | 0 |
| thymopentin | 0 | low | 1 | 0 |
| acid fuchsin | 0 | low | 1 | 0 |
| decitabine | 0 | low | 1 | 0 |
| 1,4-dideoxy-1,4-imino-d-arabinitol | 0 | low | 1 | 0 |
| pantethine | 0 | low | 2 | 0 |
| texas red | 0 | low | 1 | 0 |
| steviol | 0 | medium | 3 | 1 |
| iridoids | 0 | medium | 25 | 1 |
| ketoconazole | 0 | low | 1 | 0 |
| dactinomycin | 0 | low | 3 | 0 |
| gamma-sitosterol | 0 | medium | 13 | 3 |
| melphalan | 0 | medium | 3 | 1 |
| enkephalin, leucine | 0 | low | 4 | 0 |
| benzyloxycarbonylleucyl-leucyl-leucine aldehyde | 0 | low | 3 | 0 |
| tenofovir | 0 | medium | 8 | 2 |
| posaconazole | 0 | low | 5 | 0 |
| l 743,872 | 0 | low | 2 | 0 |
| euscaphic acid | 0 | low | 1 | 0 |
| 5-ethynyl-2'-deoxyuridine | 0 | low | 1 | 0 |
| cinnamtannin b-1 | 0 | low | 1 | 0 |
| shikonin | 0 | low | 2 | 0 |
| 8-prenylnaringenin | 0 | low | 2 | 0 |
| glycyrin | 0 | low | 1 | 0 |
| riboflavin | 0 | medium | 14 | 2 |
| maltitol | 0 | low | 3 | 0 |
| n-nonyl-1-deoxynojirimycin | 0 | low | 1 | 0 |
| licocoumarone | 0 | low | 1 | 0 |
| 2,3-bis(bromomethyl)quinoxaline-1,4-dioxide | 0 | medium | 1 | 1 |
| ammonium metavanadate | 0 | low | 1 | 0 |
| sodium bicarbonate | 0 | medium | 19 | 2 |
| dipyrone | 0 | medium | 3 | 1 |
| sodium perchlorate | 0 | low | 1 | 0 |
| cholestane-3,5,6-triol | 0 | low | 1 | 0 |
| bromochloroacetic acid | 0 | low | 16 | 0 |
| isobornyl acrylate | 0 | low | 4 | 0 |
| pyrrolopyrimidine | 0 | low | 1 | 0 |
| carbenoxolone sodium | 0 | medium | 5 | 1 |
| carbenoxolone | 0 | low | 3 | 0 |
| cinnamaldehyde | 0 | low | 5 | 0 |
| trans-4-coumaric acid | 0 | low | 2 | 0 |
| geraniol | 0 | medium | 3 | 1 |
| dimethyl fumarate | 0 | low | 2 | 0 |
| glycosides | 0 | medium | 72 | 12 |
| 4-oxothiazolidine | 0 | low | 1 | 0 |
| chalcone | 0 | low | 5 | 0 |
| isomethyleugenol | 0 | low | 48 | 0 |
| citral | 0 | low | 2 | 0 |
| piperine | 0 | medium | 7 | 3 |
| squalene | 0 | low | 8 | 0 |
| stilbenes | 0 | medium | 100 | 15 |
| xanthohumol | 0 | low | 5 | 0 |
| picibanil | 0 | low | 1 | 0 |
| sorbic acid | 0 | low | 1 | 0 |
| flavin-adenine dinucleotide | 0 | low | 7 | 0 |
| cannabidiol | 0 | medium | 7 | 1 |
| malonyl coenzyme a | 0 | medium | 14 | 2 |
| buprenorphine | 0 | medium | 2 | 1 |
| lypressin | 0 | low | 1 | 0 |
| arginine vasopressin | 0 | medium | 32 | 3 |
| pyrophosphate | 0 | low | 1 | 0 |
| palmitoyl coenzyme a | 0 | low | 5 | 0 |
| gw9662 | 0 | low | 9 | 0 |
| cgp 60474 | 0 | low | 1 | 0 |
| s 1033 | 0 | low | 6 | 0 |
| dodecylphosphocholine | 0 | low | 1 | 0 |
| methylatropine | 0 | low | 2 | 0 |
| canrenoic acid | 0 | low | 1 | 0 |
| omapatrilat | 0 | low | 3 | 0 |
| tropisetron | 0 | low | 1 | 0 |
| benidipine | 0 | medium | 6 | 1 |
| tram 34 | 0 | low | 2 | 0 |
| leuprolide | 0 | low | 1 | 0 |
| fludarabine | 0 | low | 1 | 0 |
| propylthiouracil | 0 | low | 1 | 0 |
| nsc 4347 | 0 | low | 3 | 0 |
| 4-(1,3-benzodioxol-5-yl)-6-methyl-2-oxo-3,4-dihydro-1H-pyrimidine-5-carboxylic acid ethyl ester | 0 | low | 1 | 0 |
| sesquiterpenes | 0 | medium | 17 | 1 |
| chlorprothixene | 0 | low | 1 | 0 |
| etomidate | 0 | low | 1 | 0 |
| sb 366791 | 0 | low | 1 | 0 |
| 3,3',4,5'-tetrahydroxystilbene | 0 | low | 1 | 0 |
| levosulpiride | 0 | low | 3 | 0 |
| caffeic acid | 0 | medium | 16 | 1 |
| cid755673 | 0 | low | 1 | 0 |
| (S)-monastrol | 0 | low | 1 | 0 |
| cotinine | 0 | low | 9 | 0 |
| flunarizine | 0 | low | 1 | 0 |
| curcumin | 0 | medium | 134 | 30 |
| cct018159 | 0 | low | 1 | 0 |
| secinh3 | 0 | low | 1 | 0 |
| thiazoline-2-thione | 0 | medium | 2 | 1 |
| rhodanine | 0 | medium | 17 | 8 |
| benztropine | 0 | low | 1 | 0 |
| 2',4',6'-Trihydroxydihydrochalcone | 0 | low | 1 | 0 |
| thiohydantoins | 0 | medium | 1 | 1 |
| methimazole | 0 | low | 8 | 0 |
| p-cyanophenylalanine | 0 | low | 1 | 0 |
| sulindac | 0 | low | 1 | 0 |
| capsaicin | 0 | medium | 30 | 2 |
| enclomiphene | 0 | medium | 9 | 2 |
| terbinafine | 0 | medium | 10 | 1 |
| epalrestat | 0 | medium | 17 | 8 |
| ac 55649 | 0 | low | 1 | 0 |
| chlorogenic acid | 0 | medium | 47 | 4 |
| zln024 | 0 | low | 2 | 0 |
| digitoxose | 0 | low | 1 | 0 |
| thiobarbituric acid | 0 | medium | 4 | 1 |
| thiourea | 0 | medium | 6 | 1 |
| D-fructopyranose | 0 | medium | 317 | 39 |
| thioacetamide | 0 | low | 3 | 0 |
| ferric ferrocyanide | 0 | low | 1 | 0 |
| meso-1,2-diphenylethylenediamine, (r-(r*,s*))-isomer | 0 | medium | 1 | 1 |
| capsazepine | 0 | low | 1 | 0 |
| fumonisin b1 | 0 | low | 2 | 0 |
| 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole | 0 | low | 2 | 0 |
| tamoxifen | 0 | low | 18 | 0 |
| nadp | 0 | medium | 34 | 2 |
| 1,1-diphenyl-2-picrylhydrazyl | 0 | medium | 13 | 1 |
| 17-iodoheptadecanoic acid | 0 | low | 2 | 0 |
| ethyl 6-methyl-4-phenyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate | 0 | low | 1 | 0 |
| bi-78d3 | 0 | low | 2 | 0 |
| 5-carboxytetramethylrhodamine succinimidyl ester | 0 | low | 1 | 0 |
| 4-hydroxyisoleucine | 0 | low | 4 | 0 |
| t 0070907 | 0 | low | 2 | 0 |
| sc 514 | 0 | low | 1 | 0 |
| 2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole | 0 | low | 3 | 0 |
| sirtinol | 0 | low | 1 | 0 |
| methyl-thiohydantoin-tryptophan | 0 | low | 2 | 0 |
| importazole | 0 | low | 1 | 0 |
| fusidic acid | 0 | low | 3 | 0 |
| thiopental | 0 | low | 1 | 0 |
| estrone sulfate | 0 | low | 2 | 0 |
| ranitidine | 0 | medium | 2 | 2 |
| maraviroc | 0 | medium | 2 | 1 |
| u 0126 | 0 | low | 11 | 0 |
| dieckol | 0 | medium | 1 | 1 |
| telaprevir | 0 | low | 3 | 0 |
| l 783281 | 0 | low | 7 | 0 |
| lithium | 0 | medium | 34 | 2 |
| cobaltous chloride | 0 | low | 5 | 0 |
| nitrogen dioxide | 0 | medium | 30 | 2 |
| dermatan sulfate | 0 | medium | 2 | 1 |
| hydroxylysine | 0 | low | 2 | 0 |
| raclopride | 0 | low | 1 | 0 |
| ranitidine bismuth citrate | 0 | medium | 1 | 1 |
| gestodene | 0 | medium | 2 | 1 |
| orlistat | 0 | medium | 113 | 27 |
| quinine | 0 | medium | 5 | 1 |
| androstane-3,17-diol glucuronide | 0 | low | 1 | 0 |
| glycodeoxycholic acid | 0 | low | 1 | 0 |
| rtki cpd | 0 | low | 1 | 0 |
| bis(maltolato)oxovanadium(iv) | 0 | medium | 8 | 1 |
| (5-(3-thienyl)tetrazol-1-yl)acetic acid | 0 | low | 3 | 0 |
| 2-chloro-n(6)-(3-iodobenzyl)adenosine-5'-n-methyluronamide | 0 | low | 1 | 0 |
| cystine | 0 | medium | 5 | 1 |
| ly335979 | 0 | low | 1 | 0 |
| hirsutine | 0 | low | 1 | 0 |
| slv 306 | 0 | medium | 2 | 1 |
| freedom | 0 | low | 1 | 0 |
| prucalopride | 0 | medium | 1 | 1 |
| safingol | 0 | low | 4 | 0 |
| 4-(3-3,4-p-menthadien-(1,8)-yl)olivetol | 0 | low | 1 | 0 |
| dasatinib | 0 | low | 6 | 0 |
| s 15261 | 0 | low | 2 | 0 |
| 12-ketolithocholic acid | 0 | low | 1 | 0 |
| 3-deoxyhexulose | 0 | low | 1 | 0 |
| 4-azidophenylalanine | 0 | low | 1 | 0 |
| clinitest | 0 | low | 2 | 0 |
| glutaryl-coenzyme a | 0 | low | 1 | 0 |
| pactimibe | 0 | low | 1 | 0 |
| udp-n-acetylglucosaminuronic acid | 0 | low | 1 | 0 |
| sanorg 34006 | 0 | low | 1 | 0 |
| lenabasum | 0 | low | 1 | 0 |
| cytellin | 0 | medium | 19 | 6 |
| myomycin | 0 | low | 1 | 0 |
| wogonoside | 0 | low | 1 | 0 |
| ginsenosides | 0 | medium | 40 | 4 |
| 2-(4-(2-carboxyethyl)phenethylamino)-5'-n-ethylcarboxamidoadenosine | 0 | low | 2 | 0 |
| 1,4-benzothiazine | 0 | low | 1 | 0 |
| phosphothreonine | 0 | low | 2 | 0 |
| cambinol | 0 | low | 1 | 0 |
| ovalbumin | 0 | low | 3 | 0 |
| 2-nitrophenylhydrazine | 0 | low | 2 | 0 |
| gw 7647 | 0 | low | 2 | 0 |
| sodium dodecyl sulfate | 0 | low | 8 | 0 |
| sto 609 | 0 | low | 2 | 0 |
| crocin | 0 | medium | 14 | 3 |
| galactomannan | 0 | medium | 4 | 1 |
| 3-(1-adamantyl)-6,7,8,9-tetrahydro-5h-(1,2,4)triazolo(4,3-a)azepine | 0 | low | 2 | 0 |
| sb 242084 | 0 | low | 1 | 0 |
| flavan-3-ol | 0 | medium | 10 | 2 |
| 3-(2,4-dichloro-5-methoxyphenyl)-2-sulfanyl-4(3h)-quinazolinone | 0 | low | 1 | 0 |
| 4-phenyl-2-propionamidotetraline | 0 | low | 2 | 0 |
| 2-phenylmelatonin | 0 | low | 1 | 0 |
| alpha-chymotrypsin | 0 | medium | 16 | 1 |
| ferrostatin-1 | 0 | low | 1 | 0 |
| sew2871 | 0 | low | 1 | 0 |
| 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione | 0 | medium | 3 | 1 |
| sb 415286 | 0 | low | 3 | 0 |
| 17-ketosteroids | 0 | medium | 2 | 1 |
| naphthoquinones | 0 | low | 5 | 0 |
| 2',3'-dialdehyde atp | 0 | low | 1 | 0 |
| am 630 | 0 | low | 1 | 0 |
| sc 560 | 0 | low | 1 | 0 |
| sodium borohydride | 0 | low | 1 | 0 |
| gl-4 | 0 | low | 1 | 0 |
| alpha-carotene | 0 | medium | 7 | 2 |
| osteoprotegerin | 0 | medium | 134 | 10 |
| cathepsin g | 0 | low | 3 | 0 |
| icodextrin | 0 | medium | 8 | 2 |
| flosequinan | 0 | medium | 1 | 1 |
| rhodamine 123 | 0 | low | 1 | 0 |
| 4-cresol sulfate | 0 | low | 3 | 0 |
| myelin basic protein | 0 | low | 1 | 0 |
| alsterpaullone | 0 | low | 1 | 0 |
| imd 0354 | 0 | low | 3 | 0 |
| ex 527 | 0 | low | 2 | 0 |
| iodoazomycin arabinoside | 0 | low | 1 | 0 |
| tetrathiomolybdate | 0 | low | 1 | 0 |
| 1,4-dihydropyrimidine | 0 | low | 2 | 0 |
| eupatilin | 0 | low | 1 | 0 |
| sq 109 | 0 | low | 1 | 0 |
| quercetin 3-o-glucuronide | 0 | low | 1 | 0 |
| isoliensinine | 0 | low | 1 | 0 |
| gallocatechin-3-gallate | 0 | low | 1 | 0 |
| jtk-303 | 0 | low | 1 | 0 |
| ku 55933 | 0 | low | 1 | 0 |
| sphingosine | 0 | medium | 49 | 2 |
| ubiquinone q2 | 0 | low | 1 | 0 |
| bilirubin | 0 | medium | 117 | 8 |
| dinoprostone | 0 | medium | 40 | 3 |
| dinoprost | 0 | medium | 118 | 36 |
| biochanin a | 0 | low | 2 | 0 |
| formononetin | 0 | low | 3 | 0 |
| vitexin | 0 | low | 1 | 0 |
| acacetin | 0 | low | 1 | 0 |
| apigenin | 0 | medium | 16 | 1 |
| luteolin | 0 | medium | 17 | 1 |
| 7,3'-dihydroxy-4'-methoxyisoflavone | 0 | low | 2 | 0 |
| calcitriol | 0 | medium | 87 | 16 |
| pinosylvin | 0 | low | 1 | 0 |
| quercitrin | 0 | low | 2 | 0 |
| scopoletin | 0 | low | 2 | 0 |
| vomifoliol | 0 | low | 1 | 0 |
| ubiquinone 9 | 0 | low | 1 | 0 |
| vitamin k semiquinone radical | 0 | medium | 35 | 7 |
| beta carotene | 0 | medium | 50 | 14 |
| 11-cis-retinal | 0 | low | 3 | 0 |
| leukotriene b4 | 0 | medium | 5 | 1 |
| leukotriene c4 | 0 | low | 1 | 0 |
| thromboxane a2 | 0 | medium | 32 | 3 |
| retinol palmitate | 0 | medium | 19 | 8 |
| feruloyltyramine | 0 | low | 1 | 0 |
| hymecromone | 0 | low | 1 | 0 |
| 8,11,14-eicosatrienoic acid | 0 | low | 16 | 0 |
| luteolin-7-glucoside | 0 | low | 1 | 0 |
| furylfuramide | 0 | low | 1 | 0 |
| 15-ketoprostaglandin e2 | 0 | low | 1 | 0 |
| alprostadil | 0 | medium | 43 | 13 |
| stigmasterol | 0 | low | 1 | 0 |
| rutin | 0 | medium | 22 | 3 |
| kaempferol | 0 | low | 10 | 0 |
| leukotriene e4 | 0 | medium | 4 | 1 |
| prostaglandin a2 | 0 | low | 1 | 0 |
| 6-ketoprostaglandin f1 alpha | 0 | medium | 42 | 4 |
| 11-dehydro-thromboxane b2 | 0 | medium | 25 | 11 |
| arachidonic acid omega-9 hydroperoxide | 0 | low | 2 | 0 |
| zeaxanthin | 0 | medium | 9 | 1 |
| lipoxin a4 | 0 | medium | 11 | 1 |
| gamma-linolenic acid | 0 | medium | 11 | 4 |
| alpha-linolenic acid | 0 | medium | 41 | 6 |
| prostaglandin f1 | 0 | medium | 1 | 1 |
| harmine | 0 | low | 2 | 0 |
| naringenin chalcone | 0 | low | 1 | 0 |
| genistein | 0 | medium | 26 | 2 |
| amphotericin b | 0 | low | 50 | 0 |
| clavulanic acid | 0 | low | 1 | 0 |
| pulmicort | 0 | low | 1 | 0 |
| eprosartan | 0 | medium | 4 | 2 |
| montelukast | 0 | medium | 5 | 1 |
| cyclobenzaprine | 0 | low | 2 | 0 |
| 11-octadecenoic acid | 0 | low | 2 | 0 |
| astaxanthine | 0 | medium | 11 | 1 |
| cryptoxanthins | 0 | medium | 8 | 1 |
| fucoxanthin | 0 | low | 3 | 0 |
| lutein | 0 | medium | 16 | 1 |
| azadirachtin | 0 | low | 1 | 0 |
| esculetin | 0 | low | 1 | 0 |
| esculin | 0 | low | 2 | 0 |
| pteryxin | 0 | low | 1 | 0 |
| 7-hydroxycoumarin | 0 | low | 1 | 0 |
| humulene | 0 | medium | 11 | 2 |
| oleuropein | 0 | medium | 8 | 1 |
| amentoflavone | 0 | low | 1 | 0 |
| baicalein | 0 | medium | 8 | 1 |
| chrysin | 0 | low | 5 | 0 |
| diosmetin | 0 | low | 1 | 0 |
| diosmin | 0 | medium | 5 | 2 |
| fisetin | 0 | low | 2 | 0 |
| galangin | 0 | low | 3 | 0 |
| demethylbellidifolin | 0 | low | 1 | 0 |
| hispidulin | 0 | low | 1 | 0 |
| 6-hydroxyluteolin | 0 | low | 1 | 0 |
| hyperoside | 0 | low | 3 | 0 |
| mangiferin | 0 | medium | 15 | 1 |
| mangostin | 0 | low | 3 | 0 |
| 3-methylquercetin | 0 | low | 5 | 0 |
| norlichexanthone | 0 | low | 1 | 0 |
| morin | 0 | low | 4 | 0 |
| morusin | 0 | medium | 1 | 1 |
| myricetin | 0 | medium | 11 | 2 |
| orientin | 0 | low | 2 | 0 |
| quercetagetin | 0 | low | 1 | 0 |
| tricetin | 0 | low | 1 | 0 |
| wogonin | 0 | low | 2 | 0 |
| coumestrol | 0 | low | 1 | 0 |
| daidzein | 0 | low | 11 | 0 |
| pterostilbene | 0 | low | 5 | 0 |
| epsilon-viniferin | 0 | low | 1 | 0 |
| genistein-8-c-glucoside | 0 | low | 1 | 0 |
| chicoric acid | 0 | low | 2 | 0 |
| echinacoside | 0 | low | 1 | 0 |
| caffeic acid phenethyl ester | 0 | low | 2 | 0 |
| rosmarinic acid | 0 | medium | 3 | 1 |
| salvianolic acid a | 0 | low | 7 | 0 |
| shogaol | 0 | low | 2 | 0 |
| acteoside | 0 | low | 1 | 0 |
| psi-baptigenin | 0 | low | 1 | 0 |
| tectorigenin | 0 | low | 2 | 0 |
| rottlerin | 0 | low | 7 | 0 |
| ellagic acid | 0 | medium | 11 | 1 |
| ginkgolic acid | 0 | low | 1 | 0 |
| coenzyme q10 | 0 | medium | 46 | 19 |
| anandamide | 0 | low | 12 | 0 |
| cilnidipine | 0 | medium | 10 | 5 |
| tranilast | 0 | medium | 2 | 1 |
| 8-epi-prostaglandin f2alpha | 0 | medium | 100 | 32 |
| glyceryl 2-arachidonate | 0 | low | 5 | 0 |
| 1-palmitoyl-2-oleoylglycero-3-phosphoglycerol | 0 | low | 1 | 0 |
| tocotrienol, delta | 0 | medium | 1 | 1 |
| menatetrenone | 0 | low | 1 | 0 |
| etretinate | 0 | low | 1 | 0 |
| isotretinoin | 0 | low | 4 | 0 |
| misoprostol | 0 | medium | 3 | 3 |
| s 1108 | 0 | low | 1 | 0 |
| ozagrel | 0 | low | 2 | 0 |
| fondaparinux | 0 | low | 1 | 0 |
| cinepazide | 0 | low | 1 | 0 |
| cis-vaccenic acid | 0 | low | 1 | 0 |
| 9,11-linoleic acid | 0 | low | 1 | 0 |
| 9-hydroxy-10,12-octadecadienoic acid | 0 | medium | 3 | 1 |
| 13-hydroxy-9,11-octadecadienoic acid | 0 | medium | 3 | 2 |
| 15-keto-13,14-dihydroprostaglandin f2alpha | 0 | low | 2 | 0 |
| prostaglandin i3 | 0 | low | 1 | 0 |
| 2,3-dinor-6-ketoprostaglandin f1alpha | 0 | low | 4 | 0 |
| thromboxane b2 | 0 | medium | 88 | 23 |
| 2,3-dinor-thromboxane b2 | 0 | low | 1 | 0 |
| 20-hydroxy-5,8,11,14-eicosatetraenoic acid | 0 | medium | 5 | 1 |
| 5,6-epoxy-8,11,14-eicosatrienoic acid | 0 | low | 1 | 0 |
| 8,9-epoxyeicosatrienoic acid | 0 | low | 1 | 0 |
| 8-isoprostaglandin e2 | 0 | low | 1 | 0 |
| 4-hydroxy-2-nonenal | 0 | medium | 23 | 2 |
| n-oleoylethanolamine | 0 | low | 6 | 0 |
| ubiquinone 8 | 0 | medium | 2 | 2 |
| menaquinone 6 | 0 | medium | 20 | 7 |
| sphingosine 1-phosphate | 0 | medium | 33 | 1 |
| n-palmitoylsphingosine | 0 | low | 4 | 0 |
| cholesteryl oleate | 0 | low | 1 | 0 |
| hyodeoxycholic acid | 0 | low | 1 | 0 |
| codeine | 0 | low | 2 | 0 |
| perhexiline maleate | 0 | low | 1 | 0 |
| phenylephrine hydrochloride | 0 | low | 3 | 0 |
| oleyl alcohol | 0 | low | 1 | 0 |
| dorzolamide | 0 | low | 3 | 0 |
| hydromorphone | 0 | low | 1 | 0 |
| hydroxystilbamidine | 0 | low | 1 | 0 |
| levetiracetam | 0 | low | 2 | 0 |
| meprednisone | 0 | low | 1 | 0 |
| naloxone | 0 | medium | 11 | 1 |
| vitamin k 1 | 0 | medium | 12 | 3 |
| sirolimus | 0 | medium | 97 | 13 |
| gamma-cyclodextrin | 0 | low | 1 | 0 |
| menaquinone 7 | 0 | medium | 5 | 4 |
| brefeldin a | 0 | low | 1 | 0 |
| alvocidib | 0 | low | 1 | 0 |
| fenretinide | 0 | low | 2 | 0 |
| 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin | 0 | low | 1 | 0 |
| morphine | 0 | medium | 10 | 2 |
| su 9516 | 0 | low | 1 | 0 |
| xylulose | 0 | low | 1 | 0 |
| 3-(2,4-dimethoxybenzylidene)anabaseine | 0 | low | 1 | 0 |
| a 192621 | 0 | low | 3 | 0 |
| adp beta s | 0 | low | 1 | 0 |
| arachidonyl-2-chloroethylamide | 0 | low | 1 | 0 |
| bibo 3457 | 0 | low | 1 | 0 |
| bibp 3226 | 0 | low | 1 | 0 |
| clobetasol | 0 | low | 5 | 0 |
| deamino arginine vasopressin | 0 | low | 4 | 0 |
| dexmedetomidine | 0 | medium | 4 | 1 |
| endomorphin 1 | 0 | medium | 1 | 1 |
| fluticasone | 0 | medium | 3 | 2 |
| goserelin | 0 | medium | 3 | 1 |
| iloprost | 0 | medium | 10 | 3 |
| irl 2500 | 0 | low | 1 | 0 |
| lacidipine | 0 | medium | 4 | 4 |
| enisoprost | 0 | low | 1 | 0 |
| latanoprost | 0 | low | 3 | 0 |
| enprostil | 0 | medium | 2 | 1 |
| ono-ae1-329 | 0 | low | 1 | 0 |
| lysophosphatidic acid | 0 | medium | 7 | 1 |
| lysophosphatidylcholines | 0 | medium | 32 | 2 |
| mdl 100907 | 0 | medium | 8 | 1 |
| cytochalasin b | 0 | low | 11 | 0 |
| nateglinide | 0 | medium | 178 | 74 |
| neurokinin b | 0 | low | 2 | 0 |
| pd 123319 | 0 | low | 5 | 0 |
| spirapril | 0 | medium | 3 | 2 |
| sq 29548 | 0 | low | 1 | 0 |
| sulfenamide | 0 | low | 2 | 0 |
| cl 316243 | 0 | low | 14 | 0 |
| kn 93 | 0 | low | 4 | 0 |
| silodosin | 0 | low | 1 | 0 |
| kn 62 | 0 | low | 2 | 0 |
| sulprostone | 0 | low | 1 | 0 |
| 5,9,12-octadecatrienoic acid | 0 | medium | 2 | 1 |
| stearidonic acid | 0 | low | 1 | 0 |
| 10-hydroxy-2-decenoic acid | 0 | low | 1 | 0 |
| 12-hydroxy-5,8,10-heptadecatrienoic acid | 0 | low | 1 | 0 |
| 1,2-oleoylphosphatidylcholine | 0 | low | 1 | 0 |
| biliverdine | 0 | low | 3 | 0 |
| bisdemethoxycurcumin | 0 | low | 1 | 0 |
| syringin | 0 | low | 3 | 0 |
| glycitein | 0 | low | 1 | 0 |
| glycycoumarin | 0 | low | 1 | 0 |
| andrographolide | 0 | low | 4 | 0 |
| isorhapontigenin | 0 | low | 1 | 0 |
| kukoamine a | 0 | low | 1 | 0 |
| icariin | 0 | low | 8 | 0 |
| licochalcone a | 0 | low | 2 | 0 |
| Licoflavone A | 0 | low | 1 | 0 |
| ligustilide | 0 | low | 1 | 0 |
| 2-oleoylglycerol | 0 | medium | 1 | 1 |
| neoglycyrol | 0 | low | 1 | 0 |
| 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one | 0 | low | 1 | 0 |
| tiliroside | 0 | low | 1 | 0 |
| (E)-2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucoside | 0 | low | 1 | 0 |
| tilianin | 0 | low | 1 | 0 |
| caryophyllene | 0 | low | 4 | 0 |
| 1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3h-cyclopenta(c)quinolin-8-yl)ethanone | 0 | low | 1 | 0 |
| fluvoxamine | 0 | low | 1 | 0 |
| casein kinase ii | 0 | low | 3 | 0 |
| ag-490 | 0 | low | 3 | 0 |
| su 11248 | 0 | low | 4 | 0 |
| palbociclib | 0 | low | 1 | 0 |
| fosbretabulin | 0 | medium | 3 | 2 |
| ergothioneine | 0 | low | 3 | 0 |
| lead | 0 | medium | 24 | 1 |
| butylidenephthalide | 0 | low | 2 | 0 |
| 12-hydroxy-5,8,10,14-eicosatetraenoic acid | 0 | low | 10 | 0 |
| 15-hydroxy-5,8,11,13-eicosatetraenoic acid | 0 | low | 1 | 0 |
| bay 11-7082 | 0 | medium | 6 | 1 |
| bay 11-7085 | 0 | low | 1 | 0 |
| 10-hydroxy-11,12-epoxyeicosa-5,8,14-trienoic acid | 0 | low | 1 | 0 |
| 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolocarbocyanine | 0 | low | 1 | 0 |
| diamide | 0 | low | 1 | 0 |
| 15-hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic acid | 0 | medium | 13 | 1 |
| antimony | 0 | low | 2 | 0 |
| indoleacrylic acid | 0 | low | 1 | 0 |
| 8-oxo-7,8-dihydrodeoxyguanine | 0 | low | 2 | 0 |
| methyl ferulate | 0 | low | 1 | 0 |
| triphenyltin | 0 | low | 1 | 0 |
| aluminum | 0 | low | 8 | 0 |
| strontium | 0 | medium | 4 | 2 |
| bismuth | 0 | medium | 8 | 6 |
| thallium | 0 | low | 1 | 0 |
| arsenic | 0 | medium | 80 | 1 |
| naltrexone | 0 | medium | 12 | 2 |
| dextrorphan | 0 | low | 1 | 0 |
| gallium | 0 | medium | 1 | 1 |
| cefodizime | 0 | low | 1 | 0 |
| delapril | 0 | medium | 10 | 7 |
| candoxatril | 0 | low | 1 | 0 |
| indinavir sulfate | 0 | low | 5 | 0 |
| sulfur | 0 | medium | 6 | 1 |
| geldanamycin | 0 | low | 2 | 0 |
| methoprene | 0 | low | 1 | 0 |
| diphenylhexatriene | 0 | low | 5 | 0 |
| jaceosidin | 0 | low | 1 | 0 |
| puerarin | 0 | medium | 12 | 2 |
| ajoene | 0 | low | 1 | 0 |
| bedaquiline | 0 | low | 1 | 0 |
| enalapril | 0 | medium | 183 | 99 |
| sinomenine | 0 | low | 2 | 0 |
| dimyristoylphosphatidylcholine | 0 | low | 3 | 0 |
| hercynine | 0 | low | 1 | 0 |
| deoxyribose | 0 | low | 1 | 0 |
| fumarates | 0 | medium | 66 | 34 |
| phycocyanobilin | 0 | low | 1 | 0 |
| beryllium | 0 | medium | 1 | 1 |
| acetyl acetonate | 0 | low | 1 | 0 |
| cysteine | 0 | medium | 82 | 3 |
| silicon | 0 | low | 4 | 0 |
| thallium-201 | 0 | low | 1 | 0 |
| phosphorus | 0 | medium | 60 | 13 |
| boron | 0 | medium | 1 | 1 |
| heroin | 0 | low | 2 | 0 |
| enalaprilat anhydrous | 0 | medium | 2 | 1 |
| 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid | 0 | low | 2 | 0 |
| imidapril | 0 | medium | 8 | 3 |
| bakuchiol | 0 | low | 1 | 0 |
| s-trans,trans-farnesylthiosalicylic acid | 0 | low | 2 | 0 |
| sulindac sulfone | 0 | low | 1 | 0 |
| cefepime | 0 | low | 2 | 0 |
| guajavarin | 0 | low | 1 | 0 |
| monodehydroascorbate | 0 | low | 1 | 0 |
| ici 118551 | 0 | low | 1 | 0 |
| trandolapril | 0 | medium | 41 | 25 |
| strontium radioisotopes | 0 | medium | 1 | 1 |
| troxerutin | 0 | low | 2 | 0 |
| 3,3'-dipentyl-2,2'-oxacarbocyanine | 0 | low | 1 | 0 |
| pregabalin | 0 | medium | 18 | 7 |
| 3,8-dihydroxy-6h-dibenzo(b,d)pyran-6-one | 0 | low | 3 | 0 |
| uroguanylin | 0 | low | 2 | 0 |
| guanylin | 0 | low | 2 | 0 |
| alpinumisoflavone | 0 | low | 1 | 0 |
| oxyhyponitrite | 0 | low | 1 | 0 |
| isocoumarin nm-3 | 0 | low | 1 | 0 |
| n-acetylsphingosine | 0 | low | 1 | 0 |
| triolein | 0 | medium | 2 | 1 |
| docosapentaenoic acid | 0 | medium | 3 | 1 |
| arglabin | 0 | low | 1 | 0 |
| epicinchonine | 0 | low | 1 | 0 |
| resiniferatoxin | 0 | low | 1 | 0 |
| abscisic acid | 0 | low | 7 | 0 |
| n-caproylsphingosine | 0 | low | 1 | 0 |
| carbocyanines | 0 | low | 4 | 0 |
| 25-hydroxyvitamin d 2 | 0 | medium | 29 | 8 |
| salubrinal | 0 | low | 1 | 0 |
| lyoniside | 0 | low | 1 | 0 |
| cefotaxime | 0 | low | 5 | 0 |
| epimedin b | 0 | low | 2 | 0 |
| epimedin c | 0 | low | 2 | 0 |
| cinidon-ethyl | 0 | low | 1 | 0 |
| 1,2-dielaidoylphosphatidylethanolamine | 0 | low | 1 | 0 |
| gw-5074 | 0 | low | 1 | 0 |
| 6-(bromomethylene)tetrahydro-3-(1-naphthaleneyl)-2h-pyran-2-one | 0 | low | 1 | 0 |
| ammonium sulfate | 0 | low | 1 | 0 |
| bisabolol | 0 | low | 1 | 0 |
| 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid | 0 | low | 2 | 0 |
| proguanil | 0 | low | 2 | 0 |
| monorden | 0 | low | 1 | 0 |
| coomassie brilliant blue | 0 | low | 1 | 0 |
| ono 1301 | 0 | low | 1 | 0 |
| mastoparan | 0 | low | 1 | 0 |
| saralasin | 0 | low | 2 | 0 |
| tetrodotoxin | 0 | low | 2 | 0 |
| selenium | 0 | medium | 134 | 16 |
| selenocysteine | 0 | low | 2 | 0 |
| tellurium | 0 | low | 1 | 0 |
| radium | 0 | low | 3 | 0 |
| oxalates | 0 | low | 7 | 0 |
| 1,1-diethyl-2-hydroxy-2-nitrosohydrazine | 0 | low | 1 | 0 |
| clinoptilolite | 0 | low | 1 | 0 |
| palonosetron | 0 | low | 1 | 0 |
| (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid | 0 | medium | 30 | 15 |
| maxacalcitol | 0 | medium | 5 | 1 |
| fk 409 | 0 | low | 1 | 0 |
| budralazine | 0 | low | 1 | 0 |
| 9,13-retinoic acid | 0 | low | 1 | 0 |
| dihydroergotoxine | 0 | medium | 1 | 1 |
| dizocilpine maleate | 0 | medium | 5 | 1 |
| antimycin a | 0 | low | 2 | 0 |
| prolylglycine | 0 | low | 1 | 0 |
| hexanoylcarnitine | 0 | low | 2 | 0 |
| cholestanol | 0 | medium | 5 | 3 |
| imidafenacin | 0 | low | 1 | 0 |
| flupenthixol decanoate | 0 | low | 1 | 0 |
| 24,25-dihydroxyvitamin d 3 | 0 | low | 1 | 0 |
| cilastatin | 0 | low | 1 | 0 |
| linoleamide | 0 | low | 1 | 0 |
| 1-palmitoyl-2-oleoylphosphatidylcholine | 0 | low | 1 | 0 |
| bafilomycin a1 | 0 | low | 4 | 0 |
| falcarindiol | 0 | low | 1 | 0 |
| 1-oleoyl-2-acetylglycerol | 0 | low | 1 | 0 |
| mofegiline | 0 | low | 2 | 0 |
| concanamycin a | 0 | low | 1 | 0 |
| brl 26830a | 0 | low | 1 | 0 |
| plastochromanol 8 | 0 | low | 1 | 0 |
| limaprost | 0 | low | 1 | 0 |
| n-acetyl-s-farnesylcysteine | 0 | low | 1 | 0 |
| thermozymocidin | 0 | low | 3 | 0 |
| 11-hydroxy-9,12-octadecadienoic acid | 0 | low | 1 | 0 |
| 2-cyano-3-(1-phenylindol-3-yl)acrylate | 0 | low | 1 | 0 |
| 8-hydroxylinoleic acid | 0 | low | 1 | 0 |
| 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid | 0 | medium | 1 | 1 |
| n,n,n-trimethylsphingosine | 0 | low | 1 | 0 |
| 14-hydroxydocosahexaenoate | 0 | medium | 2 | 1 |
| pregna-4,17-diene-3,16-dione | 0 | low | 1 | 0 |
| 1-palmitoyl-2-((2-(4-(6-phenyl-1,3,4-hexatrienyl)phenyl)ethyl)carbonyl)-3-phosphatidylcholine | 0 | low | 1 | 0 |
| amorphastilbol | 0 | low | 2 | 0 |
| 1,2-linoleoylphosphatidylcholine | 0 | low | 2 | 0 |
| n(4)-oleylcytosine arabinoside | 0 | low | 1 | 0 |
| everolimus | 0 | medium | 17 | 2 |
| lg100754 | 0 | low | 1 | 0 |
| emerin | 0 | low | 1 | 0 |
| riligustilide | 0 | low | 1 | 0 |
| bifenthrin | 0 | low | 1 | 0 |
| (2E,4E)-N-isobutyl-2,4-dodecadienamide | 0 | low | 1 | 0 |
| hydroxysafflor yellow a | 0 | low | 1 | 0 |
| 4-oxo-2-nonenal | 0 | low | 1 | 0 |
| rosiglitazone-metformin combination | 0 | medium | 24 | 13 |
| 18-hydroxy-5,8,11,14-eicosatetraenoic acid | 0 | medium | 1 | 1 |
| 11-glutathionylhepoxilin a3 | 0 | low | 1 | 0 |
| cdw17 antigen | 0 | low | 2 | 0 |
| trisialoganglioside gt1 | 0 | low | 1 | 0 |
| axitinib | 0 | medium | 1 | 1 |
| salvianolic acid B | 0 | low | 5 | 0 |
| i(3)so3-galactosylceramide | 0 | low | 7 | 0 |
| netupitant | 0 | low | 1 | 0 |
| salacinol | 0 | low | 2 | 0 |
| oxepins | 0 | low | 1 | 0 |
| glucuronyl glucosamine glycan sulfate | 0 | medium | 16 | 12 |
| 2',4',6'-trihydroxychalcone | 0 | low | 2 | 0 |
| beta-escin | 0 | low | 3 | 0 |
| isoacteoside | 0 | low | 1 | 0 |
| opc-67683 | 0 | low | 1 | 0 |
| clovamide | 0 | low | 1 | 0 |
| gw 1929 | 0 | low | 1 | 0 |
| linogliride | 0 | medium | 1 | 1 |
| 1-azakenpaullone | 0 | low | 1 | 0 |
| 2-[(3-iodophenyl)methylthio]-5-pyridin-4-yl-1,3,4-oxadiazole | 0 | low | 1 | 0 |
| beta-escin | 0 | medium | 65 | 1 |
| l-165041 | 0 | low | 3 | 0 |
| s-nitroso-n-acetylpenicillamine | 0 | low | 4 | 0 |
| nitrofurantoin | 0 | medium | 3 | 1 |
| sb 334867-a | 0 | low | 2 | 0 |
| lactacystin | 0 | low | 1 | 0 |
| shellac | 0 | medium | 1 | 1 |
| gadolinium dtpa | 0 | low | 13 | 0 |
| morphinans | 0 | low | 2 | 0 |
| ergoline | 0 | medium | 4 | 2 |
| adenosine-3',5'-cyclic phosphorothioate | 0 | low | 1 | 0 |
| sq-23377 | 0 | low | 7 | 0 |
| enkephalin, leucine-2-alanine | 0 | low | 1 | 0 |
| beraprost | 0 | medium | 12 | 7 |
| ginsenoside rb2 | 0 | low | 1 | 0 |
| u 62840 | 0 | medium | 1 | 1 |
| dutasteride | 0 | low | 1 | 0 |
| vilazodone hydrochloride | 0 | low | 1 | 0 |
| oleoyl-estrone | 0 | low | 1 | 0 |
| pd 184352 | 0 | low | 1 | 0 |
| prasugrel | 0 | low | 1 | 0 |
| retapamulin | 0 | low | 1 | 0 |
| isavuconazole | 0 | low | 2 | 0 |
| jwh-133 | 0 | low | 2 | 0 |
| dalcetrapib | 0 | medium | 2 | 1 |
| talabostat | 0 | low | 1 | 0 |
| bvt2733 | 0 | low | 1 | 0 |
| sk-7041 | 0 | low | 1 | 0 |
| corosolic acid | 0 | medium | 6 | 1 |
| panobinostat | 0 | low | 1 | 0 |
| rebaudioside a | 0 | medium | 15 | 3 |
| 3-tyrosine | 0 | low | 1 | 0 |
| bentiromide | 0 | low | 1 | 0 |
| phenylalanylglycine | 0 | low | 1 | 0 |
| bromopyruvate | 0 | low | 1 | 0 |
| staurosporine | 0 | medium | 3 | 1 |
| aminomethyltransferase | 0 | low | 1 | 0 |
| loa | 0 | low | 1 | 0 |
| hypericum | 0 | low | 2 | 0 |
| phosphocreatine | 0 | medium | 27 | 5 |
| tws 119 | 0 | low | 1 | 0 |
| chlorhexidine | 0 | medium | 14 | 8 |
| formazans | 0 | low | 1 | 0 |
| gs-7340 | 0 | low | 2 | 0 |
| triacsin c | 0 | low | 2 | 0 |
| methylglyoxal bis(butylamidinohydrazone) | 0 | low | 2 | 0 |
| n-acetylglucosaminono-1,5-lactone o-(phenylcarbamoyl)oxime | 0 | low | 1 | 0 |
| bimoclomol | 0 | low | 1 | 0 |
| 2-acetylpyridine semicarbazone | 0 | medium | 1 | 1 |
| n,o-bis(trimethylsilyl)trifluoroacetamide | 0 | low | 1 | 0 |
| s-allylcysteine | 0 | low | 1 | 0 |
| sulphostin | 0 | low | 1 | 0 |
| nvp-dpp728 | 0 | low | 4 | 0 |
| mk-0916 | 0 | low | 1 | 0 |
| 3-(15-hydroxypentadecyl)-2,4,4-trimethyl-2-cyclohexen-1-one | 0 | low | 1 | 0 |
| gw 501516 | 0 | medium | 5 | 1 |
| bay 58-2667 | 0 | low | 1 | 0 |
| amoxicillin-potassium clavulanate combination | 0 | medium | 12 | 1 |
| neotame | 0 | medium | 2 | 1 |
| sacubitril | 0 | medium | 13 | 2 |
| n,n'-((5-(2-amino-5-(2-methylpropyl)-4-thiazolyl)-2-furanyl)phosphinylidene)bis(alanine) diethyl ester | 0 | low | 11 | 0 |
| r 121919 | 0 | medium | 1 | 1 |
| abiraterone acetate | 0 | medium | 1 | 1 |
| n-(5-adamantane-1-yl-methoxy-pentyl)deoxynojirimycin | 0 | low | 2 | 0 |
| euk-134 | 0 | low | 1 | 0 |
| lenvatinib | 0 | medium | 4 | 1 |
| sergliflozin etabonate | 0 | medium | 9 | 1 |
| sipoglitazar | 0 | medium | 2 | 2 |
| pd 0325901 | 0 | low | 1 | 0 |
| tzd 18 | 0 | low | 2 | 0 |
| midostaurin | 0 | medium | 1 | 1 |
| seryl-leucyl-isoleucyl-glycyl--arginyl-leucinamide | 0 | low | 1 | 0 |
| em 523 | 0 | low | 1 | 0 |
| ezetimibe, simvastatin drug combination | 0 | medium | 15 | 9 |
| sincalide | 0 | medium | 13 | 2 |
| efavirenz, emtricitabine, tenofovir disoproxil fumarate drug combination | 0 | low | 1 | 0 |
| avibactam | 0 | low | 1 | 0 |
| tapentadol | 0 | low | 2 | 0 |
| capsiate | 0 | low | 1 | 0 |
| fructosyl-lysine | 0 | medium | 8 | 1 |
| etomoxir | 0 | medium | 7 | 1 |
| n(6)-cyclohexyladenosine | 0 | low | 1 | 0 |
| palbinone | 0 | low | 1 | 0 |
| brl 37344 | 0 | low | 2 | 0 |
| 4-trimethylammonio-3-((tetradecylcarbamoyl)amino)butyrate | 0 | low | 2 | 0 |
| cp 91149 | 0 | low | 4 | 0 |
| lg 1506 | 0 | low | 1 | 0 |
| ursodoxicoltaurine | 0 | low | 11 | 0 |
| ginsenoside m1 | 0 | medium | 13 | 1 |
| sun n8075 | 0 | low | 1 | 0 |
| bms201038 | 0 | low | 1 | 0 |
| pentagastrin | 0 | low | 2 | 0 |
| conophylline | 0 | low | 2 | 0 |
| cangrelor | 0 | low | 3 | 0 |
| tram 39 | 0 | low | 1 | 0 |
| mocetinostat | 0 | medium | 64 | 9 |
| mirabegron | 0 | medium | 3 | 1 |
| 3-(2,4-dichlorobenzyl)-2-methyl-n-(pentylsulfonyl)-3 h-benzimidazole-5-carboxamide | 0 | low | 1 | 0 |
| avanafil | 0 | medium | 2 | 1 |
| dw 2282 | 0 | low | 1 | 0 |
| fimasartan | 0 | low | 1 | 0 |
| zotarolimus | 0 | medium | 7 | 3 |
| lipid a | 0 | medium | 6 | 2 |
| 4-methylene-2-octyl-5-oxofuran-3-carboxylic acid | 0 | low | 1 | 0 |
| dehydroxymethylepoxyquinomicin | 0 | low | 2 | 0 |
| bts 67582 | 0 | medium | 3 | 1 |
| ro-28-1675 | 0 | low | 2 | 0 |
| varespladib methyl | 0 | medium | 1 | 1 |
| solabegron | 0 | low | 1 | 0 |
| sr 59230a | 0 | low | 2 | 0 |
| ly 465608 | 0 | low | 4 | 0 |
| l 796449 | 0 | low | 1 | 0 |
| gw 4064 | 0 | low | 6 | 0 |
| shu 9119 | 0 | low | 1 | 0 |
| ginsenoside rb1 | 0 | low | 5 | 0 |
| g(m2) ganglioside | 0 | low | 1 | 0 |
| ah 11110a | 0 | low | 1 | 0 |
| zibotentan | 0 | medium | 2 | 1 |
| mcc-950 | 0 | low | 1 | 0 |
| avosentan | 0 | medium | 2 | 1 |
| hki 272 | 0 | low | 2 | 0 |
| thiocolchicoside | 0 | medium | 1 | 1 |
| secoisolariciresinol diglucoside | 0 | low | 2 | 0 |
| ginsenoside rg3 | 0 | medium | 6 | 1 |
| sorbitan monooleate | 0 | medium | 1 | 1 |
| ammonium trichloro(dioxoethylene-o,o'-)tellurate | 0 | low | 1 | 0 |
| es-285 | 0 | low | 2 | 0 |
| tofacitinib | 0 | low | 2 | 0 |
| tocotrienols | 0 | medium | 11 | 5 |
| rucaparib | 0 | medium | 1 | 1 |
| gw0742 | 0 | low | 6 | 0 |
| eht 1864 | 0 | low | 1 | 0 |
| terutroban | 0 | low | 1 | 0 |
| darapladib | 0 | low | 2 | 0 |
| roflumilast n-oxide | 0 | low | 1 | 0 |
| phenylalanyl-glycyl-leucyl-methioninamide | 0 | medium | 1 | 1 |
| pasireotide | 0 | medium | 2 | 1 |
| zeolites | 0 | low | 2 | 0 |
| ns-220 | 0 | low | 1 | 0 |
| pitolisant | 0 | medium | 1 | 1 |
| medrogestone | 0 | medium | 1 | 1 |
| cetilistat | 0 | medium | 2 | 1 |
| bm 131246 | 0 | low | 1 | 0 |
| chir 99021 | 0 | low | 3 | 0 |
| gw 590735 | 0 | low | 1 | 0 |
| ubiquinol | 0 | medium | 6 | 4 |
| g(m1) ganglioside | 0 | low | 5 | 0 |
| vortioxetine | 0 | low | 1 | 0 |
| aluminum oxide | 0 | medium | 4 | 2 |
| rs 102895 | 0 | low | 1 | 0 |
| cgp 20712a | 0 | low | 2 | 0 |
| 2-(2-(4-phenoxy-2-propylphenoxy)ethyl)indole-5-acetic acid | 0 | low | 4 | 0 |
| ly2090314 | 0 | low | 1 | 0 |
| fidaxomicin | 0 | low | 1 | 0 |
| cereulide | 0 | low | 1 | 0 |
| methionine sulfoxide | 0 | low | 4 | 0 |
| pimavanserin | 0 | low | 1 | 0 |
| bismuth tripotassium dicitrate | 0 | low | 1 | 0 |
| cystathionine | 0 | medium | 3 | 1 |
| pazopanib | 0 | low | 1 | 0 |
| tribulus | 0 | medium | 3 | 1 |
| n-(4-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenyl)acetamide | 0 | low | 1 | 0 |
| sagittatoside b | 0 | low | 1 | 0 |
| alanylpyrrolidine-boronic acid | 0 | low | 2 | 0 |
| odanacatib | 0 | medium | 1 | 1 |
| prasugrel hydrochloride | 0 | medium | 17 | 8 |
| act 058362 | 0 | medium | 4 | 4 |
| dimethylarginine | 0 | medium | 24 | 4 |
| apixaban | 0 | medium | 8 | 1 |
| delphinidin 3-sambubioside | 0 | low | 1 | 0 |
| sargahydroquinoic acid | 0 | low | 1 | 0 |
| lr-90 | 0 | low | 1 | 0 |
| struvite | 0 | low | 1 | 0 |
| artenimol | 0 | medium | 1 | 1 |
| jte 013 | 0 | low | 2 | 0 |
| thapsigargicin | 0 | low | 1 | 0 |
| sotrastaurin | 0 | low | 1 | 0 |
| alpha-synuclein | 0 | low | 30 | 0 |
| thonningianin a | 0 | low | 1 | 0 |
| 7-aminoactinomycin d | 0 | low | 1 | 0 |
| sb 204990 | 0 | low | 1 | 0 |
| kukoamine b | 0 | low | 1 | 0 |
| angiotensin amide | 0 | low | 1 | 0 |
| 2-furoyl-ligrlo-amide | 0 | low | 2 | 0 |
| macelignan | 0 | low | 2 | 0 |
| piragliatin | 0 | medium | 10 | 6 |
| 5s,12r,18r-trihydroxy-6z,8e,10e,14z,16e-eicosapentaenoic acid | 0 | low | 4 | 0 |
| isotocin | 0 | medium | 1 | 1 |
| oxadiazoles | 0 | medium | 28 | 7 |
| mumefural | 0 | low | 1 | 0 |
| esculeoside a | 0 | low | 1 | 0 |
| baci-im | 0 | low | 1 | 0 |
| ucn 1028 c | 0 | low | 2 | 0 |
| heptelidic acid | 0 | low | 1 | 0 |
| ribose | 0 | low | 14 | 0 |
| decabromodiphenyl ethane | 0 | low | 1 | 0 |
| acebutolol | 0 | low | 17 | 0 |
| 8-oxo-2'-deoxyadenosine | 0 | low | 1 | 0 |
| lactulose | 0 | medium | 8 | 3 |
| 8,5'-cyclo-2'-deoxyadenosine | 0 | low | 1 | 0 |
| epoxomicin | 0 | low | 2 | 0 |
| wrenchnolol | 0 | low | 1 | 0 |
| abt-737 | 0 | low | 1 | 0 |
| tedizolid | 0 | low | 1 | 0 |
| px 478 | 0 | low | 1 | 0 |
| brimonidine tartrate | 0 | medium | 8 | 4 |
| bms 477118 | 0 | low | 7 | 0 |
| eluxadoline | 0 | low | 1 | 0 |
| procyanidin b1 | 0 | low | 2 | 0 |
| ascochlorin | 0 | low | 1 | 0 |
| bis(1-hydroxy-2,2,6,6-tetramethyl-4-piperidinyl)decandioate | 0 | low | 1 | 0 |
| fucoxanthinol | 0 | low | 1 | 0 |
| buprenorphine, naloxone drug combination | 0 | low | 3 | 0 |
| campest-5-en-3-one | 0 | low | 2 | 0 |
| aspalathin | 0 | low | 5 | 0 |
| nystatin a1 | 0 | low | 4 | 0 |
| azd1981 | 0 | medium | 1 | 1 |
| nimbidiol | 0 | low | 1 | 0 |
| amlodipine, valsartan drug combination | 0 | medium | 1 | 1 |
| resolvin d2 | 0 | low | 2 | 0 |
| mitoquinone | 0 | low | 8 | 0 |
| ks370g | 0 | low | 1 | 0 |
| technetium tc 99m disofenin | 0 | low | 1 | 0 |
| technetium tc 99m mebrofenin | 0 | low | 2 | 0 |
| psn 632408 | 0 | low | 1 | 0 |
| 5-(2,2-difluorobenzo(1,3)dioxol-5-ylmethylene)thiazolidine-2,4-dione | 0 | low | 1 | 0 |
| alisporivir | 0 | low | 1 | 0 |
| dorsomorphin | 0 | low | 5 | 0 |
| ulimorelin | 0 | medium | 1 | 1 |
| anacetrapib | 0 | low | 1 | 0 |
| carfilzomib | 0 | medium | 2 | 1 |
| apremilast | 0 | medium | 3 | 1 |
| gw9508 | 0 | low | 9 | 0 |
| 2,4,3',5'-tetrahydroxystilbene | 0 | low | 1 | 0 |
| lorcaserin | 0 | medium | 24 | 9 |
| fostamatinib | 0 | low | 1 | 0 |
| ginsenoside rd | 0 | low | 1 | 0 |
| trametinib | 0 | low | 1 | 0 |
| ponkoranol | 0 | low | 1 | 0 |
| bay 60-6583 | 0 | low | 1 | 0 |
| losartan potassium | 0 | medium | 118 | 16 |
| achyrofuran | 0 | low | 3 | 0 |
| d-arg-dmt-lys-phe-nh2 | 0 | low | 3 | 0 |
| norgestimate | 0 | medium | 2 | 1 |
| imidazolone | 0 | medium | 7 | 2 |
| 5-(5-nitrothiazol-2-ylthio)-1,3,4-thiadiazol-2-amine | 0 | low | 1 | 0 |
| td-5108 | 0 | medium | 1 | 1 |
| 2-(n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose | 0 | low | 6 | 0 |
| n-acetylmannosamine | 0 | medium | 2 | 1 |
| octanoylcarnitine | 0 | low | 2 | 0 |
| palmitoylcarnitine | 0 | medium | 4 | 1 |
| technetium tc 99m exametazime | 0 | medium | 8 | 1 |
| calcimycin | 0 | low | 12 | 0 |
| dihydroouabain | 0 | low | 1 | 0 |
| dextrothyroxine | 0 | low | 3 | 0 |
| veliparib | 0 | low | 1 | 0 |
| s-tetradecanoyl-coenzyme a | 0 | low | 1 | 0 |
| sepharose | 0 | low | 3 | 0 |
| indocyanine green | 0 | medium | 6 | 3 |
| scopolamine hydrobromide | 0 | medium | 4 | 1 |
| marinobufagenin | 0 | low | 1 | 0 |
| vindoline | 0 | low | 3 | 0 |
| pituitrin | 0 | medium | 27 | 3 |
| n4-(2,2-dimethyl-3-oxo-4h-pyrid(1,4)oxazin-6-yl)-5-fluoro-n2-(3,4,5-trimethoxyphenyl)-2,4-pyrimidinediamine | 0 | low | 1 | 0 |
| 1,5-anhydro-1-(5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl)-1-thioglucitol | 0 | low | 4 | 0 |
| monascin | 0 | low | 1 | 0 |
| thienopyridine | 0 | low | 2 | 0 |
| phytosterols | 0 | medium | 36 | 10 |
| enerbol | 0 | low | 1 | 0 |
| (-)-pinoresinol | 0 | low | 1 | 0 |
| glycoursodeoxycholic acid | 0 | low | 1 | 0 |
| rifamycins | 0 | low | 1 | 0 |
| rutundic acid | 0 | low | 1 | 0 |
| thienopyrimidine | 0 | low | 1 | 0 |
| clove | 0 | medium | 9 | 1 |
| ro 6-4563 | 0 | low | 1 | 0 |
| ginsenoside rh1 | 0 | low | 1 | 0 |
| acid phosphatase | 0 | low | 17 | 0 |
| 3-azabicyclo(3.1.0)hexane | 0 | low | 1 | 0 |
| chikusetsu saponin iva | 0 | low | 1 | 0 |
| cladosporin | 0 | low | 1 | 0 |
| ligstroside | 0 | low | 1 | 0 |
| 23-hydroxyursolic acid | 0 | low | 1 | 0 |
| bavachin | 0 | low | 1 | 0 |
| curcumol | 0 | medium | 1 | 1 |
| ferrous citrate | 0 | medium | 3 | 2 |
| furosine | 0 | medium | 18 | 1 |
| de-o-methyllasiodiplodin | 0 | low | 1 | 0 |
| derrone | 0 | low | 1 | 0 |
| icatibant | 0 | low | 1 | 0 |
| jaw | 0 | low | 1 | 0 |
| aflatoxin m1 | 0 | low | 1 | 0 |
| friedelane | 0 | low | 1 | 0 |
| cyanidin-3-o-beta-glucopyranoside | 0 | low | 4 | 0 |
| nad | 0 | medium | 62 | 4 |
| desmosine | 0 | low | 1 | 0 |
| mdv 3100 | 0 | medium | 2 | 1 |
| tin mesoporphyrin | 0 | low | 2 | 0 |
| macitentan | 0 | low | 1 | 0 |
| 4-(4-(3-adamantan-1-ylureido)cyclohexyloxy)benzoic acid | 0 | low | 1 | 0 |
| protectin d1 | 0 | low | 2 | 0 |
| cytochrome c-t | 0 | low | 14 | 0 |
| 2-({2-[(3-hydroxyphenyl)amino]pyrimidin-4-yl}amino)benzamide | 0 | low | 1 | 0 |
| gw 4869 | 0 | low | 1 | 0 |
| bms 309403 | 0 | low | 1 | 0 |
| calcitonin | 0 | medium | 5 | 1 |
| cosyntropin | 0 | low | 2 | 0 |
| melitten | 0 | low | 2 | 0 |
| cholecystokinin | 0 | medium | 52 | 6 |
| ceruletide | 0 | low | 5 | 0 |
| motilin | 0 | medium | 12 | 4 |
| dynorphins | 0 | low | 2 | 0 |
| bivalirudin | 0 | medium | 4 | 1 |
| atrial natriuretic factor | 0 | medium | 98 | 23 |
| tannins | 0 | medium | 1 | 1 |
| ganirelix | 0 | low | 1 | 0 |
| xenin 25 | 0 | medium | 8 | 4 |
| hes1 protein, human | 0 | low | 4 | 0 |
| glycoprotein e2, hepatitis c virus | 0 | low | 1 | 0 |
| cs1 peptide | 0 | low | 2 | 0 |
| m 35 | 0 | low | 4 | 0 |
| humanin | 0 | low | 7 | 0 |
| alamethicin | 0 | low | 1 | 0 |
| fibrinopeptide b | 0 | low | 3 | 0 |
| glucagon-like peptide 1 (7-36)amide | 0 | medium | 71 | 21 |
| gastrins | 0 | medium | 39 | 9 |
| glucagon (1-21) | 0 | low | 1 | 0 |
| beta-endorphin | 0 | low | 18 | 0 |
| somatostatin-28 | 0 | low | 1 | 0 |
| thymosin beta(4) | 0 | low | 5 | 0 |
| neuropeptide y | 0 | medium | 59 | 3 |
| pancreastatin | 0 | low | 11 | 0 |
| s6c sarafotoxin | 0 | low | 2 | 0 |
| iberiotoxin | 0 | low | 1 | 0 |
| angiotensinogen | 0 | medium | 94 | 7 |
| moricizine | 0 | low | 1 | 0 |
| cortistatin 14 | 0 | low | 1 | 0 |
| irl 1620 | 0 | low | 3 | 0 |
| glucagon-like peptide 1 (7-36) | 0 | low | 4 | 0 |
| tannins | 0 | medium | 15 | 2 |
| oligonucleotides | 0 | low | 13 | 0 |
| glucagon-like peptide 1 | 0 | medium | 3,296 | 470 |
| vivit peptide | 0 | low | 2 | 0 |
| insulin glulisine | 0 | medium | 85 | 43 |
| insulin detemir | 0 | medium | 317 | 93 |
| th9507 | 0 | medium | 2 | 1 |
| alx-0600 | 0 | low | 1 | 0 |
| incretins | 0 | medium | 1,365 | 128 |
| msh, 4-nle-7-phe-alpha- | 0 | low | 1 | 0 |
| c-peptide | 0 | medium | 2,142 | 587 |
| natriuretic peptide, c-type | 0 | low | 7 | 0 |
| exendin (9-39) | 0 | medium | 23 | 6 |
| ristocetin | 0 | low | 3 | 0 |
| cellulose | 0 | medium | 15 | 5 |
| endothelin-1 | 0 | medium | 166 | 26 |
| phosphatidylcholines | 0 | medium | 68 | 3 |
| atractyloside | 0 | low | 2 | 0 |
| (9R)-9-chloro-11,17-dihydroxy-17-(2-hydroxy-1-oxoethyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one | 0 | low | 2 | 0 |
| pamapimod | 0 | low | 2 | 0 |
| amikacin | 0 | low | 10 | 0 |
| 4-thiouridylic acid | 0 | low | 1 | 0 |
| chlorophyll a | 0 | low | 2 | 0 |
| vendex | 0 | medium | 9 | 2 |
| 3-(3-(4-((pyridin-2-yloxy)methyl)benzyl)isoxazol-5-yl)pyridin-2-amine | 0 | medium | 1 | 1 |
| ro5126766 | 0 | low | 1 | 0 |
| dihydroceramide | 0 | low | 10 | 0 |
| nsc 23766 | 0 | low | 2 | 0 |
| adenosine kinase | 0 | low | 1 | 0 |
| sodium salicylate | 0 | low | 4 | 0 |
| sphingosine kinase | 0 | low | 7 | 0 |
| ubiquinone | 0 | medium | 69 | 22 |
| pinoresinol | 0 | low | 1 | 0 |
| florbenazine f 18 | 0 | medium | 2 | 1 |
| cilastatin, imipenem drug combination | 0 | low | 1 | 0 |
| ethyl glucuronide | 0 | low | 1 | 0 |
| diazepinylbenzoic acid | 0 | low | 5 | 0 |
| 1,2-o-isopropylidene-d-glucofuranose | 0 | low | 1 | 0 |
| calpain | 0 | medium | 148 | 2 |
| sapogenins | 0 | low | 2 | 0 |
| arjunetin | 0 | low | 1 | 0 |
| hydroxyoctadecadienoic acid | 0 | low | 1 | 0 |
| arjunic acid | 0 | low | 1 | 0 |
| ginsenoside rh4 | 0 | low | 1 | 0 |
| pyrazolopyridine | 0 | low | 1 | 0 |
| 23-epi-26-deoxyactein | 0 | low | 1 | 0 |
| nothofagin | 0 | low | 1 | 0 |
| menotropins | 0 | low | 1 | 0 |
| chitosan | 0 | medium | 48 | 2 |
| icotinib | 0 | low | 1 | 0 |
| technetium tc 99m sestamibi | 0 | medium | 19 | 2 |
| 15-deoxyprostaglandin j2 | 0 | low | 1 | 0 |
| n(6)-(1-carboxyethyl)lysine | 0 | medium | 4 | 1 |
| 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine | 0 | medium | 1 | 1 |
| s-nitro-n-acetylpenicillamine | 0 | low | 1 | 0 |
| yil 781 | 0 | low | 1 | 0 |
| sodium oxybate | 0 | medium | 2 | 1 |
| bucladesine | 0 | low | 5 | 0 |
| sodium lactate | 0 | medium | 1 | 1 |
| sodium nitrite | 0 | low | 9 | 0 |
| raltegravir potassium | 0 | low | 1 | 0 |
| amphotericin b, deoxycholate drug combination | 0 | low | 2 | 0 |
| sodium glutamate | 0 | medium | 15 | 1 |
| b 807-27 | 0 | low | 1 | 0 |
| merocyanine dye | 0 | low | 1 | 0 |
| ro13-9904 | 0 | medium | 22 | 1 |
| sodium pertechnetate tc 99m | 0 | medium | 4 | 2 |
| sodium ethylxanthate | 0 | low | 2 | 0 |
| piperacillin, tazobactam drug combination | 0 | low | 9 | 0 |
| chiniofon | 0 | low | 2 | 0 |
| gadofosveset trisodium | 0 | low | 1 | 0 |
| pf 915275 | 0 | low | 1 | 0 |
| srt1460 | 0 | low | 3 | 0 |
| srt1720 | 0 | low | 4 | 0 |
| srt2183 | 0 | low | 2 | 0 |
| mogroside v | 0 | low | 1 | 0 |
| amorfrutin b | 0 | low | 2 | 0 |
| fps-zm1 | 0 | low | 1 | 0 |
| s-adenosylmethionine | 0 | medium | 15 | 3 |
| pf-04279405 | 0 | low | 1 | 0 |
| preminent | 0 | medium | 2 | 1 |
| canagliflozin | 0 | medium | 692 | 164 |
| 2',3'-o-(2,4,6-trinitrophenyl)adenosine 5'-triphosphate | 0 | low | 1 | 0 |
| ethyl cellulose | 0 | low | 1 | 0 |
| saudin | 0 | low | 1 | 0 |
| insulin, isophane | 0 | medium | 434 | 178 |
| sitagliptin phosphate, metformin hydrochloride drug combination | 0 | low | 5 | 0 |
| oxymatrine | 0 | low | 1 | 0 |
| ar 231453 | 0 | low | 4 | 0 |
| niraparib | 0 | medium | 1 | 1 |
| mk 2206 | 0 | low | 1 | 0 |
| suvorexant | 0 | low | 3 | 0 |
| navitoclax | 0 | low | 1 | 0 |
| egg white | 0 | medium | 6 | 1 |
| telotristat | 0 | low | 1 | 0 |
| 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene | 0 | low | 3 | 0 |
| quetiapine fumarate | 0 | low | 21 | 0 |
| s-(1,2-dicarboxyethyl)cysteine | 0 | low | 2 | 0 |
| cardiovascular agents | 0 | medium | 212 | 30 |
| neurotensin | 0 | medium | 20 | 5 |
| fibrinopeptide a | 0 | low | 7 | 0 |
| apelin-13 peptide | 0 | low | 4 | 0 |
| mannans | 0 | medium | 69 | 29 |
| bms-790052 | 0 | medium | 4 | 2 |
| lysophosphatidylserine | 0 | low | 1 | 0 |
| plx4032 | 0 | medium | 1 | 1 |
| kotalanol | 0 | low | 3 | 0 |
| azd7687 | 0 | medium | 2 | 2 |
| triiodothyronine, reverse | 0 | low | 6 | 0 |
| 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid ethyl amide | 0 | low | 2 | 0 |
| glycolipids | 0 | medium | 71 | 4 |
| elafin | 0 | low | 1 | 0 |
| baricitinib | 0 | medium | 3 | 3 |
| piperidines | 0 | medium | 587 | 199 |
| resolvin d1 | 0 | low | 7 | 0 |
| cyanidin 3-galactoside | 0 | low | 1 | 0 |
| thymosin | 0 | low | 6 | 0 |
| glucagon-like peptide 1 | 0 | low | 1 | 0 |
| interleukin-8 | 0 | medium | 112 | 15 |
| dabrafenib | 0 | low | 2 | 0 |
| as1949490 | 0 | low | 1 | 0 |
| hamamelitannin | 0 | low | 1 | 0 |
| punicalagin | 0 | low | 5 | 0 |
| bm 42304 | 0 | medium | 1 | 1 |
| isosilybin | 0 | low | 1 | 0 |
| formylchromone | 0 | low | 2 | 0 |
| colistin | 0 | medium | 1 | 1 |
| hydroxocobalamin | 0 | low | 2 | 0 |
| fosinopril | 0 | medium | 15 | 12 |
| sofosbuvir | 0 | medium | 6 | 1 |
| 5-(4-amino-1-propan-2-yl-3-pyrazolo[3,4-d]pyrimidinyl)-1,3-benzoxazol-2-amine | 0 | medium | 1 | 1 |
| int-777 | 0 | low | 2 | 0 |
| opium | 0 | low | 3 | 0 |
| gsk 2334470 | 0 | low | 1 | 0 |
| srt3025 | 0 | low | 1 | 0 |
| akb-9778 | 0 | medium | 1 | 1 |
| amg-837 | 0 | low | 6 | 0 |
| 1-palmitoyl-2-glutaroyl-sn-glycero-3-phosphorylcholine | 0 | medium | 1 | 1 |
| deberza | 0 | low | 3 | 0 |
| uridine diphosphate n-acetylgalactosamine | 0 | low | 3 | 0 |
| pf-04620110 | 0 | low | 1 | 0 |
| fructose-1,6-diphosphate | 0 | low | 5 | 0 |
| gyy 4137 | 0 | low | 3 | 0 |
| tug-469 | 0 | low | 2 | 0 |
| aripiprazole lauroxil | 0 | low | 1 | 0 |
| lmt-28 | 0 | low | 1 | 0 |
| ly2940680 | 0 | low | 1 | 0 |
| methylcellulose | 0 | low | 9 | 0 |
| jujuboside a | 0 | low | 1 | 0 |
| isoquercitrin | 0 | low | 3 | 0 |
| 1,2-dioleoyl-sn-glycero-3-phosphoglycerol | 0 | low | 1 | 0 |
| oligomycin a | 0 | low | 1 | 0 |
| vasoactive intestinal peptide | 0 | medium | 14 | 1 |
| phosphomannopentaose sulfate | 0 | low | 1 | 0 |
| antcin k | 0 | low | 1 | 0 |
| natriuretic peptide, brain | 0 | medium | 301 | 78 |
| heme | 0 | medium | 30 | 4 |
| gsk2656157 | 0 | low | 1 | 0 |
| 7-methyl-5-(1-((3-(trifluoromethyl)phenyl)acetyl)-2,3-dihydro-1h-indol-5-yl)-7h-pyrrolo(2,3-d)pyrimidin-4-amine | 0 | low | 1 | 0 |
| chondroitin | 0 | medium | 4 | 1 |
| heparitin sulfate | 0 | medium | 22 | 1 |
| neuromedin b | 0 | low | 1 | 0 |
| novobiocin | 0 | low | 2 | 0 |
| tetracycline | 0 | medium | 14 | 4 |
| minocycline | 0 | medium | 16 | 5 |
| salicylates | 0 | medium | 40 | 8 |
| dicumarol | 0 | low | 1 | 0 |
| piroxicam | 0 | low | 2 | 0 |
| acenocoumarol | 0 | low | 3 | 0 |
| mobic | 0 | low | 1 | 0 |
| rk 682 | 0 | low | 2 | 0 |
| ascorbate-2-phosphate | 0 | low | 1 | 0 |
| 6-o-palmitoylascorbic acid | 0 | low | 1 | 0 |
| demeclocycline | 0 | low | 1 | 0 |
| phenprocoumon | 0 | low | 1 | 0 |
| teriflunomide | 0 | medium | 1 | 1 |
| tigecycline | 0 | low | 2 | 0 |
| a 769662 | 0 | low | 2 | 0 |
| s 1 (combination) | 0 | low | 1 | 0 |
| dolutegravir | 0 | low | 4 | 0 |
| byl719 | 0 | medium | 1 | 1 |
| rgfp966 | 0 | low | 1 | 0 |
| 6-s-hexadecyl-2-methoxythioascorbic acid | 0 | low | 2 | 0 |
| indapamide, perindopril drug combination | 0 | medium | 34 | 19 |
| betalains | 0 | low | 1 | 0 |
| epidermal growth factor | 0 | medium | 29 | 5 |
| microcystin | 0 | low | 1 | 0 |
| gastrin-releasing peptide | 0 | low | 1 | 0 |
| calca protein, human | 0 | low | 3 | 0 |
| kaolinite | 0 | low | 1 | 0 |
| clay | 0 | low | 1 | 0 |
| charybdotoxin | 0 | low | 3 | 0 |
| bismuth oxybromide | 0 | medium | 1 | 1 |
| transforming growth factor beta | 0 | medium | 207 | 23 |
| phytoestrogens | 0 | medium | 19 | 4 |
| oleuropein aglycone | 0 | low | 1 | 0 |
| semaglutide | 0 | medium | 408 | 78 |
| okadaic acid | 0 | low | 4 | 0 |
| ceritinib | 0 | low | 1 | 0 |
| sr9009 | 0 | low | 1 | 0 |
| tug-891 | 0 | low | 1 | 0 |
| pf-05231023 | 0 | medium | 3 | 2 |
| (1-(3-isopropyl-1,2,4-oxadiazol-5-yl)piperidin-4-yl)methyl methanesulfonate | 0 | medium | 2 | 1 |
| resolvin D4 | 0 | low | 1 | 0 |
| gkt137831 | 0 | low | 2 | 0 |
| mirogabalin | 0 | medium | 2 | 2 |
| bay 85-3934 | 0 | low | 1 | 0 |
| bay 94-8862 | 0 | medium | 109 | 30 |
| saroglitazar | 0 | medium | 17 | 4 |
| pyrethrins | 0 | low | 3 | 0 |
| cefuroxime axetil | 0 | low | 1 | 0 |
| jd5037 | 0 | low | 1 | 0 |
| globotriaosylceramide | 0 | low | 1 | 0 |
| 2-methylthio-n6-threonylcarbamoyladenosine | 0 | low | 1 | 0 |
| carboxyethyl-hydroxychroman | 0 | medium | 1 | 1 |
| g007-lk | 0 | low | 1 | 0 |
| lipoxin b4 | 0 | low | 1 | 0 |
| maysin | 0 | low | 1 | 0 |
| bgp 15 | 0 | low | 1 | 0 |
| ML355 | 0 | low | 1 | 0 |
| sar131675 | 0 | low | 1 | 0 |
| cucurbitane | 0 | low | 2 | 0 |
| kiss1 protein, human | 0 | medium | 11 | 1 |
| rome | 0 | medium | 11 | 3 |
| 1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-1h-benzotriazole-5-carboxylic acid | 0 | low | 1 | 0 |
| selinexor | 0 | medium | 1 | 1 |
| osimertinib | 0 | low | 1 | 0 |
| agar | 0 | medium | 2 | 1 |
| octaphlorethol a | 0 | low | 1 | 0 |
| resolvin d3 | 0 | low | 2 | 0 |
| mjn110 | 0 | low | 1 | 0 |
| ziyuglycoside ii | 0 | low | 1 | 0 |
| fructosylvaline | 0 | low | 1 | 0 |
| as 1842856 | 0 | low | 1 | 0 |
| hirudin | 0 | medium | 8 | 2 |
| formycin triphosphate | 0 | low | 1 | 0 |
| glutaminase | 0 | medium | 6 | 1 |
| ginsenoside rg5 | 0 | low | 2 | 0 |
| cyclin d1 | 0 | low | 9 | 0 |
| lysophosphatidylinositol | 0 | low | 2 | 0 |
| lysophosphatidylethanolamine | 0 | medium | 1 | 1 |
| caseins | 0 | medium | 33 | 11 |
| bafilomycin b1 | 0 | low | 1 | 0 |
| ckd732 | 0 | medium | 1 | 1 |
| nattokinase | 0 | low | 1 | 0 |
| ginsenoside rk3 | 0 | low | 1 | 0 |
| technetium tc 99m sulfur colloid | 0 | medium | 12 | 1 |
| oligomycins | 0 | low | 5 | 0 |
| ellagitannin | 0 | low | 2 | 0 |
| nonachlor | 0 | low | 4 | 0 |
| praliciguat | 0 | medium | 4 | 2 |
| gypenoside LXXV | 0 | low | 1 | 0 |
| g(m3) ganglioside | 0 | low | 13 | 0 |
| chromium histidinate | 0 | low | 3 | 0 |
| 6,6-dideuteroglucose | 0 | low | 1 | 0 |
| nitrophenols | 0 | medium | 5 | 2 |
| lewis x antigen | 0 | low | 2 | 0 |
| peptide yy | 0 | medium | 5 | 1 |
| glucagon-like peptide 2 | 0 | medium | 33 | 4 |
| calpastatin | 0 | low | 2 | 0 |
| angiotensin i | 0 | medium | 28 | 2 |
| isookanin | 0 | low | 1 | 0 |
| ascophyllum | 0 | low | 4 | 0 |
| gadoxetic acid disodium | 0 | low | 2 | 0 |
| cibinetide | 0 | medium | 2 | 1 |
| hyaluronoglucosaminidase | 0 | medium | 13 | 3 |
| adrenomedullin | 0 | medium | 30 | 2 |
| epoetin alfa | 0 | low | 7 | 0 |
| lithospermic acid | 0 | low | 1 | 0 |
| gliovirin | 0 | low | 1 | 0 |
| diospyros | 0 | low | 9 | 0 |
| nephrin | 0 | medium | 37 | 2 |
| carboxyatractyloside | 0 | low | 1 | 0 |
| d-ala(2),mephe(4),met(0)-ol-enkephalin | 0 | low | 1 | 0 |
| ginkgolide b | 0 | low | 2 | 0 |
| oridonin | 0 | low | 2 | 0 |
| morroniside | 0 | low | 2 | 0 |
| chebulinic acid | 0 | low | 1 | 0 |
| chebulagic acid | 0 | low | 1 | 0 |
| ginsenoside rg4 | 0 | low | 1 | 0 |
| hexenuronic acid | 0 | low | 1 | 0 |
| daptomycin | 0 | low | 5 | 0 |
| peoniflorin | 0 | low | 3 | 0 |
| vitamin b 12 | 0 | medium | 182 | 31 |
| aconitine | 0 | low | 1 | 0 |
| humulin s | 0 | medium | 240 | 50 |
| insulin glargine | 0 | medium | 1,331 | 521 |
| ecallantide | 0 | low | 2 | 0 |
| insulin degludec | 0 | medium | 281 | 86 |
| norgestrel | 0 | medium | 3 | 1 |
| s 8932 | 0 | low | 2 | 0 |
| oxyntomodulin | 0 | medium | 710 | 179 |
| transforming growth factor alpha | 0 | low | 5 | 0 |
| insulin, 3-iodo-tyr(a14)- | 0 | low | 2 | 0 |
| cyclosporine | 0 | medium | 43 | 4 |
| epimedin a | 0 | low | 2 | 0 |
| flavin mononucleotide | 0 | medium | 4 | 3 |
| silybin | 0 | medium | 10 | 1 |
| cytochalasin d | 0 | low | 1 | 0 |
| peptide yy | 0 | medium | 102 | 20 |
| lactoferrin | 0 | medium | 13 | 1 |
| akebia saponin d | 0 | low | 1 | 0 |
| catalpol | 0 | medium | 5 | 1 |
| neohesperidin | 0 | low | 1 | 0 |
| poncirin | 0 | low | 1 | 0 |
| 7-o-galloyl-d-sedoheptulose | 0 | low | 7 | 0 |
| ethylmethylhydroxypyridine succinate | 0 | medium | 2 | 1 |
| orabase | 0 | medium | 7 | 1 |
| technetium tc 99m medronate | 0 | low | 3 | 0 |
| technetium tc-99m tetrofosmin | 0 | low | 7 | 0 |
| apyrase | 0 | low | 10 | 0 |
| thromboplastin | 0 | medium | 38 | 6 |
| muramidase | 0 | medium | 18 | 1 |
| kutkin | 0 | low | 1 | 0 |
| lewis y antigen | 0 | low | 1 | 0 |
| amyloid beta-peptides | 0 | medium | 9 | 1 |
| chondroitin sulfates | 0 | medium | 8 | 1 |
| exendin 3 | 0 | low | 1 | 0 |
| promega | 0 | medium | 5 | 3 |
| exudates | 0 | medium | 281 | 33 |
| angiogenin | 0 | medium | 4 | 1 |
| bixin | 0 | low | 1 | 0 |
| technetium tc 99m dimercaptosuccinic acid | 0 | low | 2 | 0 |
| entecavir | 0 | medium | 2 | 1 |
| acyclovir | 0 | low | 6 | 0 |
| levoleucovorin | 0 | low | 2 | 0 |
| cyclic gmp | 0 | medium | 55 | 7 |
| sepiapterin | 0 | low | 2 | 0 |
| deoxyguanosine | 0 | medium | 103 | 19 |
| guanosine diphosphate | 0 | low | 1 | 0 |
| guanosine monophosphate | 0 | low | 1 | 0 |
| guanosine triphosphate | 0 | low | 8 | 0 |
| guanine | 0 | medium | 31 | 5 |
| guanosine | 0 | medium | 18 | 5 |
| hypoxanthine | 0 | medium | 2 | 1 |
| inosinic acid | 0 | low | 3 | 0 |
| inosine | 0 | medium | 5 | 1 |
| inosine diphosphate | 0 | medium | 4 | 4 |
| sapropterin | 0 | medium | 16 | 3 |
| 3-methyladenine | 0 | low | 3 | 0 |
| guanosine 5'-o-(3-thiotriphosphate) | 0 | low | 2 | 0 |
| 7,8-dihydrobiopterin | 0 | low | 2 | 0 |
| neopterin | 0 | low | 8 | 0 |
| clozapine | 0 | medium | 71 | 7 |
| dacarbazine | 0 | low | 2 | 0 |
| didanosine | 0 | low | 2 | 0 |
| ganciclovir | 0 | low | 2 | 0 |
| valacyclovir | 0 | low | 2 | 0 |
| olanzapine | 0 | medium | 85 | 12 |
| oxypurinol | 0 | low | 1 | 0 |
| 2,2'-(hydroxynitrosohydrazono)bis-ethanamine | 0 | low | 1 | 0 |
| guanylyl imidodiphosphate | 0 | low | 1 | 0 |
| rifapentine | 0 | medium | 1 | 1 |
| 3-benzyladenine | 0 | low | 1 | 0 |
| 8-hydroxyguanosine | 0 | medium | 16 | 5 |
| 5,11-methenyltetrahydrohomofolate | 0 | low | 1 | 0 |
| tak 491 | 0 | medium | 2 | 1 |
| nn 414 | 0 | medium | 4 | 1 |
| 2-amino-5-iodo-6-phenyl-4-pyrimidinone | 0 | low | 1 | 0 |
| pcf 39 | 0 | low | 1 | 0 |
| sildenafil citrate | 0 | medium | 43 | 19 |
| aprepitant | 0 | medium | 2 | 1 |
| hymenialdisine | 0 | low | 1 | 0 |
| vardenafil dihydrochloride | 0 | medium | 11 | 4 |
| way 200070 | 0 | low | 1 | 0 |
| 8-bromocyclic gmp | 0 | low | 2 | 0 |
| 8-hydroxyguanine | 0 | medium | 3 | 1 |
| trypan blue | 0 | low | 2 | 0 |
| azure c | 0 | low | 1 | 0 |
| 8-hydroxy-2'-deoxyguanosine | 0 | medium | 115 | 21 |
| bms 536924 | 0 | low | 1 | 0 |
| clozapine n-oxide | 0 | low | 1 | 0 |
| amg531 | 0 | low | 1 | 0 |
| echinochrome a | 0 | low | 1 | 0 |
| n,n'-monomethylenebis(pyridiniumaldoxime) | 0 | low | 1 | 0 |
| 8-nitroguanosine 3',5'-cyclic monophosphate | 0 | low | 1 | 0 |
| formycins | 0 | low | 2 | 0 |
| 5-methyltetrahydrofolate | 0 | medium | 3 | 1 |
| ns 309 | 0 | low | 2 | 0 |
| cytidylyl-3'-5'-guanosine | 0 | low | 2 | 0 |
| imidacloprid | 0 | low | 2 | 0 |
| cyclic guanosine monophosphate-adenosine monophosphate | 0 | low | 1 | 0 |
| rvx 208 | 0 | medium | 10 | 5 |
| heme arginate | 0 | low | 1 | 0 |
| carthamine | 0 | low | 1 | 0 |
| glucosepane | 0 | low | 3 | 0 |
| defibrotide | 0 | medium | 2 | 1 |
| 7-methyl-2-deoxyguanosine | 0 | low | 1 | 0 |
| 5-(n-4-chlorobenzyl)-n-(2',4'-dimethyl)benzamil | 0 | low | 1 | 0 |
| n-(3-((2-hydroxynaphthalen-1-ylmethylene)amino)phenyl)-2-phenylpropionamide | 0 | low | 1 | 0 |
| alcian blue | 0 | low | 2 | 0 |
| lipoteichoic acid | 0 | low | 2 | 0 |
| cholestyramine resin | 0 | medium | 14 | 4 |
| eye | 0 | medium | 42 | 2 |
| fructooligosaccharide | 0 | medium | 7 | 3 |
| maltodextrin | 0 | medium | 9 | 4 |
| ferric carboxymaltose | 0 | medium | 2 | 1 |
| mitotempo | 0 | low | 1 | 0 |
| acetylcellulose | 0 | medium | 1 | 1 |
| abaloparatide | 0 | low | 1 | 0 |
| tauromuricholate | 0 | low | 1 | 0 |
| molnupiravir | 0 | low | 1 | 0 |
| angucyclinone | 0 | low | 1 | 0 |
| ego | 0 | low | 1 | 0 |
| concanavalin a | 0 | low | 6 | 0 |
| trypsinogen | 0 | low | 1 | 0 |
| nirmatrelvir | 0 | low | 1 | 0 |
| gq1b ganglioside | 0 | low | 1 | 0 |
| metallothionein | 0 | medium | 32 | 4 |
| propane-2-sulfonic acid octadec-9-enyl-amide | 0 | low | 1 | 0 |
| vermiculite | 0 | medium | 1 | 1 |
| 2',7'-bis(carboxyethyl)-5(6)-carboxyfluorescein | 0 | low | 2 | 0 |
| phosphorus radioisotopes | 0 | low | 6 | 0 |
| galanin-like peptide | 0 | medium | 6 | 1 |
| leptin | 0 | medium | 1,183 | 134 |
| reamberin | 0 | medium | 3 | 1 |
| pyrimidinones | 0 | medium | 13 | 1 |
| porphyran | 0 | low | 1 | 0 |
| alarin | 0 | medium | 5 | 1 |
| ly2605541 | 0 | medium | 7 | 5 |
| phenanthrenes | 0 | low | 6 | 0 |